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Multiplicative Expansion of the Pool of Fully Synthetic Tetracycline Antibiotics 
Abstract 
This thesis describes the development of chemical pathways for the preparation of more 
than 80 novel fully synthetic tetracyclines with structural variability at positions C5 and C5a. 
Progress toward the synthesis of 5-hetero-tetracyclines, another new class of tetracycline 
antibiotics, is also described. The results detailed herein – including successful C-ring-forming 
Michael–Claisen cyclizations of numerous modified AB precursors with just a few of the 
extraordinarily diverse D-ring precursors known to be effective nucleophiles in this key coupling 
reaction – represent the first steps toward a multiplicative expansion of the pool of fully synthetic 
tetracyclines. 
Novel and versatile ȕ-functionalization reaction sequences employing 
tris(methylthio)methyllithium and 2-lithio-1,3-dithiane have been developed to transform the AB 
enone 10 (the key precursor to fully synthetic tetracyclines) into a diverse range of ȕ-substituted 
AB enone products, including a highly efficient, single-operation method for the synthesis of a ȕ-
methyl ester-substituted AB enone (20). It is demonstrated that the six-membered C ring of 
tetracyclines comprising a C5a quaternary carbon center (e.g. 29) can be assembled by 
stereocontrolled coupling reactions of ȕ-substituted AB enones and o-toluate ester anion D-ring 
precursors. A C5a–C11a-bridged cyclopropane tetracycline precursor (37) was found to undergo 
efficient and regioselective ring-opening reactions with a range of nucleophiles in the presence 
iv 
 
of magnesium bromide, thus providing another avenue for the preparation of fully synthetic 
tetracyclines containing an all-carbon quaternary center at position C5a. 
The AB enone 10 has also been transformed into structurally diverse Ȗ-substituted AB 
precursors, which in turn have been converted into fully synthetic tetracyclines with 
unprecedented modifications at position C5, including 5-fluorotetracyclines such as 94. 
Numerous fully synthetic tetracyclines and tetracycline precursors have been shown to serve as 
diversifiable branch-points, allowing maximally expedient synthesis of C5- and C5a-substituted 
tetracyclines by late-stage diversification. 
The substrate scope of the Michael–Claisen cyclization reaction has been expanded to 
include new heterocyclic enone electrophiles such as dihydro-4-pyridones, affording 
cycloadducts such as 142. In this way, the viability of an iterative Michael–Claisen strategy for 
constructing 5-hetero-tetracyclines has been established. Numerous examples in this thesis serve 
to further demonstrate the broad applicability of the Michael–Claisen cyclization reaction as a 
powerful method for the assembly of stereochemically complex six-membered rings. 
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Introduction 
 The tetracyclines are a class of broad-spectrum antibiotics that have been widely 
used in human and veterinary medicine for more than 50 years.1 The first tetracycline 
antibiotic was discovered in 1948 when Benjamin Duggar of Lederle Laboratories 
isolated the natural product chlorotetracycline (Aureomycin®, 1, Figure 1.1) from the 
culture broth of a novel species of Streptomyces.2 Within two years a research team from 
Chas. Pfizer and Co. had isolated a second natural tetracycline, oxytetracycline 
(Terramycin®, 2),3 and in 1953 tetracycline itself (3) was prepared from 
chlorotetracycline by catalytic hydrogenolysis of the carbon-chlorine bond, a 
transformation discovered by Lloyd Conover of Pfizer.4 Subsequently, tetracycline was 
found to be a natural product and,5 later still, Lederle researchers isolated 6-
demethyltetracyclines (see structures 4 and 5) from culture broths of a mutant strain of 
Streptomyces.6 
                                                 
1 Tetracyclines in Biology, Chemistry and Medicine; Nelson, M.; Hillen, W.; Greenwald, R. A., Eds.; 
Birkhauser: Boston, 2001. 
2 (a) Duggar, B. M. Ann. N. Y. Acad. Sci. 1948, 51, 177–181. (b) Duggar, B. M. Aureomycin and 
Preparation of Same. U.S. Patent 2,482,055, Sept 13, 1949. 
3 (a) Finlay, A. C.; Hobby, G. L.; P’an, S. Y.; Regna, P. P.; Routien, J. B.; Seeley, D. B.; Shull, G. M.; 
Sobin, B. A.; Solomons, I. A.; Vinson, J. W.; Kane, J. H. Science 1950, 111, 85. (b) Sobin, B. A.; Finlay, 
A. C. Terramycin and its Production. U.S. Patent 2,516,080, July 18, 1950. 
4 (a) Booth, J. H.; Morton, J.; Petisi, J. P.; Wilkinson, R. G.; Williams, J. H. J. Am. Chem. Soc. 1953, 75, 
4621. (b) Conover, L. H.; Moreland, W. T.; English, A. R.; Stephens, C. R.; Pilgrim, F. J. J. Am. Chem. 
Soc. 1953, 75, 4622–4623. 
5 Minieri, P. P.; Sokol, H.; Firman, M. C. Process for the Preparation of Tetracycline and 
Chlorotetracycline. U. S. Patent 2,734,018, Feb 7, 1956. 
6 McCormick, J. R. D.; Sjolander, N. O.; Hirsch, U.; Jensen, E. R.; Doerschuk, A. P. J. Am. Chem. Soc. 
1957, 79, 4561-4563. 
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Figure 1.1 Natural tetracycline antibiotics. 
 
 All tetracyclines approved for human or veterinary use are fermentation products 
or are derived from fermentation products by semisynthesis. This is also true of most 
beta-lactam and all macrolide antibiotics. Tracing the paths of human efforts to produce 
new antibiotics from natural products not accessible by synthesis reveals an evolutionary 
process marked by specific, impactful discoveries. In the case of the tetracyclines, Pfizer 
scientists achieved a major enabling advance approximately 10 years after the class had 
been identified when they demonstrated that the C6-hydroxyl group of the natural 
products oxytetracycline (2), tetracycline (3) and 6-demethyltetracycline (4) could be 
removed reductively.7 The 6-deoxytetracyclines produced, including 6-deoxy-6-
                                                 
7 (a) Stephens, C. R.; Murai, K.; Rennhard, H. H.; Conover, L. H.; Brunings, K. J. J. Am. Chem. Soc. 1958, 
80, 5324–5325. (b) McCormick, J. R. D.; Jensen, E. R.; Miller, P. A.; Doerschuk, A. P. J. Am. Chem. Soc. 
1960, 82, 3381–3386. (c) Stephens, C. R.; Beereboom, J. J.; Rennhard, H. H.; Gordon, P. N.; Murai, K.; 
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demethyltetracycline (sancycline, 6, Figure 1.2), were found to be more stable than the 
parent compounds, yet retained broad-spectrum antibacterial activity. The important and 
now generic antibiotics doxycycline (Pfizer, 1967, 7) and minocycline (Lederle, 1972, 8) 
followed as a consequence, the latter arising from the additional discovery that 
electrophilic aromatic substitution at C7 becomes possible when the more stable 6-
deoxytetracyclines are used as substrates.8 
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Figure 1.2 Semisynthetic tetracycline antibiotics. 
 
 Decades later, a team of Wyeth scientists led by Frank Tally synthesized 7,9-
disubstituted tetracycline derivatives, leading to the discovery of the antibiotic tigecycline 
                                                                                                                                                 
Blackwood, R. K.; Schach von Wittenau, M. J. Am. Chem. Soc. 1963, 85, 2643–2652. (d) Blackwood, R. 
K.; Stephens, C. R. J. Am. Chem. Soc. 1962, 84, 4157–4159. 
8 (a) Martell, M. J.; Boothe, J. H. J. Med. Chem. 1967, 10, 44–46. (b) Church, R. F. R.; Schaue, R. E.; 
Weiss, M. J. J. Org. Chem. 1971, 36, 723–725. (c) Spencer, J. L.; Hlavka, J. J.; Petisi, J.; Krazinski, H. M.; 
Boothe, J. H. J. Med. Chem. 1963, 6, 405–407. (d) Zambrano, R. T. U.S. Patent 3,483,251, Dec 9, 1969. 
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(Tigacyl®, US approval 2005, 9).9 Tigecycline is the most important member of a class 
of tetracyclines known as glycylcyclines which retain activity against many tetracycline-
resistant bacteria (vide infra). As shown in Scheme 1.1 below, tigecycline (9) is 
synthesized from minocycline (7) by an efficient three-step sequence comprising: (1) 
nitration at the C9 position of minocycline upon addition of potassium nitrate to a 
solution of minocycline in concentrated sulfuric acid, (2) palladium-catalyzed reduction 
of the nitro group, and (3) acylation of the resulting aniline with 2-(tert-
butylamino)acetyl chloride hydrochloride. 
 
Scheme 1.1. Synthesis of tigecycline (9) from minocycline (8). 
 
                                                 
9 (a) Sum, P.-E.; Lee, V. J.; Testa, R. T.; Hlavka, J. J.; Ellestad, G. A.; Bloom, J. D.; Gluzman, Y.; Tally, F. 
P. J. Med. Chem. 1994, 37, 184–188. (b) Sum, P.-E.; Petersen, P. Bioorg. Med. Chem. Lett. 1999, 9, 1459–
1462. 
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 A generalized structure-activity relationship profile of tetracyclines was 
formulated following extensive semisynthetic investigations (Figure 1.3). Structural 
modification of the D ring and upper periphery of tetracyclines provided compounds with 
enhanced, equal or reduced antibacterial activity; this region is therefore considered 
“variable”. Antibacterial activity was diminished or abolished by modification of the 
lower periphery and A ring, indicating that the functional groups at these positions are 
essential for the antibiotic action of tetracyclines. These observations were rationalized 
by X-ray crystal structures of tetracycline bound to its target, the bacterial ribosome (vide 
infra).10 The limitations of semisynthesis have meant that relatively few structural 
variations have been explored along the upper periphery of tetracyclines (C4, C4a, C5, 
C5a and C6). This region is considered variable largely on the basis that natural 
tetracyclines have different substitution patterns at C5 and C6. Like many “old” classes 
of antibiotics, tetracyclines have never been systematically modified by de novo synthesis 
and knowledge of structure-activity relationships is limited or non-existent at many 
positions on the scaffold.11 
                                                 
10 (a) Brodersen, D. E.; Clemons, W. M., Jr.; Carter, A. P.; Morgan-Warren, R. J.; Wimberly, B. T.; 
Ramakrishnan, V. Cell 2000, 103, 1143–1154. (b) Pioletti, M.; Schlünzen, F.; Harms, J.; Zarivach, R.; 
Glühmann, M.; Avila, H.; Bashan, A.; Bartels, H.; Auerbach, T.; Jacobi, C.; Hartsch, T.; Yonath, A.; 
Franceschi, F. EMBO J. 2001, 20, 1829–1839. 
11 Von Nussbaum, F.; Brands, M.; Hinzen, B.; Weigand, S.; Häbich, D. Angew. Chem. Int. Ed. 2006, 45, 
5072-5129. 
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Figure 1.3 Summary of 50 years of structure-activity relationships data. 
 
From the time that the structures of the tetracycline antibiotics were first revealed 
by Woodward and collaborators,12 many laboratories have sought to develop a practical 
route for their synthesis. Strategically, the original route developed by Woodward and 
collaborators for the synthesis of sancycline employed a "left-to-right" or DoA mode of 
construction. The Shemyakin and Muxfeldt research groups adopted a similar 
directionality in their remarkable syntheses of tetracycline (3, 1967) and oxytetracycline 
(2, 1968), respectively, using a bicyclic CD-ring precursor as starting material.13,14 
                                                 
12 (a) Hochstein, F.A.; Stephens, C. R.; Conover, L. H.; Regna, P. P.; Pasternack, R.; Gordon, P. N.; 
Pilgrim, F. J.; Brunings, K. J.; Woodward, R. B. J. Am. Chem. Soc. 1953, 75, 5455-5475. (b) Stephens, C. 
R.; Conover, L. H.; Hochstein, F. A.; Regna, P. P.; Pilgrim, F. J.; Brunings, K. J. J. Am. Chem. Soc. 1952, 
74, 4976-4977. 
13 (a) Gurevich, A. I.; Karapetyan, M. G.; Kolosov, M. N.; Korobko, V. G.; Onoprienko, V. V.; Popravko, 
S. A.; Shemyakin, M. M. Tetrahedron Lett. 1967, 8, 131-134. (b) Kolosov, M. N.; Popravko, S. A.; 
Shemyakin, M. M. Lieb. Ann. 1963, 668, 86-91. 
14 (a) Muxfeldt, H.; Hardtmann, G.; Kathawala, F.; Vedejs, E.; Mooberry, J. B. J. Am. Chem. Soc. 1968, 90, 
6534–6536. (b) Muxfeldt, H.; Haas, G.; Hardtmann, G.; Kathawala, F.; Mooberry, J. B.; Vedejs, E. J. Am. 
Chem. Soc. 1979, 101, 689–701. 
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 The Myers laboratory adopted a completely different synthetic approach to the 
tetracyclines, aiming to form the C ring by convergent coupling of D- and AB-ring 
precursors.15,16 This strategy was devised following consideration of structure-activity 
relationship data and X-ray crystal structures of tetracycline bound to the bacterial 
ribosome (its putative target).10 Much of the functionality known to be required for 
binding to the ribosome was contained (in protected form) in the AB precursor 10 
(Scheme 1.2 below). It was intended that structural variation would be permitted in the 
D-ring portion of tetracyclines, which had emerged as the most promising site for the 
attachment of new substituents. 
To date more than 3,000 fully synthetic molecules of the tetracycline class, 
broadly defined, have been prepared by a general and convergent process that involves a 
Michael–Claisen coupling of the AB enone 10 with structurally diverse D-ring precursors 
followed by deprotection, a route of typically 3-4 steps (Scheme 1.2).17,18 Most of the 
candidate antibiotics prepared in this way would have been difficult if not impossible to 
obtain by semisynthesis. Thus, the development of a practical, convergent synthesis of 
tetracyclines has dramatically expanded the pool of accessible compounds, allowing 
unprecedented modifications at positions C6, C7, C8, C9 and C10. 
                                                 
15 Charest, M. G.; Lerner, C. D.; Brubaker, J. D.; Siegel, D. R.; Myers, A. G. Science 2005, 308, 395–398. 
16 Sun, C.; Wang, Q.; Brubaker, J. D.; Wright, P. M.; Lerner, C. D.; Noson, K.; Charest, M. G.; Siegel, D. 
R.; Wang, Y.-M.; Myers, A. G. J. Am. Chem. Soc. 2008, 130, 17913–17927. 
17 Clark, R. B.; He, M.; Fyfe, C.; Lofland, D.; O’Brien, W. J.; Plamondon, L.; Sutcliffe, J. A.; Xiao, X.-Y. 
J. Med. Chem. 2011, 54, 1511–1528. 
18 Sun, C.; Hunt, D. K.; Clark, R. B.; Lofland, D.; O’Brien, W. J.; Plamondon, L.; Xiao, X.-Y. J. Med. 
Chem. 2011, 54, 3704–3731. 
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Scheme 1.2. The Myers synthetic approach to tetracyclines. 
 
 Three distinct synthetic routes to the AB enone 10 have been reported.15,19,20 The 
convergency and scalability of the second- and third-generation routes have enabled 
preparation of large quantities of this key intermediate. The third-generation route (see 
Chapter 4 Introduction for complete discussion) is characterized by a highly 
diastereoselective A-ring-forming Michael–Claisen coupling reaction, meaning that all 
four carbon-carbon bonds needed to assemble tetracyclines from three readily available 
components – a D-ring precursor, B-ring precursor 11 and isoxazole precursor 12 (Figure 
1.4) – are formed using this powerful method for bond-pair construction (see Scheme 1.4 
for details of these cyclization reactions). 
                                                 
19 Brubaker, J. D.; Myers, A. G. Org. Lett. 2007, 9, 3523–3526. 
20 Kummer, D. A.; Li, D.; Dion, A.; Myers, A. G. Chem Sci. 2011, 2, 1710–1718. 
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Figure 1.4. Construction of tetracyclines by iterative Michael–Claisen cyclizations; 
bonds and rings formed by Michael–Claisen reactions are highlighted in orange. 
 
Michael–Claisen Reaction Sequences 
 Michael–Claisen and Michael–Dieckmann reaction sequences have been widely 
employed in organic synthesis to construct naphthalene derivatives and non-aromatic six-
membered rings.21 The origins of this method for bond-pair construction can be traced to 
1978, when three different cyclization protocols were introduced by independent research 
groups. Hauser and Rhee used a sulfoxide-stabilized o-toluate ester anion as the 
nucleophilic component in a Michael–Dieckmann cyclization reaction with methyl 
crotonate (Scheme 1.3, eq 1). In this case, aromatization occurred upon thermal 
elimination of phenylsulfenic acid.22 The use of phthalide and cyanophthalide anions as 
                                                 
21 (a) Mal, D.; Pahari, P. Chem. Rev. 2007, 107, 1892–1918. (b) Mitchell, A. S.; Russell, R. A. Tetrahedron 
1995, 51, 5207–5236. (c) Rathwell, K.; Brimble, M. A. Synthesis 2007, 5, 643–662. 
22 Hauser, F. M.; Rhee, R. P. J. Org. Chem. 1978, 43, 178–180. 
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nucleophilic components was described by Broom and Sammes (eq 2),23 and Kraus and 
Sugimoto (eq 3),24 respectively. Formal loss of water and hydrogen cyanide, respectively, 
led to naphthoate ester products in these procedures. 
SOAr
CO2Et
CH3
OH
CO2CH3
O
O
O
CH3
CO2CH3
OH
CN
O
OH
OH
CO2Et
CH3O
CH3O
CH3
CO2CH3
CH3O
CH3O OH
CH3
O
CH3
O
1. LDA, THF, –78 °C;
CH3 CO2CH3
2. toluene, 115 °C
1. LDA, THF, –78 °C;
CH3 CO2CH3
2. CF3CO2H
LDA, THF, –78 °C;
CO2Et
LDA, THF, –78 °C;
OCH3
O
CH3
70%
32%
79%
(1)
(2)
(3)
(4)
, –78 0 °C
–78 23 °C  
Scheme 1.3. Early examples of Michael–Claisen and Michael–Dieckmann cyclizations. 
 
In 1979, the Weinreb and Staunton research groups first reported that simple o-
toluate ester anions (unsubstituted at the benzylic position) undergo Michael–Claisen 
                                                 
23 Broom, N. J. P.; Sammes, P. G. J. Chem. Soc., Chem. Comm. 1978, 162–164. 
24 Kraus, G. A.; Sugimoto, H. Tetrahedron Lett. 1978, 26, 2263–2266. 
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cyclization reactions with ȕ-methoxycyclohexenones and Ȗ-pyrones to form naphthyl 
ketones (eq 4, Scheme 1.3), a sequence sometimes referred to as Staunton–Weinreb 
annulation.25 Experimental evidence indicates that the mechanism of this reaction 
sequence involves sequential conjugate addition, ȕ-elimination of alkoxide, re-lithiation 
at the benzylic position (in the presence of excess base), followed by Claisen cyclization. 
  There are numerous examples of the formation of non-aromatic 6-membered rings 
by Michael–Claisen and Michael–Dieckmann reaction sequences.26 However, the 
stereochemical features of these cyclization reactions have only rarely been discussed,27 
frequently because they were of little consequence (aromatization followed cyclization). 
The Michael–Claisen cyclizations developed as part of Myers’ synthesis of tetracyclines 
are unusual in their stereochemical complexity, stereocontrol and efficiency. The C-ring-
forming cyclizations of D-ring precursors with AB enone 10 appear to proceed with 
complete stereocontrol at C5a (attack upon a single diastereoface of the enone; see 
Scheme 1.4 for an example).16 This selectivity may arise as a consequence of 
stereoelectronic factors (pseudoaxial addition to the enone) and/or steric effects (addition 
                                                 
25 (a) Dodd, J. H.; Weinreb, S. M. Tetrahedron Lett. 1979, 38, 3593–3596. (b) Dodd, J. H.; Starrett, J. E.; 
Weinreb, S. M. J. Am. Chem. Soc. 1984, 106, 1811–1812. (c) Leeper, F. J.; Staunton, J. J. Chem. Soc., 
Chem. Comm. 1979, 5, 206-207. (d) Leeper, F. J.; Staunton, J. J. Chem. Soc. Perkin Trans. 1 1984, 1053–
1059. 
26 (a) Tarnchompoo, B.; Thebtaranonth, C.; Thebtaranonth, Y. Synthesis 1986, 9, 785-786. (b) Boger, D. L.; 
Zhang, M. J. Org. Chem. 1992, 57, 3974-3977. (c) Nishizuka, T.; Hirosawa, S.; Kondo, S.; Ikeda, D.; 
Takeuchi, T. J. Antibiotics 1997, 50, 755-764. (d) Hill, B.; Rodrigo, R. Org. Lett. 2005, 7, 5223-5225. (e) 
Tatsuta, K.; Yoshimoto, T.; Gunji, H.; Okado, Y.; Takahashi, M. Chem. Lett. 2000, 646–647. 
27 For examples of stereocontrol in Michael–Claisen and Michael–Dieckmann cyclization reactions, see: (a) 
Franck, R. W.; Bhat, V.; Subramaniam, C. S. J. Am. Chem. Soc. 1986, 108, 2455-2457. (b) Tatsuta, K.; 
Yamazaki, T.; Mase, T.; Yoshimoto, T. Tetrahedron Lett. 1998, 39, 1771-1772. (c) White, J. D.; Demnitz, 
F. W. J.; Qing, X.; Martin, W. H. C. Org. Lett. 2008, 10, 2833-2836. 
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of the nucleophile to the S-face opposite the tert-butyldimethylsilyloxy substituent, which 
is also axial; see Figure 1.5 below). The C-ring-forming cyclization depicted in Scheme 
1.4 occurs with >20:1 stereoselectivity at C6. 
 
Scheme 1.4. Diastereoselective Michael–Claisen cyclizations to form the C ring and the 
A ring of tetracyclines. 
 
 As noted above, the key step of the third-generation synthesis of the AB enone is 
another highly diastereoselective Michael–Claisen coupling, in this case forming the A 
ring of tetracyclines (Scheme 1.4). Conjugate addition of the sodium enolate of isoxazole 
precursor 12 to the B-ring precursor 11 occurs with complete control of relative 
stereochemistry at C4 and C4a, affording cycloadduct 13 in 80% yield as a single 
14 
 
diastereomer (following Claisen cyclization). The stereochemistry at C4a is believed to 
result from approach of the enolate from the less sterically hindered diastereoface of 
cyclohexenone 11 (opposite the cyclopentene cage). 
 
Figure 1.5. X-ray crystal structure of AB enone 10. 
 
Antibacterial Action of Tetracyclines 
The 70S bacterial ribosome is made up of two subunits – the small subunit, 30S, 
through which mRNA tunnels and which contains on its surface the decoding site where 
the mRNA sequence is read in blocks of three nucleotides; and the large subunit, 50S, 
which possesses catalytic ribozyme peptidyltransferase activity and is the site of peptide 
chain elongation.28,29 As mRNA tunnels through the 30S subunit, a short stretch of the 
                                                 
28 Antibiotics – Actions, Origins, Resistance; Walsh, C.; ASM Press – Washington, D.C., 2003. 
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molecule protrudes through to the interface with the 50S subunit. This stretch consists of 
six nucleotides which occupy two codon sites: the aminoacyl (A) site, and the peptidyl 
(P) site. Upstream of the peptidyl site is the exit codon (E) site, where deacylated tRNA 
moves from the P site following peptidyl transfer. 
Aminoacyl-tRNAs arrive at the unoccupied A site in complex with EF-Tu 
(elongation factor thermo unstable). The existence of Watson-Crick base pairs between 
the A site mRNA codon and the anti-codon loop of the aminoacyl-tRNA leads to 
appropriate orientation and complex formation. The P site is occupied by a tRNA 
molecule carrying the nascent peptide chain. The aminoacylated ends of the tRNA 
molecules occupying the A and P sites are approximately 75 Å away from the tRNA 
binding sites, in the catalytic center of the 50S subunit. In each chain elongation step, the 
aminoacyl moiety of the A site tRNA attacks the adjacent peptide chain of the peptidyl-
tRNA. The peptidyl chain (lengthened by one amino acid) is now tethered to the tRNA 
docked in the A site, and the P site is occupied by a deacylated tRNA molecule. Before 
the next chain elongation step occurs, the deacylated tRNA moves from the P site to the 
E site and the peptidyl-tRNA relocates to the P site, opening up the A site for docking of 
an aminoacyl-tRNA possessing an anticodon loop complementary to the three mRNA 
nucleotides now being presented in the A site. The translocation process is catalyzed by 
EF-G (elongation factor G). 
                                                                                                                                                 
29 Wilson, D. N. Crit. Rev. Biochem. Mol. Biol. 2009, 44, 393-433. 
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Tetracyclines inhibit bacterial protein synthesis by binding to the 30S subunit near 
the A site, thereby blocking accommodation of aminoacyl-tRNAs into the A site. 
Following an initial decoding event involving interaction of the anticodon loop of 
aminoacyl-tRNA (complexed at this stage with EF-Tu and GTP) with the mRNA codon, 
the release of aminoacyl-tRNA from EF-Tu is inhibited as the anticodon loop clashes 
with bound tetracycline during rotation into the A site.29,10a This explanation fits with the 
observation that tetracycline does not affect the level of ribosomal binding of the ternary 
complex of aminoacyl-tRNA with EF-Tu and GTP (although binding occurs more 
slowly). Selective inhibition of bacterial protein synthesis is possible because of 
structural differences between the ribosomal RNA of bacterial and eukaryotic ribosomes, 
as well as selective concentration in susceptible bacterial cells.30 
Tetracycline binds to the ribosome in complex with Mg2+, as depicted in Figure 
1.6 below.10a The C11-C12 keto-enol portion of tetracycline binds to Mg2+, which is then 
also coordinated by the phosphate oxygens of RNA nucleotides G1197, G1198 and 
C1054 in helix 34 of the 30S ribosomal subunit. In addition, the phenolic hydroxyl group 
at C10 and tertiary carbinol at C12a appear to engage in hydrogen bonding interactions 
with the ribose portion of C1054 and a phosphate oxygen of G1198, respectively. 
Furthermore, there is an apparent interaction between the A ring of tetracycline and a 
phosphate oxygen of residue G966 in helix 31, as well as a hydrophobic interaction 
between the aromatic D ring of tetracycline and the base of C1054 in helix 31. 
                                                 
30 Chopra, I.; Roberts, M. Microbiol. Mol. Biol. Rev. 2001, 65, 232-260. 
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Figure 1.6. Tetracycline bound to its primary binding site in the bacterial ribosome.10a 
 
Tetracycline and glycylcyclines (such as tigecycline, 9) share a common 
ribosomal binding site, to which selected glycylcyclines appear to bind five times more 
efficiently.31 It has been proposed that the bulky C9 side-chain of tigecycline either 
causes the antibiotic to bind to the ribosome in a different orientation to tetracycline, or 
the ribosomal RNA conformation is altered to accommodate the bulkier drug molecule.32 
One (or both) of these effects probably leads to the higher affinity binding of tigecycline 
                                                 
31 Bergeron, J; Ammirati, M.; Danley, D.; James, L.; Norcia, M.; Retsema, J.; Strick, C. A.; Su, W. G.; 
Sutcliffe, J.; Wondrack, L. Antimicrob. Agents Chemother. 1996, 40, 2226-2228. 
32 Bauer, G.; Berens, C.; Projan, S. J.; Hillen, W. J. Antimicrob. Chemother. 2004, 53, 592-599. 
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compared to tetracycline and also helps explain the fact that tigecycline retains activity 
against many tetracycline-resistant bacteria (vide infra). 
All bacterial cells are bounded by a cytoplasmic membrane, a symmetric lipid 
bilayer which is permeable to uncharged, lipophilic molecules. In addition, Gram-
negative bacterial cells are also bounded by a second barrier – the outer membrane – 
which is significantly less permeable to lipophilic molecules than the cytoplasmic 
membrane. Unlike the cytoplasmic membrane, the bilayer of the outer membrane is 
asymmetric.33 The outer leaflet (of the outer membrane) consists of lipopolysaccharides, 
while the inner leaflet is made up of phospholipids. The “gel-like” nature of the 
lipopolysaccharide leaflet makes the outer membrane a more effective permeability 
barrier than the inner membrane. 
Donnan potential is the electric potential arising between two solutions of unequal 
ionic solute concentration separated by a partially permeable membrane. In all mediums 
containing tetracycline, an equilibrium exists between a net uncharged, metal-free form 
of tetracycline (denoted “tc” in Figure 1.7 below) and a complex in which deprotonated 
tetracycline coordinates a magnesium dication, [M-tc]+.34 The position of the equilibrium 
in any medium depends on both pH and magnesium ion concentration. The higher the pH 
and the higher the magnesium concentration, the higher will be the concentration of the 
                                                 
33 Nikaido, H. Microbio. Mol. Biol. Rev. 2003, 67, 593-656. 
34 Key references for bacterial cell penetration of tetracyclines: (a) Yamaguchi, A.; Ohmori, H.; Kaneko-
Ohdera, M.; Nomura, T.; Sawai, T. Antimicrob. Agents Chemother. 1991, 35, 53-56. (b) Nikaido, H.; 
Thanassi, D. G. Antimicrob. Agents Chemother. 1993, 37, 1393-1399. (c) Schnappinger, D.; Hillen, W. 
Arch. Microbiol. 1996, 165, 359-369. 
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hydrophilic chelate complex, to which the cytoplasmic membrane is impermeable. In E. 
coli, the cytoplasmic pH is higher than the external pH by about 1.7 pH units, and the 
cytoplasmic magnesium ion concentration is also higher. Therefore, the proportion of 
tetracycline in its uncharged (permeable) form is significantly higher in the periplasm 
than in the cytoplasm. The pH difference is dependent on the proton motive force and 
explains why tetracycline accumulation is energy dependent. 
 
Figure 1.7. Diagrammatic representation of Gram-negative cell penetration by 
tetracycline (tc). 
 
A high concentration of acidic groups at the surface of the outer membrane means 
that Mg2+ ions are abundant at this location. Tetracyclines, like most antibacterials, are 
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thought to penetrate the outer membrane of Gram-negative cells predominantly by 
passing through aqueous channels provided by porin proteins imbedded in the outer 
membrane. Porin proteins favor passage of charged, hydrophilic solutes, and tetracyclines 
pass through these channels in complex with Mg2+ (denoted [M-tc]+ in the Figure 
1.7).34,35 The Donnan potential across the outer membrane leads to accumulation of [M-
tc]+ in the periplasm (relative to the exterior) and, following equilibration, passage of 
neutral and metal-free tetracycline across the cytoplasmic membrane, which is permeable 
to uncharged, lipophilic small molecules. Tetracycline has pKa values of 3.3, 7.7, and 
9.7, and at pH 7.4, 7.1% of tetracycline exists in uncharged form. The uncharged form of 
tetracycline is weakly lipophilic. Although diffusion across the outer membrane is 
relatively slow, it may still occur at a significant rate with more lipophilic tetracyclines 
such as minocycline.34b 
O’Shea and Moser found that antibacterial agents with activity against Gram-
negative bacteria (which, with few exceptions, are a subset of compounds with Gram-
positive activity) are significantly more polar (less lipophilic) than “Gram-positive only” 
agents.36 Antibacterials with Gram-negative activity have a mean relative polar surface 
area 12% higher than compounds which are only active against Gram-positive bacteria, 
as well as significantly lower values for clogD7.4 (the calculated log of the octanol-water 
partition coefficient based on the distribution of charged and uncharged forms of the 
                                                 
35 Koebnik, R.; Locher, K. P.; Van Gelder, P. Mol. Microbiol. 2000, 37, 239-253. 
36 O’Shea, R.; Moser, H. E. J. Med. Chem. 2008, 51, 2871-2878. 
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compound at pH 7.4). Furthermore, Gram-negative agents have a smaller mean molecular 
mass, with a seemingly strict upper limit of 600 Da. 
This analysis of physicochemical properties was modified by Silver to 
differentiate between antibacterials whose targets are located in the cytoplasm (and which 
reach their targets by diffusion) and those which need not penetrate the inner membrane 
to exert their antibacterial effect.37 Specifically, antibacterials were divided into two 
groups: (i) drugs with cytoplasmic targets which enter the cytoplasm by diffusion 
(including tetracyclines); (ii) drugs with no requirement for diffusion across the lipid 
bilayer of the cytoplasmic membrane, i.e. antibacterials with extracytoplasmic targets 
plus those with cytoplasmic targets which are known to move across the cytoplasmic 
membrane by means other than diffusion (such as the aminoglycosides, whose transport 
is energy dependent). The difference between these two groups is even more significant 
than for Gram-positive-only agents versus drugs with Gram-negative activity. 
“Extracytoplasmic and transported” antibacterials are even more polar (on average) than 
Gram-negative agents as a whole. 
                                                 
37 Silver, L. L. Clinical Microbio. Rev. 2011, 24, 71–109. 
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Figure 1.8. Analyses of physicochemical properties of antibacterials (divided into two 
groups) and drugs in other therapeutic areas; A: antibacterials divided into Gram-
negative agents and Gram-positive-only agents; B: antibacterials divided into those with 
cytoplasmic targets and those which act extracytoplasmically or are actively transported 
across the cytoplasmic membrane. 
 
The requirements that Gram-negative antibacterials have higher polarity and 
lower molecular weight are believed to be driven by the properties of porin proteins. All 
known porins have a characteristic ȕ-barrel structure and significantly conserved 
transmembrane ȕ-strands (according to analysis of amino acid sequence and a limited 
number of crystal structures).38 The presence of charged amino acid side chains on 
opposite sides of the porin channels leads to highly directional orienting of water 
                                                 
38 (a) Cowan, S. W.; Schirmer, T.; Rummel, G.; Steiert, M.; Ghosh, R.; Pauptit, R. A.; Jansonius, J. N.; 
Rosenbusch, J. P. Nature 1992, 358, 727–733. (b) Dutzler, R.; Rummel, G.; Alberti, S.; Hernández-Allés, 
S.; Phale, P. S.; Rosenbusch, J. P.; Benedi, V. J.; Schirmer, T. Structure 1999, 7, 425–434. 
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molecules, and disruption of this ordered structure is thermodynamically disfavored. 
Passage of lipophilic molecules is most strongly disfavored because the energy cost for 
removal of the hydration sphere of channel-lining amino acids and temporary 
replacement with the small molecule is prohibitively high.39 When hydrophilic solutes 
come into the channel, the broken hydrogen bonds between water molecules and channel-
lining amino acids are temporarily replaced by hydrogen bonds between the hydrophilic 
solute and polar amino acid side chains. Passage of an antibacterial through these 
openings requires that the activation energy for removal of the hydration sphere of 
channel-lining amino acids and temporary replacement with the drug molecule is not 
prohibitively high. Charged, hydrophilic molecules are therefore more likely to penetrate 
the outer membrane of Gram-negative cells. 
Cell penetration is clearly a crucial factor in determining antibacterial activity of 
any tetracycline, and the conflict between the broad requirements for passage through the 
two membranes of Gram-negative bacteria presents a very significant challenge in 
tetracycline drug discovery. Modified tetracyclines with higher influx rates could hold 
significant advantages over existing tetracyclines, but as the conditions that mediate 
compound uptake through the bacterial cell envelope are still incompletely understood, 
rational design with respect to this feature is extremely difficult.40 
 
                                                 
39 Nikaido, H.; Rosenberg, E. Y.; Foulds, J. J. Bacteriology 1983, 153, 232–240. 
40 Brotz-Oesterhelt, H.; Sass, P. Future Microbiology 2010, 5, 1553–1579. 
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Tetracycline Resistance 
 Decades of clinical and agricultural use have led to widespread bacterial 
resistance to tetracyclines. The tetracycline “resistome” may be the largest assortment of 
resistance genes acting against an individual class of antibiotics. A 2010 review stated 
that there were over 1,189 reported tetracycline genes that had been classified into 41 
resistance determinant classes (of which 26 are efflux pumps and 11 are ribosomal 
protection proteins).41 
The majority of tetracycline efflux proteins are members of the major facilitator 
superfamily of integral membrane transporters.42 Although no crystal structure is 
currently available, tetracycline efflux proteins are predicted to be water-filled channels 
surrounded by six transmembrane helices. The flow of protons down a pH gradient 
provides the energy required to pump tetracycline out of the cytoplasm.43 Export of 
tetracycline protects ribosomes within the cell by reducing cytoplasmic drug 
concentration. 
Each tetracycline efflux protein has an associated tetracycline repressor protein 
responsible for regulating expression of the efflux pump. Expression of TetA (a widely 
distributed and clinically important efflux pump found in Gram-negative bacteria) is 
regulated by TetR, a protein which forms a dimer and binds to DNA operator sequences 
                                                 
41 Thaker, M.; Spanogiannopoulos; Wright, G. D. Cell. Mol. Life Sci. 2010, 67, 419–431. 
42 Paulsen, I. T.; Brown, M. H.; Skurray, R. A. Microbiol. Rev. 1996, 60, 575–608. 
43 Yamaguchi, A.; Ono, N.; Akasaka, T.; Noumi, T.; Sawai, T. J. Biol. Chem. 1990, 265, 15525–15530. 
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tetO1 and tetO2. Upon entering the cytoplasm, tetracycline forms a complex with Mg2+ 
and the complex in turn binds to the TetR–DNA complex, leading to a conformational 
change within the TetR dimer which dramatically reduces its affinity for the DNA 
operator sequences, leading to dissociation of the protein–DNA complex and 
transcription of both TetA and TetR. 
A crystal structure of the complex formed between TetR and tetracycline–Mg2+ 
provided a detailed view of the binding interactions between the antibiotic and the 
repressor protein (Figure 1.9A below).44 Although there is significant sequence variation 
amongst the repressor proteins responsible for regulating the expression of different 
efflux proteins, the amino acid residues involved in hydrogen bonding to tetracycline and 
Mg2+ coordination are largely conserved. The crystal structure of the complex formed 
between tetracycline and TetR revealed that the repressor protein completely surrounds 
the antibiotic, forming an extensive network of contacts around the tetracycline scaffold 
(tetracycline has a Kd of ~ 1 nM for Tet(R), compared with ~1 µM for the bacterial 
ribosome). In contrast, the interactions between tetracycline and its primary binding site 
in the 30S ribosomal subunit are largely confined to the highly oxygenated “lower” 
periphery of the molecule, while the upper periphery of the antibiotic projects away from 
the binding site into free aqueous solution (see Figure 1.9B). As a result of this 
difference, it is conceivable that the attachment of new substituents in this region (C4a, 
C5, C5a and C6) could disrupt the interaction with TetR (and potentially combat 
                                                 
44 (a) Hinrichs, W.; Kisker, C.; Duvel, M.; Saenger, W. Science 1994, 264, 418–420. (b) Kisker, C.; 
Hinrichs, W.; Tovar, K.; Hillen, W.; Saenger, W. J. Mol. Biol. 1995, 247, 260–280. (c) Orth, P.; 
Schnappinger, D.; Hillen, W.; Saenger, W.; Hinrichs, W. Nature Struct. Biol. 2000, 7, 215–219. 
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resistance due to tetracycline efflux) without compromising the ribosomal binding 
required for antibacterial activity.41 It has been demonstrated that natural and non-natural 
tetracyclines with diverse substitution patterns along the upper periphery have different 
binding affinities for TetR.45 
A.                         B. 
 
 
 
 
 
 
 
 
Figure 1.9. A. Tetracycline bound to the tet repressor (TetR). B. Tetracycline bound to 
the 30S subunit of the bacterial ribosome. 
 
                                                 
45 Degenkolb, J.; Takahashi, M.; Ellestad, G. A.; Hillen, W. Antimicrob. Agents Chemother. 1991, 35, 
1591-1595. 
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Multi-drug efflux pumps expel a range of structurally dissimilar compounds from 
bacterial cells, including antibiotics of many different classes.46 The non-selective export 
of multiple antibacterial agents means that these pumps are often associated with multi-
drug resistance. Any given bacterial species may express a number of different multi-
drug efflux pumps; some are constitutively expressed (conferring intrinsic multi-drug 
resistance) while the expression of others may be induced by the presence of certain 
substrates. Across different species of bacteria there is significant variation in the 
structure and substrate scope of efflux pumps, so the impact of multi-drug efflux systems 
on antibacterial susceptibility is highly species-dependent. Multi-drug efflux pumps can 
be either single component or multi-component systems. Those expressed in some Gram-
negative bacteria are tripartite systems, with a constituent inner membrane transporter 
protein, periplasmic accessory protein (or membrane-fusion protein) and outer membrane 
protein channel.46 
Tetracyclines are substrates for some multi-drug efflux pumps, including those 
expressed in Pseudomonas aeruginosa, a particularly problematic pathogen. Resistance 
of Pseudomonas strains to multiple classes of otherwise effective antibiotics is a result of 
both slow permeation (poor influx) and highly efficient efflux of drug molecules.47 
Tigecycline is exported from Pseudomonas by multi-drug pumps less efficiently than 
                                                 
46 (a) Piddock, L. J. V. Clin. Microbiol. Rev. 2006, 19, 382-402. (b) Piddock, L. J. V. Nature Rev. 
Microbiol. 2006, 4, 629-636. 
47 Li, X. Z.; Livermore, D. M.; Nikaido, H. Antimicrob. Agents Chemother. 1994, 38, 1732-1741. 
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older tetracyclines, but efflux is still sufficient to confer resistance.48 Given that 
glycylcyclines are exported less efficiently and that the relative contributions of different 
multi-drug pumps to net efflux varies significantly between different tetracyclines, it is 
possible that efflux pump-mediated drug resistance could be overcome through chemical 
modification of existing, otherwise effective drugs. 
Ribosomal protection proteins (RPPs) are thought to give rise to tetracycline 
resistance by binding to tetracycline–ribosome complex at a distinct site (i.e. away from 
the primary tetracycline binding site), causing a ribosomal conformation change which 
weakens the interaction between tetracycline and the ribosome.49 Tetracycline is thus 
“dislodged” from its primary binding site (Figure 1.10 below). Upon tetracycline release, 
GTP is hydrolyzed and the RPP dissociates from the ribosome.50 RPPs have significant 
sequence homology with elongation factors EF-Tu and EF-G, both of which are also 
GTPases.51 The mechanism by which RPPs “recognize” ribosomes bound by tetracycline 
has not been conclusively established. It is possible that tetracycline binding induces a 
conformational change which promotes RPP binding. Alternatively, since Tet(O) (a 
prevalent and well-studied RPP) cannot bind to a ribosome with an occupied A site, the 
ability of tetracycline to block the ribosome in a state with an open A site may explain the 
                                                 
48 Dean, C. R.; Visalli, M. A.; Projan, S. J.; Sum, P.-E.; Bradford, P. A. Antimicrob. Agents Chemother. 
2003, 47, 972-978. 
49 Connell, S. R.; Tracz, D. M.; Nierhaus, K. H.; Taylor, D. E. Antimicrob. Agents Chemother. 2003, 47, 
3675-3681. 
50 Burdett, V. J. Bacteriol. 1996, 178, 3246-3251. 
51 (a) Taylor, D. E.; Chau, A. Antimicrob. Agents Chemother. 1996, 40, 1-5. (b) Kobayashi, T.; Nonaka, L.; 
Maruyama, F.; Suzuki, S. J. Mol. Evol. 2007, 65, 228-235. 
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binding preference of RPPs.52 It is not known whether RPPs prevent rebinding of 
tetracycline after causing tetracycline release. 
 
Figure 1.10. Ribosomal protection resistance mechanism.41 
 
Glycylcycline antibiotics such as tigecycline retain activity against bacteria 
expressing ribosomal protection proteins. Tigecycline and older tetracyclines all bind to 
the same primary binding site in the ribosome, but tigecycline binds more strongly and in 
a slightly different orientation. It is possible that RPPs bind less strongly to the 
tigecycline–ribosome complex than to the tetracycline–ribosome complex, or that RPP 
                                                 
52 Connell, S. R.; Trieber, C. A.; Einfeldt, E.; Dinos, G. P.; Taylor, D. E.; Nierhaus, K. EMBO J. 2003, 22, 
945-953. 
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binding to the tigecycline–ribosome complex causes little or no conformational change 
(i.e. tigecycline is simply harder to dislodge). 
Glycylcyclines also show a high level of activity against organisms carrying 
tetracycline efflux resistance determinants. Someya and co-workers studied the 
glycylcycline antibiotic 9-(N,N-dimethylaminoglycylamido)-6-demethyl-6-deoxy-
tetracycline (DMG-DMDOT)  and found that it does induce expression of the TetA 
efflux protein, indicating that this glycylcycline is a substrate for TetR.53 There are 
therefore two possible explanations for the potent activity of this glycylcycline in the 
presence of tetracycline efflux determinants: (1) the efflux protein is not able to recognize 
the glycylcycline, or (2) the efflux protein–glycylcycline complex cannot be translocated 
across the bacterial membrane. Indirect results suggest that the glycylcycline does not 
bind to the efflux protein TetA (at least not to the tetracycline binding site), thus 
explaining the ability of this antibiotic to overcome resistance caused by tetracycline-
specific efflux. 
 
                                                 
53 Someya, Y.; Yamaguchi, A.; Sawai, T. Antimicrobial Agents and Chemotherapy 1995, 39, 247-249. 
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Chapter 2 
Synthesis of C5a-Substituted Tetracyclines  
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Introduction 
Previous work has demonstrated that our fully synthetic approach to tetracyclines 
allows modifications at positions C6, C7, C8, C9 and C10 that are not feasible by 
semisynthesis (Scheme 2.1).54,55 Given that the AB plus D strategy for tetracycline 
synthesis had proven to be robust across a range of different carbocyclic and heterocyclic 
D-ring precursors, we questioned whether the key C-ring-forming coupling reaction 
would still be effective with new AB precursors of wide structural variability, potentially 
enabling modifications at positions on the A and B rings of tetracycline that have never 
previously been modified. The development of chemical pathways that expand our 
synthetic platform to allow efficient preparation of tetracyclines of variable composition 
at positions C5 and C5a is the subject of this thesis. 
Fully synthetic tetracyclines
with variable D-ring portions
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Scheme 2.1. Synthesis of tetracyclines by coupling of AB enone 10 with D-ring 
precursors of wide structural variability followed by deprotection. 
 
                                                 
54 (a) Charest, M. G.; Lerner, C. D.; Brubaker, J. D.; Siegel, D. R.; Myers, A. G. Science 2005, 308, 395–
398. (b) Sun, C.; Wang, Q.; Brubaker, J. D.; Wright, P. M.; Lerner, C. D.; Noson, K.; Charest, M. G.; 
Siegel, D. R.; Wang, Y.-M.; Myers, A. G. J. Am. Chem. Soc. 2008, 130, 17913–17927. 
55 (a) Clark, R. B.; He, M.; Fyfe, C.; Lofland, D.; O’Brien, W. J.; Plamondon, L.; Sutcliffe, J. A.; Xiao, X.-
Y. J. Med. Chem. 2011, 54, 1511–1528. (b) Sun, C.; Hunt, D. K.; Clark, R. B.; Lofland, D.; O’Brien, W. J.; 
Plamondon, L.; Xiao, X.-Y. J. Med. Chem. 2011, 54, 3704–3731. 
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The limitations of semisynthesis have meant that modification of C5a has not 
previously been viable. Unpublished research by W. Rogalski and R. Kirchlechner led to 
the synthesis of analogs such as racemic 6-demethyl-6-deoxy-7-chloro-5a-
methyltetracyclines, with both the natural and unnatural stereochemistry at C5a 
(compounds 14 and 15, Figure 2.2 below).57 The racemic stereoisomer with natural C5a 
stereochemistry (14) showed good activity against Gram-positive bacteria (including 
some tetracycline-resistant strains of S. aureus, in which it was more active than 
minocycline) but was completely inactive against Gram-negative organisms tested. The 
corresponding C5a-epimer 15 was less active across all strains tested but did retain poor 
activity against tetracycline-resistant Gram-positive organisms. 6-Demethyl-6-deoxy-7-
methoxy-epi-5a-methyltetracycline (compound 16, unnatural stereochemistry at C5a) was 
found to be completely inactive. 
 
Figure 2.2. Racemic, fully synthetic tetracyclines possessing methyl substituents at C5a, 
prepared by W. Rogalski and R. Kirchlechner.57 
 
To apply our general route for tetracycline synthesis to C5a-substituted analogs it 
was first necessary to develop methodology to prepare AB enones containing different E-
substituents, and then to determine if these modified AB enones would successfully 
                                                 
57 Cunha, B. A. Clinical Uses of Tetracyclines. In Handbook of Experimental Pharmacology; Hlavka, J. J. 
and Boothe, J. H., Eds.; Springer-Verlag: New York, 1985; pp 393–403. 
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undergo Michael–Claisen cyclization reactions with D-ring precursors, transformations 
that would give rise to a quaternary, stereogenic center at position C5a (Scheme 2.2). 
 
Scheme 2.2. Synthesis of fully synthetic tetracyclines with an all-carbon quaternary 
center at C5a from ȕ-substituted AB enones. 
 
The most rapid and straightforward approach to the synthesis of E-substituted AB 
enones appeared to be the direct functionalization of the AB enone 10. While 
introduction of simple alkyl groups such as E-methyl proved to be relatively 
straightforward (though low-yielding), introduction of more highly oxidized E-
substituents was less so, and provided us with the opportunity to pursue a number of 
chemical innovations. The subsequent stereocontrolled construction of the C ring, 
comprising an all-carbon quaternary center at position C5a, was viewed to be a 
challenging transformation, and its successful implementation we view to be a significant 
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advance. During the course of our investigations we also serendipitously discovered a 
C5a–C11a-bridged cyclopropane-containing tetracycline intermediate that has proven to 
be an extraordinarily versatile precursor to a diverse array of C5a-substituted 
tetracyclines, providing another avenue for the synthesis of this novel class of substituted 
tetracycline antibiotics. 
 
Results 
As a first step toward the stereocontrolled construction of all-carbon quaternary, 
C5a-substituted tetracyclines we first sought to develop methods to transform the AB 
enone 10 into ȕ-substituted AB enones as novel cyclization substrates. A conventional 
reaction sequence served for the synthesis of the simple ȕ-methyl-substituted AB enone 
18 (Scheme 2.3). Specifically, conjugate addition of lithium dimethylcuprate to the AB 
enone 10 in the presence of trimethylsilylchloride58 afforded the corresponding E-methyl-
substituted trimethylsilyl enol ether 17 in 85% yield (1D-NOESY experiments support 
the 5a-S-stereochemistry depicted, in accord with all precedent in this system);54b 
oxidation of this intermediate with palladium acetate in dimethyl sulfoxide (DMSO) at 80 
°C then afforded the ȕ-methyl-substituted AB enone 18 in modest yield (44% yield on 
160-mg scale, and 34% yield on 2.8-g scale).59,60 Attempted oxidation of the intermediate 
                                                 
58 Corey, E. J.; Boaz, N. W. Tetrahedron Lett. 1985, 26, 6019–6022. 
59 Ito, Y.; Hirao, T.; Saegusa, T. J. Org. Chem. 1978, 43, 1011–1013. 
60 The highest yield of the ȕ-methyl-substituted enone 18 was obtained when the oxidation was performed 
on a small scale (160 mg, 1.15 equiv Pd(OAc)2, DMSO, 80 °C, 16 h) and the work-up was carried out 
before the starting material had been completely consumed. Mass recovery from this reaction was 
consistently poor. 
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trimethylsilyl enol ether 17 with the alternative oxidant o-iodoxybenzoic acid (IBX) was 
not successful.61 
 
Scheme 2.3. Synthesis of ȕ-methyl-substituted AB enone 18 from the ȕ-unsubstituted AB 
enone 10. 
 
To transform the AB enone 10 into ȕ-substituted AB enones with more highly 
oxidized E-substituents we were led to explore novel chemistry, as precedented methods 
were deemed to be too indirect or were impracticable in the present application.62,63,64 
First, we developed a versatile sequence for E-functionalization of the AB enone 10 
                                                 
61 Nicolaou, K. C.; Gray, D. L. F.; Montagnon, T.; Harrison, S. T. Angew. Chem. Int. Ed. 2002, 41, 996–
1000. 
62 Enones with ester, aldehyde and alkoxymethyl substituents at the ȕ-position can be prepared indirectly 
from unsubstituted enone starting materials via ȕ-cyano-substituted enones: (a) Fukuta, Y.; Mita, T.; 
Fukuda, N.; Kanai, M.; Shibasaki, M. J. Am. Chem. Soc. 2006, 128, 6312–6313. (b) Nicolaou, K. C.; Li, A. 
Angew. Chem. Int. Ed. 2008, 47, 6579–6582. (c) Isobe, M.; Nishikawa, T.; Pikul, S.; Goto, T. Tetrahedron 
Lett. 1987, 28, 6485–6488. 
63 Though not successful in the current application (using the AB enone 10 as substrate), 
phosphoniosilylation methodology has been used to introduce ȕ-alkoxycarbonyl substituents in enone 
substrates: (a) Kim, S.; Lee, P. H.; Kim, S. S. Bull. Korean Chem Soc. 1989, 10, 218–219. (b) Kim, J. H.; 
Jung, H. K. Bull. Korean Chem Soc. 2004, 25, 1729–1732. 
64 Alternative synthetic sequences for the preparation of enones with E-alkoxymethyl and ȕ-aldehyde 
substituents from unsubstituted enone starting materials: (a) Kienzle, F.; Minder, R. E. Helv. Chim. Acta 
1976, 59, 439–452. (b) Heguaburu, V.; Schapiro, V.; Pandolfi, E. Tetrahedron Lett. 2010, 51, 6921–6923. 
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initiated by conjugate addition of the Seebach reagent tris(methylthio)methyllithium65 
(THF, –78 ĺ –45 °C) followed by trapping of the resulting enolate at –45 °C with 
chlorotrimethylsilane (Scheme 2.4 below).66,67 The corresponding E-
tris(methylthio)methyl trimethylsilyl enol ether (19) was isolated as a single stereoisomer 
(stereochemistry not determined) in 89% yield after purification by flash-column 
chromatography. We found that oxidation of the trimethylsilyl enol ether function and 
transformation of the tris(methylthio)methyl group occurred simultaneously upon 
treatment of a solution of 19 in the solvent mixture 500:1 methanol–water with an excess 
of N-bromosuccinimide (NBS, 5 equiv) at 23 °C, affording the AB enone containing a ȕ-
methyl ester substituent (20) in 85% yield. The detailed mechanism of the transformation 
of the intermediate 19 into the ȕ-substituted AB enone 20 is not known, but presumably 
involves some variation of a sequence involving D-bromination of the trimethylsilyl enol 
ether, bromonium-induced conversion of the tris(methylthio)methyl substituent into the 
corresponding methyl ester (with incorporation of one molar equivalent each of methanol 
and water), and elimination of hydrogen bromide. 
                                                 
65 (a) Seebach, D. Angew. Chem. Int. Ed. 1967, 6, 442–443. (b) Bürstinghaus, R.; Seebach, D. Chem. Ber. 
1977, 110, 841–851. (c) Gröbel, B.-T.; Seebach, D. Synthesis 1977, 357–402. (d) 
“Tris(methylthio)methane” Electronic Encyclopedia of Reagents for Organic Synthesis 2007. 
66 Other examples of conjugate addition–enolate trapping reactions of tris(methylthio)methyllithium with 
Į,ȕ-unsaturated carbonyl compounds: (a) Damon, R. E.; Schlessinger, R. H. Tetrahedron Lett. 1976, 19, 
1561–1564. (b) Mikolajczyk, M.; KielbasiĔski, P.; Wieczorek, M. W.; Blaszczyk, J.; Kolbe, A. J. Org. 
Chem. 1990, 55, 1198–1203. 
67 The regioselectivity observed upon reaction of tris(methylthio)methyllithium with Į,ȕ-unsaturated 
carbonyl compounds is substrate-dependent. For an example of a 1,2-addition reaction, see: Dailey, O. D., 
Jr.; Fuchs, P. L. J. Org. Chem. 1980, 45, 216-236. 
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Scheme 2.4. Two-step syntheses of modified AB enones with methyl ester, thioester and 
trifluoroethyl ester groups at the ȕ-position, starting from the ȕ-unsubstituted AB enone 
10. 
 
By modification of the reaction solvent we found that different esters could be 
synthesized, including active esters. For example, treatment of a solution of the 
trimethylsilyl enol ether 19 in tert-butanol with NBS (4 equiv) at 23 °C afforded the AB 
enone 21 bearing an S-methyl thioester at the ȕ-position in 82% yield (Scheme 2.4 
above).68 Alternatively, addition of NBS (5 equiv) to a solution of substrate 19 in 2,2,2-
trifluoroethanol and water (500:1 mixture) at 23 °C afforded the corresponding ȕ-
trifluoroethyl ester-substituted AB enone 22 in 87% yield. Interestingly, treatment of a 
solution of 19 in 2,2,2-trifluoroethanol (no added water) with NBS (5 equiv) afforded ȕ-
                                                 
68 Degani, I.; Dughera, S.; Fochi, R.; Gatti, A. Synthesis 1996, 4, 467–469. 
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trifluoroethyl ortho ester-substituted enone 23 as a major by-product (37% yield, Scheme 
2.5). 
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Scheme 2.5. Formation of a ȕ-trifluoroethyl ortho ester-substituted AB enone (23). 
 
In a further optimization, we found that transformation of the ȕ-unsubstituted AB 
enone 10 to the ȕ-methyl ester-substituted AB enone 20 could be achieved directly, and 
most efficiently (90% yield), in a single operation (Scheme 2.6 below). 
 
Scheme 2.6. Synthesis of the ȕ-methyl ester-substituted AB enone 20 from the ȕ-
unsubstituted AB enone 10 in a single operation. 
 
The transformations of Schemes 2.4–2.6 represent novel, direct and highly 
efficient ȕ-functionalization reactions of an enone substrate. Important foundational 
precedents include the conversion of a ȕ-cyano-substituted trimethylsilyl enol ether to the 
corresponding ȕ-cyano enone upon sequential treatment with NBS and triethylamine62a as 
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well as the original discovery that dithianes undergo oxidative hydrolysis in the presence 
of N-halosuccinimides.69 
 A related strategy was effective for the synthesis of the AB enone 25 bearing a ȕ-
carbaldehyde substituent, which in turn provided an expedient route to AB enones with ȕ-
alkoxymethyl substituents (Scheme 2.7). Thus, conjugate addition of the Corey–Seebach 
reagent 2-lithio-1,3-dithiane70 to the AB enone 10 in the presence of 
hexamethylphosphoramide (HMPA)71 at –78 °C followed by quenching of the resulting 
enolate intermediate with chlorotrimethylsilane provided the ȕ-(1,3-dithian-2-yl) 
trimethylsilyl enol ether 24 as a single stereoisomer (90% yield; stereochemistry not 
determined). Treatment of the latter product with NBS (6 equiv) in the solvent mixture 
100:1 tert-butanol–water at 23 °C afforded the ȕ-carbaldehyde AB enone 25 in 90% 
yield. Selective reduction of the aldehyde group occurred upon warming a solution of 25 
and sodium triacetoxyborohydride in benzene at 40 °C. The resulting primary alcohol 
was then protected as a methoxymethyl ether in the presence of chloromethyl methyl 
ether and N,N-diisopropylethylamine in benzene at 50 °C to afford the ȕ-
methoxymethoxymethyl AB enone 26 (85% yield over two steps). 
                                                 
69 Corey, E. J.; Erickson, B. W. J. Org. Chem. 1971, 36, 3553–3560. 
70 (a) Corey, E. J.; Seebach, D. Angew. Chem. Int. Ed. 1965, 4, 1075–1077. (b) Seebach, D.; Corey, E. J. J. 
Org. Chem. 1975, 40, 231–237. (c) Page, P. C. B.; van Niel, M. B.; Prodger, J. C. Tetrahedron 1989, 45, 
7643–7677. 
71 (a) Brown, C. A.; Yamaichi, A. J. Chem. Soc., Chem Commun. 1979, 100–101. (b) Lucchetti, J.; 
Dumont, W.; Krief, A. Tetrahedron Lett. 1979, 20, 2695–2696. (c) Mukhopadhyay, T.; Seebach, D. Helv. 
Chim. Acta 1982, 65, 385–391. 
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Scheme 2.7. Synthesis of the ȕ-methoxymethoxymethyl AB enone 26 from the AB 
enone 10 via the ȕ-carbaldehyde AB enone 25. 
 
ȕ-Methoxymethoxymethyl AB enone 26 could also be prepared in fewer steps but 
much lower (and highly variable) yield by reaction of the AB enone 10 with 
(methoxymethoxy)methyllithium (prepared in situ from tri-n-
butyl[(methoxymethoxy)methyl]stannane72 and n-butyllithium) in the presence of HMPA 
at –78 °C, trapping of the resulting enolate with chlorotrimethylsilane (affording the E-
methoxymethoxymethyl trimethylsilyl enol ether 27 in 40–55% yield), and then 
oxidation of the intermediate 27 with palladium acetate in DMSO at 50 °C (providing AB 
enone 26 in 25–52% yield; Scheme 2.8). 
                                                 
72 For preparation of tri-n-butyl[(methoxymethoxy)methyl]stannane, see: Danheiser, R. L.; Romines, K. R.; 
Koyama, H.; Gee, S. K.; Johnson, C. R.; Medich, J. R. Org. Synth. 1993, 71, 133; Org. Synth. 1998, Coll. 
Vol. 9, 704. 
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Scheme 2.8. Alternative synthesis of the ȕ-methoxymethoxymethyl AB enone 26 from 
the AB enone 10. 
 
Having established versatile methodology for the synthesis of ȕ-substituted AB 
enone substrates, we next investigated the feasibility of constructing the C ring of 
tetracyclines with an all-carbon quaternary C5a stereocenter by a Michael–Claisen 
cyclization reaction (Schemes 2.9 and 2.10). The D-ring precursor 28 was chosen for 
initial cyclization experiments. This precursor comprises the D-ring functionality of 
minocycline (8) and was known from prior research to be an effective substrate in 
Michael–Claisen cyclization reactions.54b Addition of the ȕ-methyl-substituted AB enone 
18 (1 equiv) to a bright red solution of the o-toluate ester anion formed by deprotonation 
of the minocycline D-ring precursor 28 (3 equiv) with lithium diisopropylamide (LDA, 3 
equiv) in the presence of N,N,N’,N’-tetramethylethylenediamine (TMEDA, 6 equiv) at –
78 °C, followed by warming to –10 °C, provided the Michael–Claisen cyclization 
product 29 in 80% yield as a single stereoisomer after purification by flash-column 
chromatography. A minor by-product (compound 30, 4%), thought to be the product of 
1,2-addition-cyclization (by lactonization), was isolated separately.73 
                                                 
73 Michael–Claisen cyclization product 29 was obtained in 60% yield and 1,2-addition-cyclization product 
30 was not observed when the cyclization reaction was performed without TMEDA as an additive. 
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Scheme 2.9. Stereocontrolled formation of an all-carbon quaternary center by Michael–
Claisen cyclization of an o-toluate ester anion with ȕ-methyl-substituted AB enone 18. 
 
The stereochemical assignment of the Michael–Claisen cyclization product (29), 
with C5a-R configuration, is supported by nOe studies; this stereochemistry is 
homologous with that of Michael–Claisen cyclization products derived from the non-
substituted AB enone 10.54b In both cases, addition appears to occur from a single 
diastereoface of the enone, that opposite the C12a tert-butyldimethylsilyloxy substituent. 
There are two examples in the literature of Michael–Claisen cyclization reactions of 
achiral ȕ-methyl cyclohexenones with o-toluate ester anions,74 but we are unaware of any 
examples beyond those described in this thesis of the stereocontrolled construction of a 
six-membered ring containing a quaternary center by a Michael–Claisen cyclization 
reaction. 
                                                 
74 Hill, B.; Rodrigo, R. Org. Lett. 2005, 7, 5223–5225. 
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Michael–Claisen reaction of the ȕ-methoxymethoxymethyl AB enone 26 and the 
minocycline D-ring precursor 31 (with OBn protection at C10, chosen so as to allow later 
deprotection of the methoxymethyl ether at C5a without concomitant cleavage of the C10 
phenoxy protective group) was also efficient, affording the cyclization product 32, with a 
protected C5a-hydroxymethyl-substituted quaternary center, in 72% yield (Scheme 2.10). 
Reaction of the ȕ-methyl ester AB enone 20 with the anion formed from the minocycline 
D-ring precursor 28 afforded a complex mixture of products containing the desired 
Michael–Claisen cyclization product 33 as one component. Cycloadduct 33 was isolated 
in 23% yield after purification by sequential flash-column chromatography and reverse-
phase high-performance liquid chromatography (rp-HPLC). 
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Scheme 2.10. Stereocontrolled formation of an all-carbon quaternary center by Michael–
Claisen cyclization reactions of o-toluate ester anions with ȕ-substituted AB enones. 
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Two-step deprotection of cyclization products 29 and 33 under typical 
conditions54b,75 provided C5a-methylminocycline (34, 100% yield, Scheme 2.11) and 
C5a-carbomethoxyminocycline (35, 89% yield), respectively, after purification by rp-
HPLC. 
 
Scheme 2.11. Synthesis of C5a-methylminocycline (34) and C5a-carbomethoxy-
minocycline (35) by two-step deprotection of cyclization products 29 and 33, 
respectively. 
 
In a search for a versatile branch point for the synthesis of various C5a-substituted 
tetracyclines we were led to a serendipitous but highly effective solution (Scheme 2.12). 
Removal of the methoxymethyl ether protective group within the Michael–Claisen 
cyclization product 32 was achieved by treatment with perchloric acid76 providing the 
substituted neopentyl alcohol 36 (73% yield). Addition of phosgene to a solution of 36 in 
                                                 
75 Stork, G.; Hagedorn, A. A. III. J. Am. Chem. Soc. 1978, 100, 3609–3611. 
76 Perchloric acid is a strong oxidizing agent and can form explosive mixtures. For safety information, see: 
(a) Wolsey, W. C. J. Chem. Educ. 1973, 50, A335–A337. (b) Muse, L. A. J. Chem. Educ. 1972, 49, A463–
A466. 
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dichloromethane–pyridine (10:1) at 0 °C unexpectedly afforded the C5a–C11a-bridged 
cyclopropane tetracycline precursor 37 in 81% yield. 
 
Scheme 2.12. Discovery of a C5a–C11a-bridged cyclopropane tetracycline precursor 
(37). 
 
 
Scheme 2.13. Bridged tetracycline product formed by an internal nucleophilic addition 
involving the (C11–C12) 1,3-diketone of tetracycline.77 
After the fact, the formation of cyclopropane 37 is easily rationalized. In this 
context it is interesting to note that Barton and co-workers had previously reported that 
the (C11–C12) 1,3-diketone of tetracycline can participate in an internal nucleophilic 
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addition, albeit in that case with addition to an electrophilic carbonyl group that had been 
introduced at position C4 (Scheme 2.13 above).77 
Cyclopropanes with geminal electron-withdrawing substituents are known to 
undergo nucleophilic ring-opening,78 a transformation often enhanced in the presence of 
Lewis acids.79 We were led to explore the use of magnesium salts as Lewis acid activators 
in this system in view of the well documented affinity of Mg2+ for binding to the (C11–
C12) 1,3-diketone function of tetracyclines, complexation which is critical for inhibition 
of the ribosome.56 We observed that the bridged cyclopropane intermediate 37 underwent 
regioselective ring-opening at the bridging carbon atom in the presence of various 
nucleophiles and magnesium bromide as Lewis acid (Chart 2.1). The ring-opened 
products were readily deprotected in the typical two-step sequence to furnish the 
corresponding C5a-substituted tetracyclines. For example, reaction of the C5a–C11a-
bridged cyclopropane tetracycline precursor 37 with pyrrolidine (10 equiv) in the 
presence of a stoichiometric amount of anhydrous magnesium bromide in THF at 23 °C, 
followed by direct deprotection of the crude ring-opened product (38), provided C5a-
pyrrolidinomethylminocycline (39) in 74% yield over the three steps after purification by 
rp-HPLC. 
                                                 
77 Barton, D. H. R.; Ley, S. V.; Meguro, K.; Williams, D. J. J. Chem. Soc., Chem. Commun. 1977, 790–
791. 
78 For an overview, see: “Electrophilic Cyclopropanes in Organic Synthesis” Danishefsky, S. Acc. Chem. 
Res. 1979, 12, 66–72. 
79 Examples of Lewis acid-promoted ring-opening of activated cyclopropanes: (a) Swain, N. A.; Brown, R. 
C. D.; Bruton, G. J. Org. Chem. 2004, 69, 122–129. (b) Tanimori, S.; He, M.; Nakayama, M. Synth. 
Commun. 1993, 23, 2861–2868. (c) Lifchits, O.; Charette, A. B. Org. Lett. 2008, 10, 2809–2812. 
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Chart 2.1. Fully synthetic tetracyclines prepared from the C5a–C11a-bridged 
cyclopropane intermediate 37 by magnesium bromide-promoted ring-opening followed 
by two-step deprotection. 
 
A number of different amines and alcohols were found to function effectively as 
nucleophiles in the magnesium bromide-promoted cyclopropane ring-opening reaction 
(Chart 2.1). Ring-opening reactions were typically performed with a large excess of 
nucleophile ( 7 equiv) and stoichiometric or superstoichiometric quantities of anhydrous 
magnesium bromide in THF (in the cases of low molecular weight alcohols as 
nucleophiles, the alcohol was used as solvent) at a range of temperatures (23–75 °C, see 
experimental section for details). Partial (and inconsequential) loss of the benzyl ether 
50 
 
phenolic protective group was observed to occur in the cyclopropane ring-opening 
reaction in some instances. 
The C5a–C11a-bridged cyclopropane intermediate 37 also served as a precursor 
to tetracyclines with aminomethyl (49) and piperazinylmethyl (51) substituents at 
position C5a (Scheme 2.14), highly versatile compounds which functioned as further 
branch-points for the synthesis of C5a-substituted tetracyclines (Figures 2.3 and 2.4). 
Thus, treatment of cyclopropane 37 with sodium azide in dimethylformamide at 23 °C 
afforded the azido-substituted ring-opened product 48 in 78% yield after purification by 
flash-column chromatography. Addition of trimethylphosphine (2 equiv) to a solution of 
the azide 48 and 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile (Boc-ON, 2 
equiv) in THF at –10 °C followed by warming to 23 °C afforded the corresponding tert-
butyl carbamate (51% yield).80 Two-step deprotection of the tert-butyl carbamate 
intermediate was best achieved by an inverted deprotection sequence (hydrogenolysis 
followed by treatment with hydrofluoric acid),81 providing C5a-aminomethylminocycline 
49 after purification by rp-HPLC (69% yield over two steps). In addition, magnesium 
bromide-promoted ring-opening of cyclopropane 37 with N-tert-butoxycarbamyl-
piperazine followed by deprotection of the ring-opened product 50 provided C5a-
piperazinylmethylminocycline (51, 58% yield over three steps). 
                                                 
80 Ariza, X.; Urpí, F.; Viladomat, C.; Vilarrasa, J. Tetrahedron Lett. 1998, 39, 9101–9102. 
81 The hydrogenolysis deprotection step (typically the final step) was slow and low-yielding in the presence 
of primary and secondary amines. To synthesize the amines 49 and 51 most efficiently the usual order of 
deprotection steps was reversed and the hydrogenolysis reaction was performed on substrates in which 
primary or secondary amines were protected as tert-butyl carbamates. For discussion of the inhibitory 
effects of amines on Pd-catalyzed hydrogenolysis, see: Sajiki, H.; Hirota, K. Tetrahedron 1998, 54, 13981–
13996. 
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Scheme 2.14. Synthesis of substrates for final-step diversification from cyclopropane 37. 
 
 
Figure 2.3. Selected fully synthetic tetracyclines prepared by final-step diversification of 
C5a-aminomethylminocycline (49). 
 
Final-step diversification of 49 and 51 was readily achieved, affording a range of 
novel tetracyclines with C5a substituents incorporating amides, sulfonamides and amines 
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(Figures 2.3 and 2.4). In this manner the C5a–C11a-bridged cyclopropane 37 served as a 
common precursor for the synthesis of more than 25 structural variants of minocycline 
with a diverse range of substituents at C5a. 
 
Figure 2.4. Fully synthetic tetracyclines prepared by final-step diversification of C5a-
piperazinylmethylminocycline (51). 
 
Antibacterial Activities 
 Minimum inhibitory concentrations (MICs) were determined in whole-cell 
antibacterial assays using a panel of tetracycline-sensitive and tetracycline-resistant 
Gram-positive and Gram-negative bacteria. Initial experiments were performed with 
assistance from members of the Kahne research group, and more thorough analyses of 
antibacterial activity were conducted at Tetraphase Pharmaceuticals. In summary, 
analogs of minocycline possessing angular substituents at C5a were found to be 
significantly less active than the parent compound against both Gram-positive and Gram-
negative bacteria. 
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MIC assays for C5a-methylminocycline (34), minocycline (8) and tetracycline (3) 
against tetracycline-susceptible E. coli and leaky E. coli strains are depicted in Figure 2.5 
below. Leaky E. coli has a less asymmetric and more permeable outer membrane than the 
corresponding E. coli strain due to knockout of a lipopolysaccharide gene. As discussed 
in Chapter 1, the outer membrane of Gram-negative bacteria is asymmetric and consists 
of both lipopolysaccharides and phospholipids.82 The “gel-like” nature of the 
lipopolysaccharide component makes the outer membrane a more effective permeability 
barrier than the inner membrane, and most antibacterials (including tetracyclines) 
penetrate the outer membrane predominantly by passing through aqueous channels 
provided by porin proteins. 
To determine MIC values, 96-well plates containing the bacterial strain and an 
appropriate medium were treated with different concentrations of drug molecules. Each 
pair of rows corresponds to a different small molecule and the drug concentration 
decreases uniformly across each plate (from left to right, as depicted). Following 
incubation, the wells were treated with a stain which (in the examples shown in Figure 
2.5 below) turned black in the presence of bacteria, indicating that the drug concentration 
was insufficient to prevent bacterial growth. 
                                                 
82 Nikaido, H. Microbio. Mol. Biol. Rev. 2003, 67, 593-656. 
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 Complete antibacterial activity data for C5a-substituted analogs is presented in the 
tables at the end of this chapter (pages 57–62). The C5a-modified compounds 
synthesized in this study were found to be significantly less active than minocycline (the 
parent compound) against both Gram-positive and Gram-negative bacteria. Analogs with 
smaller substituents (e.g. methyl) at C5a exhibited modest activity against some bacterial 
strains, while most of the compounds with larger substituents appended at C5a were 
almost completely inactive as antibiotics. The detrimental effect of C5a-substitution on 
activity did not seem to be dependent on the tetracycline resistance determinants 
possessed by a given bacterial strain. 
ȕ-Methyl-substituted AB enone 18 was also transformed into C5a-
methyltigecycline (54) via the four-step synthetic sequence presented in Scheme 2.15 
below. 5a-Methyltigecycline was found to have greatly reduced potency relative to 
tigecycline. Indeed, the detrimental effect on activity (C5a-methyl vs. C5a-unsubstituted) 
was even more pronounced for tigecycline than for minocycline, indicating that the 
introduction of substituents at this position diminishes (or eliminates) antibiotic activity 
regardless of the D-ring substitution pattern. 
56 
 
 
Scheme 2.15. Synthesis of C5a-methyltigecycline (54). 
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Conclusion 
Synthetic methodological advances have permitted efficient and stereocontrolled 
construction of fully synthetic tetracyclines containing an all-carbon quaternary, 
stereogenic center at position C5a, a structurally novel class of compounds in this 
important family of therapeutic agents. We anticipate that the new strategies presented 
herein for the introduction of ester, thioester and aldehyde substituents at the ȕ-position 
of cyclohexenones will be of value in many contexts. The discovery of a highly 
diversifiable bridged cyclopropane-containing tetracycline intermediate enabled efficient 
synthesis of numerous C5a-substituted tetracyclines. Although it is conceivable that 
many of these structures could also have been accessed by Michael–Claisen cyclization 
reactions of individually prepared ȕ-substituted AB enones, the discovery of a 
diversifiable late-stage intermediate greatly expedited the process of synthesis, in that a 
single Michael–Claisen cycloadduct served as a precursor to large numbers of C5a-
substituted tetracyclines. The C5a-modified analogs synthesized in this study were found 
to be significantly less active than the corresponding C5a-unsubstituted tetracyclines 
against both Gram-positive and Gram-negative bacteria. 
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Experimental Section 
General experimental procedures: All reactions were performed in round-bottom 
flasks fitted with rubber septa under a positive pressure of argon, unless otherwise noted. 
Air- and moisture-sensitive liquids were transferred via syringe or stainless steel cannula. 
Organic solutions were concentrated by rotary evaporation (house vacuum, ca. 25–40 
Torr) at ambient temperature, unless otherwise noted. Analytical thin-layer 
chromatography (TLC) was performed using glass plates pre-coated with silica gel (0.25 
mm, 60 Å pore-size, 230–400 mesh, Merck KGA) impregnated with a fluorescent 
indicator (254 nm). TLC plates were visualized by exposure to ultraviolet light, then were 
stained with either an aqueous sulfuric acid solution of ceric ammonium molybdate 
(CAM) or an aqueous sodium carbonate solution of potassium permanganate (KMnO4) 
followed by brief heating on a hot plate. Flash-column chromatography was performed as 
described by Still et al.,83 employing silica gel (60 Å, 32–63 ȝM, standard grade, 
Dynamic Adsorbents, Inc.). 
Materials: Commercial solvents and reagents were used as received with the following 
exceptions. Diisopropylamine, trimethylsilyl chloride, and hexamethylphosphoramide 
were distilled from calcium hydride under an atmosphere of argon or dinitrogen. 
Tetrahydrofuran was purified by the method of Pangborn et al.84 The molarity of n-
                                                 
83 W. C. Still, M. Khan, A. Mitra, J. Org. Chem. 1978, 43, 2923–2925. 
84 A. B. Pangborn, M. A. Giardello, R. H. Grubbs, R. K. Rosen, F. J. Timmers, Organometallics 1996, 15, 
1518–1520. 
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butyllithium solutions was determined by titration against a standard solution of 
diphenylacetic acid in tetrahydrofuran (average of three determinations).85 
Instrumentation: Proton magnetic resonance (1H NMR) spectra were recorded on 
Varian INOVA 500 (500 MHz) or 600 (600 MHz) NMR spectrometers at 23 °C. Proton 
chemical shifts are expressed in parts per million (ppm, į scale) and are referenced to 
residual protium in the NMR solvent (CHCl3, į 7.26). Data are represented as follows: 
chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet 
and/or multiple resonances, br = broad, app = apparent), integration, and coupling 
constant (J) in Hertz. Carbon nuclear magnetic resonance spectra (13C NMR) were 
recorded on Varian INOVA 500 (125 MHz) NMR spectrometers at 23 °C. Carbon 
chemical shifts are expressed in parts per million (ppm, į scale) and are referenced to the 
carbon resonances of the NMR solvent (CDCl3, į 77.0). Fluorine nuclear magnetic 
resonance spectra (19F NMR) were recorded on a Varian INOVA 400 NMR spectrometer 
at 23 °C. Infrared (IR) spectra were obtained using a Shimadzu 8400S FT-IR 
spectrometer and were referenced to a polystyrene standard. Data are represented as 
follows: frequency of absorption (cm–1), intensity of absorption (s = strong, m = medium, 
w = weak, br = broad). High-resolution mass spectra were obtained at the Harvard 
University Mass Spectrometry Facility. X-ray crystallographic analyses were performed 
at the Harvard University X-ray Crystallographic Laboratory by Dr. Shao-Liang Zheng. 
 
 
                                                 
85 W. G. Kofron, L. M. Baclawski, J. Org. Chem. 1976, 41, 18791880. 
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Minimum Inhibitory Concentration (MIC) Values. MIC values were used to 
determine the efficacy of a particular antibiotic by measuring its ability to inhibit growth 
at a range of different concentrations. A 96-well plate (Corning Costar 3596) was 
prepared by adding 100 µL of media to all wells and an additional 87.2 µL of media to 
the first column of wells. 12.8 µL of drug solution in dimethyl sulfoxide (DMSO) was 
then added to the first well of each row (2.0 mg/mL drug solution provides final 
concentration of 64 µg/mL in the first column of wells). A serial dilution was performed 
across the plate, discarding the final 100 µL of media. Cells were prepared by 
reinoculating an overnight culture into fresh lysogeny broth (LB) until they reached an 
OD600 = ~ 0.6, then by diluting the cells 100-fold in fresh LB in a media reservoir. 100 
µL of cells from the media reservoir were then added to each row of the plate. Cells were 
incubated for 24 h at 37 °C. A 1 mg/mL aqueous solution of thiazolyl blue tetrazolium 
bromide (MTT) was prepared and 50 µL of this solution was added to each well. 
Following incubation for a further 1 h, MICs were determined by measuring the first well 
that stained successfully (indicating respiration by the organism). The drug concentration 
present in the last well in which the stain did not appear provided the MIC value for a 
particular drug molecule in this bacterial strain. The MIC value for each drug was 
verified by a duplicate (two rows for each small molecule) and the growth of bacteria in 
the absence of small molecule was confirmed using a DMSO control. 
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ȕ-Methyl-substituted trimethylsilyl enol ether 17. A round-bottomed flask charged 
with copper (I) iodide (1.89 g, 9.95 mmol, 1.6 equiv) was flame-dried under high 
vacuum. After cooling to room temperature, the flask was blanketed with dry argon. 
Tetrahydrofuran (50 mL) was added and the resulting suspension was cooled to 0 °C. A 
solution of methyllithium in ethyl ether (1.6 M, 12.2 mL, 19.6 mmol, 3.15 equiv) was 
added dropwise via syringe over 5 min. The resulting solution was stirred at 0 °C for 20 
min, then was cooled to –78 °C. A solution of the AB enone 10 (3.0 g, 6.22 mmol, 1 
equiv) and chlorotrimethylsilane (1.25 mL, 9.95 mmol, 1.6 equiv) in tetrahydrofuran (10 
mL) was added to the cuprate solution dropwise via syringe at –78 °C. After stirring at –
78 °C for 90 min, the cooling bath was removed and the product solution was diluted 
with ethyl acetate (100 mL) and hexanes (100 mL). A mixture of saturated aqueous 
ammonium chloride solution and saturated aqueous ammonium hydroxide solution (19:1, 
100 mL) was then added carefully. The phases were separated and the organic phase was 
washed sequentially with saturated aqueous ammonium chloride solution (100 mL) and 
saturated aqueous sodium chloride solution (2 x 100 mL). The organic phase was dried 
over anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. The product was purified by flash-column chromatography (7% ethyl 
acetate-hexanes), providing ȕ-methyl-substituted trimethylsilyl enol ether 17 as a white 
solid (3.01 g, 85%). 
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Rf = 0.57 (15% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.48 (dd, 2H, J = 
8.0, 1.5 Hz), 7.36-7.31 (m, 3H), 5.36 (AB quartet, 2H), 4.69 (d, 1H, J = 3.0 Hz), 3.76 (d, 
1H, J = 10.0 Hz), 2.55-2.52 (m, 1H), 2.44 (s, 6H), 2.32-2.25 (m, 2H), 1.84 (d, 1H, J = 
13.5 Hz), 1.18 (d, 3H, J = 7.5 Hz), 0.87 (s, 9H), 0.22 (s, 3H), 0.11 (s, 3H), –0.04 (s, 9H); 
13C NMR (125 MHz, CDCl3) į 189.7, 181.5, 167.4, 147.2, 135.2, 128.6, 128.5, 128.4, 
110.7, 108.3, 80.7, 72.2, 61.1, 46.3, 41.9, 26.2, 26.0, 25.1, 24.0, 18.8, –0.5, –2.8, –3.6; 
FTIR (neat film), 2955 (w), 1721 (m), 1653 (w), 1614 (w), 1510 (m), 1471 (w), 1250 
(m), 1198 (m), 1148 (m), 936 (m), 833 (s) cm–1; HRMS–ESI (m/z): [M+H]+ calcd for 
C30H47N2O5Si2, 571.3018; found, 571.3041. 
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ȕ-Methyl-substituted AB enone 18.60 Palladium (II) acetate (75 mg, 0.329 mmol, 1.15 
equiv) was added to a solution of ȕ-methyl-substituted trimethylsilyl enol ether 17 (163 
mg, 0.286 mmol, 1 equiv) in anhydrous dimethyl sulfoxide (3.0 mL) at 23 °C. The 
resulting mixture was heated to 80 °C. After stirring at this temperature for 16 h, the 
reaction mixture was allowed to cool to 23 °C. The cooled suspension was diluted with 
ethyl acetate (20 mL) and the whole was filtered through a pad of Celite. Hexanes (20 
mL) were added to the filtrate and the resulting solution was washed sequentially with 
saturated aqueous sodium bicarbonate solution (20 mL) and saturated aqueous sodium 
chloride solution (2 x 20 ml). The organic phase was dried over anhydrous sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The product was 
purified by flash-column chromatography (10% ethyl acetate-hexanes), affording the ȕ-
methyl-substituted AB enone 18 as a pale yellow solid (63 mg, 44%). 
Rf = 0.26 (15% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.50 (d, 2H, J = 
7.0 Hz), 7.40-7.32 (m, 3H), 5.93 (s, 1H), 5.35 (AB quartet, 2H), 3.74 (d, 1H, J = 11.0 
Hz), 2.81-2.70 (m, 3H), 2.46 (s, 6H), 2.01 (s, 3H), 0.82 (s, 9H), 0.26 (s, 3H), 0.05 (s, 3H); 
13C NMR (125 MHz, CDCl3) į 193.1, 188.1, 181.2, 167.5, 161.2, 135.0, 128.5, 128.5, 
124.7, 108.4, 82.5, 72.5, 59.8, 47.5, 42.0, 30.4, 25.9, 24.4, 19.0, –2.5, –4.2; FTIR (neat 
film), 2930 (w), 1719 (s), 1672 (m), 1510 (m), 1472 (w), 1175 (m), 1045 (m), 936 (s), 
829 (m) cm–1; HRMS–ESI (m/z): [M+H]+ calcd for C27H37N2O5Si, 497.2466; found, 
497.2494. 
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ȕ-Tris(methylthio)methyl trimethylsilyl enol ether 19. A solution of n-butyllithium in 
hexanes (2.5 M, 518 µL, 1.30 mmol, 1.25 equiv) was added dropwise via syringe to a 
solution of tris(methylthio)methane (176 µL, 1.30 mmol, 1.25 equiv) in tetrahydrofuran 
(11 mL) at –78 °C. The resulting colorless solution was stirred at this temperature for 20 
min, whereupon a solution of the AB enone 10 (500 mg, 1.04 equiv, 1 equiv) in 
tetrahydrofuran (3.0 mL) was added dropwise via syringe, forming a bright orange-
yellow solution. The reaction solution was allowed to warm slowly to –45 °C over 60 
min, then chlorotrimethylsilane (199 µL, 1.55 mmol, 1.5 equiv) was added. The (yellow) 
reaction mixture was stirred at –45 °C for 30 min, then was partitioned between aqueous 
potassium phosphate buffer solution (pH 7.0, 0.2 M, 20 mL) and dichloromethane (30 
mL). The phases were separated and the aqueous phase was extracted with 
dichloromethane (20 mL). The organic extracts were combined and the combined 
solution was dried over anhydrous sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated, affording an orange-yellow oil. The crude product was purified 
by flash-column chromatography (6% ethyl acetate–hexanes), providing ȕ-
tris(methylthio)methyl trimethylsilyl enol ether 19 as a pale yellow foam (654 mg, 89%). 
Rf = 0.69 (20% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 7.49-7.47 (m, 2H), 
7.37-7.32 (m, 3H), 5.37 (AB quartet, 2H), 5.36 (d, 1H, J = 2.0 Hz), 4.00 (d, 1H, J = 9.3 
Hz), 3.15-3.12 (m, 1H), 2.52 (dd, 1H, J = 14.4, 4.2 Hz), 2.45 (s, 6H), 2.42-2.39 (m, 1H), 
2.18 (s, 9H), 2.14-2.06 (m, 1H), 0.86 (s, 9H), 0.22 (s, 3H), 0.12 (s, 3H), –0.01 (s, 9H); 13C 
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NMR (125 MHz, CDCl3) į 189.6, 181.6, 167.2, 150.5, 135.2, 128.6, 128.5, 128.4, 108.7, 
103.8, 81.6, 75.1, 72.2, 61.7, 46.6, 42.1, 41.7, 26.1, 21.2, 19.0, 14.1, –0.3, –2.6, –3.3; 
FTIR (neat film), 1722 (m), 1651 (w), 1614 (w), 1510 (m), 1472 (w), 1254 (m), 1206 
(w), 903 (m), 839 (s) cm–1; HRMS–ESI (m/z): [M+H]+ calcd for C33H53N2O5S3Si2, 
709.2650; found, 709.2617. 
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ȕ-Methyl ester-substituted AB enone 20. N-Bromosuccinimide (151 mg, 0.846 mmol, 
5.0 equiv) was added in one portion to a stirring solution of ȕ-tris(methylthio)methyl 
trimethylsilyl enol ether 19 (120 mg, 0.169 mmol, 1 equiv) in methanol (4.5 mL) and 
water (9.0 µL, 3.0 equiv, 500:1 mixture of methanol and water) at 23 °C. The pale yellow 
reaction solution was allowed to stir at 23 °C for 30 min, then was concentrated. The 
resulting yellow oil was dissolved in dichloromethane (20 mL) and the resulting solution 
was washed with saturated aqueous sodium bicarbonate solution (20 mL). The phases 
were separated and the aqueous phase was extracted with dichloromethane (20 mL). The 
organic extracts were combined and the combined solution was dried over anhydrous 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
crude product was purified by flash-column chromatography (11% ethyl acetate-hexanes, 
grading to 15%), providing the ȕ-methyl ester-substituted AB enone 20 as a yellow solid 
(78 mg, 85%). 
Rf = 0.26 (15% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.50 (d, 2H, J = 
6.9 Hz), 7.40-7.33 (m, 3H), 6.82 (d, 1H, J = 1.8 Hz), 5.36 (AB quartet, 2H), 3.87 (s, 3H), 
3.65 (d, 1H, J = 10.5 Hz), 3.21 (d, 1H, J = 18.8 Hz), 2.91-2.84 (m, 2H), 2.46 (s, 6H), 0.80 
(s, 9H), 0.26 (s, 3H), 0.03 (s, 3H); 13C NMR (125 MHz, CDCl3) į 194.2, 187.0, 181.1, 
167.4, 166.1, 147.1, 134.9, 131.4, 128.6, 128.5, 128.5, 108.3, 82.5, 72.6, 59.3, 52.9, 47.2, 
41.9, 25.9, 24.6, 19.0, –2.5, –4.1; FTIR (neat film), 1721 (s), 1684 (m), 1609 (w), 1510 
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(m), 1252 (m), 1173 (m), 1030 (m), 831 (m), 737 (m) cm–1; HRMS–ESI (m/z): [M+H]+ 
calcd for C28H37N2O7Si, 541.2365; found, 541.2368. 
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Single-operation synthesis of ȕ-methyl ester-substituted AB enone 20. A solution of 
n-butyllithium in hexanes (2.5 M, 104 µL, 0.259 mmol, 1.25 equiv) was added dropwise 
via syringe to a solution of tris(methylthio)methane (35.2 µL, 0.259 mmol, 1.25 equiv) in 
tetrahydrofuran (2.0 mL) at –78 °C. The resulting colorless solution was stirred at this 
temperature for 20 min, whereupon a solution of the AB enone 10 (100 mg, 0.207 mmol, 
1 equiv) in tetrahydrofuran (0.4 mL) was added dropwise via syringe, forming a bright 
orange-yellow solution. The reaction solution was allowed to warm slowly to –45 °C 
over 30 min, then chlorotrimethylsilane (39.7 µL, 0.311 mmol, 1.5 equiv) was added. 
The resulting (yellow) mixture was allowed to warm to 23 °C over 30 min, whereupon 
methanol (4.0 mL), water (8.0 µL, 2.1 equiv, 500:1 mixture of methanol and water) and 
N-bromosuccinimide (221 mg, 1.24 mmol, 6.0 equiv) were added in sequence. The 
reaction mixture was allowed to stir at 23 °C for 30 min, then was concentrated. The 
resulting oily (yellow) suspension was dissolved in dichloromethane (15 mL) and the 
resulting solution was washed with saturated aqueous sodium bicarbonate solution (15 
mL). The phases were separated and the aqueous phase was extracted with 
dichloromethane (15 mL). The organic extracts were combined and the combined 
solution was dried over anhydrous sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The crude product was purified by flash-column 
chromatography (7% acetone-hexanes), providing the ȕ-methyl ester-substituted AB 
enone 20 as a yellow solid (101 mg, 90%). 
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ȕ-S-Methyl thioester-substituted AB enone 21. N-Bromosuccinimide (48 mg, 0.271 
mmol, 4.0 equiv) was added in one portion to a stirring solution of ȕ-
tris(methylthio)methyl trimethylsilyl enol ether 19 (48 mg, 0.068 mmol, 1 equiv) in tert-
butanol (3.0 mL) at 23 °C. The resulting bright yellow suspension was allowed to stir at 
23 °C for 45 min (slowly clearing to give a yellow solution). The reaction mixture was 
diluted with dichloromethane (20 mL) and the resulting solution was washed with 
saturated aqueous sodium bicarbonate solution (20 mL). The phases were separated and 
the aqueous phase was extracted with dichloromethane (20 mL). The organic extracts 
were combined and the combined solution was dried over anhydrous sodium sulfate. The 
dried solution was filtered and the filtrate was concentrated. The crude product was 
purified by flash-column chromatography (8% ethyl acetate-hexanes), providing the ȕ-S-
methyl thioester-substituted AB enone 19 as a pale yellow solid (31 mg, 82%). 
Rf = 0.51 (20% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.51-7.50 (m, 2H), 
7.41-7.35 (m, 3H), 6.72 (d, 1H, J = 2.4 Hz), 5.36 (AB quartet, 2H), 3.70 (d, 1H, J = 10.7 
Hz), 3.30 (d, 1H, J = 19.5 Hz), 2.98-2.93 (m, 1H), 2.89 (dd, 1H, J = 10.5, 3.7 Hz), 2.49 
(s, 6H), 2.45 (s, 3H), 0.82 (s, 9H), 0.26 (s, 3H), 0.05 (s, 3H); 13C NMR (125 MHz, 
CDCl3) į 194.2, 192.9, 186.8, 181.0, 167.4, 153.2, 134.9, 128.6, 128.5, 128.5, 127.8, 
108.3, 82.6, 72.6, 59.3, 47.3, 41.9, 25.9, 25.9, 24.4, 19.0, 11.9, –2.5, –4.0; FTIR (neat 
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film), 1721 (m), 1684 (w), 1661 (w), 1510 (m), 1136 (w), 1040 (m), 937 (s), 735 (s) cm–
1; HRMS–ESI (m/z): [M+H]+ calcd for C28H37N2O6SSi, 557.2136; found, 557.2109. 
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ȕ-Trifluoroethyl ester-substituted AB enone 22. N-Bromosuccinimide (100 mg, 0.564 
mmol, 5.0 equiv) was added in one portion to a stirring solution of ȕ-
tris(methylthio)methyl trimethylsilyl enol ether 19 (80 mg, 0.113 mmol, 1 equiv) in 
2,2,2-trifluoroethanol (3.0 mL) and water (6.0 µL, 500:1 mixture of 2,2,2-trifluoroethanol 
and water) at 23 °C. The bright orange reaction solution was allowed to stir at 23 °C for 
45 min, then was concentrated. The resulting yellow oil was dissolved in 
dichloromethane (20 mL) and the resulting solution was washed with saturated aqueous 
sodium bicarbonate solution (20 mL). The phases were separated and the aqueous phase 
was extracted with dichloromethane (20 mL). The organic extracts were combined and 
the combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The crude product was purified by flash-column 
chromatography (10% ethyl acetate-hexanes), providing the ȕ-trifluoroethyl ester-
substituted AB enone 22 as a yellow solid (60 mg, 87%). 
Rf = 0.33 (15% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.50 (d, 2H, J = 
6.9 Hz), 7.41-7.35 (m, 3H), 6.90 (d, 1H, J = 2.3 Hz), 5.36 (AB quartet, 2H), 4.68-4.62 
(m, 2H), 3.65 (d, 1H, J = 11.0 Hz), 3.22 (d, 1H, J = 18.8 Hz), 2.95-2.87 (m, 2H), 2.47 (s, 
6H), 0.80 (s, 9H), 0.27 (s, 3H), 0.04 (s, 3H); 13C NMR (125 MHz, CDCl3) į 194.0, 186.7, 
181.0, 167.4, 164.1, 145.2, 134.9, 132.7, 128.6, 128.5, 128.5, 122.5 (q, J = 276.5 Hz), 
108.3, 82.4, 72.7, 61.3 (q, J = 37.5 Hz), 59.3, 47.0, 41.9, 25.9, 24.5, 18.9, –2.5, –4.1; 
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FTIR (neat film), 1742 (m), 1721 (s), 1688 (m), 1607 (w), 1510 (m), 1167 (s), 936 (s) 
cm–1; HRMS–ESI (m/z): [M+H]+ calcd for C29H36F3N2O7Si, 609.2238; found, 609.2299. 
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ȕ-Trifluoroethyl ortho ester-substituted enone 23. N-Bromosuccinimide (100 mg, 
0.564 mmol, 5.0 equiv) was added in one portion to a stirring solution of ȕ-
tris(methylthio)methyl trimethylsilyl enol ether 19 (80 mg, 0.113 mmol, 1 equiv) in 
2,2,2-trifluoroethanol (3.0 mL) at 23 °C. The bright orange reaction solution was allowed 
to stir at 23 °C for 45 min, then was concentrated. The resulting yellow oil was dissolved 
in dichloromethane (20 mL) and the resulting solution was washed with saturated 
aqueous sodium bicarbonate solution (20 mL). The phases were separated and the 
aqueous phase was extracted with dichloromethane (20 mL). The organic extracts were 
combined and the combined solution was dried over anhydrous sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated. The crude product was purified by 
flash-column chromatography (4% acetone-hexanes, grading to 6%), affording the ȕ-
trifluoroethyl ester-substituted AB enone 22 as a yellow solid (33 mg, 48%). Further 
purification by preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 
mm, UV detection at 250 nm, Solvent A: water, Solvent B: methanol, injection volume: 
10.0 mL (8.5 mL water, 1.5 mL methanol), gradient elution with 85o100% B over 40 
min, flow rate: 15.0 mL/min, fractions eluting at 27-29 min collected and concentrated] 
provided the ȕ-trifluoroethyl ortho ester-substituted enone 23 as a white solid (33 mg, 
37%). 
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Rf = 0.48 (15% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.50 (d, 2H, J = 
7.3 Hz), 7.41-7.35 (m, 3H), 6.31 (d, 1H, J = 2.3 Hz), 5.37 (s, 2H), 4.04-3.97 (m, 6H), 
3.61 (d, 1H, J = 10.5 Hz), 2.93 (d, 1H, J = 17.4 Hz), 2.87-2.82 (m, 2H), 2.46 (s, 6H), 0.84 
(s, 9H), 0.25 (s, 3H), 0.11 (s, 3H); 13C NMR (125 MHz, CDCl3) į 192.5, 186.4, 180.9, 
167.4, 151.9, 134.9, 128.6, 128.6, 128.5, 126.8, 122.9 (q, J = 277.4 Hz), 112.0, 108.3, 
82.3, 72.7, 61.3 (q, J = 36.6 Hz), 59.4, 47.4, 41.7, 25.9, 23.8, 18.9, -2.4, -3.7; FTIR (neat 
film), 1724 (m), 1688 (w), 1611 (w), 1514 (m), 1288 (s), 1175 (s) cm–1; HRMS–ESI 
(m/z): [M+H]+ calcd for C33H40F9N2O8Si, 791.2405; found, 791.2459. 
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ȕ-(1,3-Dithian-2-yl) trimethylsilyl enol ether 24. A solution of n-butyllithium in 
hexanes (2.5 M, 2.91 mL, 7.27 mmol, 1.15 equiv) was added to a solution of 1,3-dithiane 
(862 mg, 6.95 mmol, 1.1 equiv) in tetrahydrofuran (60 mL) at –78 °C. The resulting 
solution was stirred at this temperature for 30 min, at which point 
hexamethylphosphoramide (2.44 mL, 13.9 mmol, 2.2 equiv) was added dropwise. After 
stirring at –78 °C for a further 2 min, a solution of the AB enone 10 (3.05 g, 6.32 mmol, 1 
equiv) in tetrahydrofuran (15 mL) was added to the reaction solution dropwise via 
syringe. The brownish-yellow reaction mixture was stirred at –78 °C for 40 min 
whereupon chlorotrimethylsilane (1.20 mL, 9.48 mmol, 1.5 equiv) was added. After 
stirring at –78 °C for 40 min, aqueous potassium phosphate buffer solution (pH 7.0, 0.2 
M, 100 mL) was added to the reaction solution. The resulting mixture was allowed to 
warm to 23 °C, then was extracted with dichloromethane (3 x 100 mL). The organic 
extracts were combined and the combined solution was dried over anhydrous sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The product was 
purified by flash-column chromatography (8% ethyl acetate-hexanes), affording ȕ-(1,3-
dithian-2-yl) trimethylsilyl enol ether 24 as a white foam (3.85 g, 90%). 
Rf = 0.53 (30% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.48 (d, 2H, J = 
7.0 Hz), 7.38-7.31 (m, 3H), 5.36 (AB quartet, 2H), 4.98 (d, 1H, J = 3.0 Hz), 4.12 (d, 1H, 
J = 5.0 Hz), 3.89 (d, 1H, J = 9.5 Hz), 2.96-2.82 (m, 5H), 2.46 (s, 6H), 2.34-2.29 (m, 1H), 
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2.28-2.23 (m, 2H), 2.15-2.09 (m, 1H), 1.90-1.80 (m, 1H), 0.86 (s, 9H), 0.21 (s, 3H), 0.10 
(s, 3H), –0.01 (s, 9H); 13C NMR (125 MHz, CDCl3) į 189.4, 181.5, 167.3, 149.5, 135.1, 
128.7, 128.5, 128.4, 108.5, 104.8, 81.0, 72.3, 61.3, 54.9, 46.1, 41.9, 37.1, 31.1, 30.8, 26.1, 
25.7, 21.8, 18.9, –0.4, –2.7, –3.6; FTIR (neat film), cm–1 2953 (w), 1721 (s), 1653 (w), 
1614 (w), 1510 (s), 1472 (w), 1454 (w), 1254 (s), 1204 (w), 1150 (w), 1024 (w), 934 (s), 
901 (s), 835 (s); HRMS–ESI (m/z): [M+H]+ calcd for C33H51N2O5S2Si2, 675.2772; found, 
675.2783. 
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ȕ-Carbaldehyde AB enone 25. N-Bromosuccinimide (158 mg, 0.889 mmol, 6.0 equiv) 
was added in one portion to a stirring solution of ȕ-(1,3-dithian-2-yl) trimethylsilyl enol 
ether 24 (100 mg, 0.148 mmol, 1 equiv) in tert-butanol (4.0 mL) and water (40 µL) at 23 
°C. The reaction mixture was stirred at this temperature for 1 h, then was partitioned 
between dichloromethane (20 mL) and saturated aqueous sodium bicarbonate solution 
(20 mL). The phases were separated and the aqueous phase was extracted with 
dichloromethane (20 mL). The organic extracts were combined and the combined 
solution was dried over anhydrous sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The crude product was purified by flash-column 
chromatography (12% ethyl acetate-hexanes), affording the ȕ-carbaldehyde AB enone 25 
as a yellow solid (68 mg, 90%). 
Rf = 0.18 (15% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 9.82, (s, 1H), 7.50 
(d, 2H, J = 6.9 Hz), 7.41-7.35 (m, 3H), 6.66 (d, 1H, J = 2.7 Hz), 5.36 (AB quartet, 2H), 
3.58 (d, 1H, J = 11.0 Hz), 3.17 (d, 1H, J = 19.7 Hz), 2.90 (dd, 1H, J = 10.8, 4.8 Hz), 
2.77-2.71 (m, 1H), 2.44 (s, 6H), 0.78 (s, 9H), 0.27 (s, 3H), 0.05 (s, 3H); 13C NMR (125 
MHz, CDCl3) į 194.6, 193.4, 186.5, 181.2, 167.4, 152.5, 137.2, 134.9, 128.6, 128.5, 
128.5, 108.3, 83.2, 72.7, 59.4, 47.0, 41.8, 25.9, 21.5, 19.0, –2.5, –4.0; FTIR (neat film), 
1721 (m), 1694 (m), 1607 (w), 1510 (m), 1173 (w), 1036 (m), 937 (s), 737 (s) cm–1; 
HRMS–ESI (m/z): [M+H]+ calcd for C27H35N2O6Si, 511.2259; found, 511.2286. 
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ȕ-Methoxymethoxymethyl AB enone 26. Sodium triacetoxyborohydride (205 mg, 0.918 
mmol, 3.5 equiv) was added in one portion to a solution of the ȕ-carbaldehyde AB enone 
25 (134 mg, 0.262 mmol, 1 equiv) in benzene (2.0 mL) at 23 °C. The resulting solution 
was heated to 40 °C. After stirring at 40 °C for 5 ½ h, the reaction mixture was allowed 
to cool to 23 °C. The cooled solution was diluted with dichloromethane (30 mL), and the 
resulting solution was added slowly and carefully to saturated aqueous sodium 
bicarbonate solution (30 mL). The phases were separated and the aqueous phase was 
extracted with dichloromethane (30 mL). The organic extracts were combined and the 
combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. N,N-Diisopropylethylamine (229 µL, 1.31 
mmol, 5.0 equiv) and chloromethyl methyl ether (59.8 µL, 0.787 mmol, 3.0 equiv) were 
added sequentially to a solution of the crude reduction product in benzene (1.5 mL) at 23 
°C. The reaction flask was sealed and the solution was heated to 50 °C. After stirring at 
50 °C for 24 h, the reaction mixture was allowed to cool to 23 °C. The cooled solution 
was partitioned between dichloromethane (30 mL) and saturated aqueous sodium 
bicarbonate solution (30 mL). The layers were separated and the aqueous phase was 
extracted with dichloromethane (30 mL). The organic extracts were combined and the 
combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated, affording an orange oil. The product was 
purified by flash-column chromatography (15% ethyl acetate-hexanes, grading to 17% 
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ethyl acetate-hexanes), providing the ȕ-methoxymethoxymethyl AB enone 26 as a pale 
yellow solid (124 mg, 85% yield, two steps). 
Rf = 0.40 (30% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.50 (d, 2H, J = 
7.0 Hz), 7.40-7.32 (m, 3H), 6.21 (s, 1H), 5.35 (AB quartet, 2H), 4.67 (AB quartet, 2H), 
4.16 (m, 2H), 3.74 (d, 1H, J = 10.0 Hz), 3.38 (s, 3H), 2.80-2.74 (m, 3H), 2.45 (s, 6H), 
0.82 (s, 9H), 0.26 (s, 3H), 0.05 (s, 3H); 13C NMR (125 MHz, CDCl3) į 193.1, 187.7, 
181.1, 167.5, 159.7, 135.0, 128.5, 128.5, 128.5, 122.4, 108.4, 96.0, 83.0, 72.6, 68.4, 59.6, 
55.5, 47.5, 41.9, 25.9, 25.8, 19.0, –2.5, –4.1; FTIR (neat film), cm–1 2951 (w), 2930 (w), 
1719 (s), 1674 (m), 1510 (s), 1175 (m), 1152 (m), 1038 (s), 934 (s), 829 (s), 735 (s); 
HRMS–ESI (m/z): [M+H]+ calcd for C29H41N2O7Si, 557.2678; found, 557.2690. 
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Michael–Claisen cyclization product 29. A freshly prepared solution of lithium 
diisopropylamide in tetrahydrofuran (1.0 M, 1.21 mL, 1.21 mmol, 3.0 equiv) was added 
dropwise via syringe to a solution of phenyl ester 28 (449 mg, 1.21 mmol, 3.0 equiv) and 
TMEDA (365 µL, 2.42 mmol, 6.0 equiv) in tetrahydrofuran (15 mL) at –78 °C, forming a 
bright red solution.  After stirring at  –78 °C for 40 min, a solution of the ȕ-methyl-
substituted AB enone 18 (200 mg, 0.403 mmol, 1 equiv) in tetrahydrofuran (3.0 ml) was 
added to the reaction solution dropwise via syringe. The resulting mixture was allowed to 
warm slowly to –10 °C over 80 min, then was partitioned between aqueous potassium 
phosphate buffer solution (pH 7.0, 0.2 M, 60 mL) and dichloromethane (60 mL). The 
phases were separated and the aqueous phase was extracted with dichloromethane (2 × 40 
mL). The organic extracts were combined and the combined solution was dried over 
anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated, affording an orange-yellow oil. The product was purified by flash-column 
chromatography (15% ethyl acetate-hexanes, grading to 20%), providing the Michael–
Claisen cyclization product 29 as a yellow solid (249 mg, 80%). 
Rf = 0.28 (20% ethyl acetate-hexanes); 1H NMR (600 MHz, CDCl3) į 15.96 (s, 1H), 7.49 
(d, 2H, J = 7.8 Hz), 7.39-7.33 (m, 3H), 7.26-7.24 (m, 1H), 7.04 (d, 1H, J = 8.5 Hz), 5.36 
(s, 2H), 4.16 (d, 1H, J = 10.0 Hz), 3.20 (d, 1H, J = 16.1 Hz), 2.75 (d, 1H, J = 16.1 Hz), 
2.66 (s, 6H), 2.54-2.50 (m, 7H), 2.37 (d, 1H, J = 14.4 Hz), 2.16 (dd, 1H, J = 14.8, 4.5 
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Hz), 1.56 (s, 9H), 1.12 (s, 3H), 0.90 (s, 9H), 0.25 (s, 3H), 0.21 (s, 3H); 13C NMR (125 
MHz, CDCl3) į 186.8, 185.6, 181.7, 178.3, 167.6, 152.3, 150.4, 145.4, 136.4, 135.1, 
128.5, 128.4, 128.3, 124.2, 123.9, 122.3, 112.0, 108.1, 83.8, 81.7, 72.4, 60.7, 47.0, 44.2, 
41.9, 40.6, 32.4, 32.1, 29.8, 27.7, 26.4, 19.2, –1.9, –2.3; FTIR (neat film), 1759 (w), 1721 
(m), 1613 (w), 1510 (m), 1456 (w), 1265 (m), 1152 (m), 737 (s) cm–1; HRMS–ESI (m/z): 
[M+H]+ calcd for C42H55N3O9Si, 774.3780; found, 774.3796. 
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C5a-Methylminocycline (34). Concentrated aqueous hydrofluoric acid solution (48 
wt%, 2.0 mL) was added to a solution of the Michael–Claisen cyclization product 14 
(249 mg, 0.322 mmol, 1 equiv) in acetonitrile (3.0 mL) in a polypropylene reaction vessel 
at 23 °C. The reaction solution was stirred vigorously at 23 °C for 17 h, then was poured 
into water (100 mL) containing dipotassium hydrogenphosphate trihydrate (20.0 g). The 
resulting mixture was extracted with ethyl acetate (100 mL, then 2 x 50 mL). The organic 
extracts were combined and the combined solution was dried over anhydrous sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated, affording an 
orange-brown solid. Methanol (3.0 mL) and dioxane (3.0 mL) were added to the crude 
product, forming an orange-brown solution. Palladium black (13.7 mg, 0.129 mmol, 0.4 
equiv) was added in one portion at 23 °C. An atmosphere of hydrogen was introduced by 
briefly evacuating the flask, then flushing with pure hydrogen (1 atm). The reaction 
mixture was stirred at 23 °C for 1 h, then was filtered through a plug of Celite. The 
filtrate was concentrated, affording a brownish yellow solid. The product was purified by 
preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV detection 
at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: acetonitrile, 2 
batches, injection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL 
acetonitrile), gradient elution with 5o40% B over 50 min, flow rate: 7.5 mL/min]. 
Fractions eluting at 24-31 min were collected and concentrated, affording C5a-
methylminocycline trifluoroacetate 17 as a yellow solid (188 mg, 100%, two steps). 
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1H NMR (600 MHz, CD3OD, trifluoroacetate) G 7.90 (d, 1H, J = 9.4 Hz), 7.07 (d, 1H, J = 
9.4 Hz), 4.13 (d, 1H, J = 1.0 Hz), 3.25 (s, 6H), 3.17 (d, 1H, J = 15.8 Hz), 3.07-3.02 (m, 
1H), 3.04 (s, 6H), 2.80 (d, 1H, J = 15.7 Hz), 2.05 (dd, 1H, J = 13.8, 2.9 Hz), 1.93 (dd, 
1H, J = 14.1, 13.9 Hz), 1.26 (s, 3H); HRMS–ESI (m/z): [M+H]+ calcd for C24H29N3O7, 
472.2078; found, 472.2087. 
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Michael–Claisen cyclization product 33. A freshly prepared solution of lithium 
diisopropylamide in tetrahydrofuran (1.0 M, 0.416 mL, 0.416 mmol, 3.0 equiv) was 
added dropwise via syringe to a solution of phenyl ester 28 (155 mg, 0.416 mmol, 3.0 
equiv) and TMEDA (126 µL, 0.832 mmol, 6.0 equiv) in tetrahydrofuran (6 mL) at –78 
°C, forming a bright red solution. After stirring at –78 °C for 40 min, a solution of the ȕ-
methyl ester-substituted AB enone 20 (75 mg, 0.139 mmol, 1 equiv) in tetrahydrofuran 
(1.5 ml) was added to the reaction solution dropwise via syringe. The resulting mixture 
was allowed to warm slowly to –10 °C over 75 min, then was partitioned between 
aqueous potassium phosphate buffer solution (pH 7.0, 0.2 M, 25 mL) and 
dichloromethane (25 mL). The phases were separated and the aqueous phase was further 
extracted with dichloromethane (2 × 20 mL). The organic extracts were combined and the 
combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated, affording a yellow solid. The crude product was 
purified first by flash-column chromatography (15% acetone-hexanes), then by 
preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV detection 
at 350 nm, Solvent A: water, Solvent B: methanol, injection volume: 6.0 mL (5.0 mL 
methanol, 1.0 mL water), gradient elution with 85o100% B over 40 min, flow rate: 15 
mL/min]. Fractions eluting at 25-28 min were collected and concentrated, providing the 
Michael–Claisen cyclization product 33 as a yellow solid (26 mg, 23%). 
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Rf = 0.34 (25% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 15.97 (s, 1H), 7.49 
(d, 2H, J = 7.3 Hz), 7.39-7.33 (m, 3H), 7.24 (d, 1H, J = 8.3 Hz), 7.03 (d, 1H, J = 8.3 Hz), 
5.37 (s, 2H), 4.11 (d, 1H, J = 9.3 Hz), 3.84 (d, 1H, J = 16.1 Hz), 3.36 (s, 3H), 2.80 (d, 1H, 
J = 16.1 Hz), 2.67-2.64 (m, 1H), 2.64 (s, 6H), 2.57-2.53 (m, 2H), 2.51 (s, 6H), 1.57 (s, 
9H), 0.82 (s, 9H), 0.23 (s, 3H), 0.17 (s, 3H); 13C NMR (125 MHz, CDCl3) į 187.6, 186.2, 
181.5, 176.3, 175.2, 167.6, 152.4, 150.0, 145.4, 135.0, 134.2, 128.5, 128.5, 128.3, 124.6, 
124.4, 123.1, 108.0, 106.8, 83.8, 80.9, 72.5, 60.6, 52.4, 46.6, 44.2, 44.1, 41.9, 38.2, 27.7, 
26.2, 19.1, –2.1, –2.9; FTIR (neat film), 1761 (w), 1722 (m), 1512 (m), 1234 (s), 1150 
(s), 833 (m), 733 (s) cm–1; HRMS–ESI (m/z): [M+H]+ calcd for C43H56N3O11Si, 
818.3679; found, 818.3760. 
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C5a-Carbonyloxymethylminocycline (35). Concentrated aqueous hydrofluoric acid 
solution (48 wt%, 0.8 mL) was added to a solution of the HPLC-purified product 33 from 
the cyclization step above (25.0 mg, 0.031 mmol, 1 equiv) in acetonitrile (1.2 mL) in a 
polypropylene reaction vessel at 23 °C. The reaction solution was stirred vigorously at 23 
°C for 17 h, then was poured into water (30 mL) containing dipotassium 
hydrogenphosphate trihydrate (10.0 g). The resulting mixture was extracted with ethyl 
acetate (30 mL, then 2 x 20 mL). The organic extracts were combined and the combined 
solution was dried over anhydrous sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated, affording an orange solid. Palladium black (4.9 mg, 0.046 
mmol, 1.5 equiv) was added in one portion to a solution of the crude product in methanol 
(1.5 mL) and dioxane (1.5 mL) at 23 °C. An atmosphere of hydrogen was introduced by 
briefly evacuating the flask, then flushing with pure hydrogen (1 atm). The reaction 
mixture was stirred at 23 °C for 30 min, then was filtered through a plug of Celite. The 
filtrate was concentrated, affording a yellow solid. The product was purified by 
preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV detection 
at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: acetonitrile, injection 
volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL acetonitrile), gradient 
elution with 5o40% B over 50 min, flow rate: 7.5 mL/min]. Fractions eluting at 27-32 
min were collected and concentrated, affording C5a-carbomethoxyminocycline 
trifluoroacetate 35 as a yellow solid (17.1 mg, 89%). 
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1H NMR (600 MHz, CD3OD) į 7.81 (d, 1H, J = 9.2 Hz), 7.03 (d, 1H, J = 9.2 Hz), 4.14 
(s, 1H), 3.66 (d, 1H, J = 15.7 Hz), 3.61 (s, 3H), 3.14 (s, 6H), 2.97 (s, 6H), 2.87-2.83 (m, 
2H), 2.53 (dd, 1H, J = 14.3, 2.6 Hz), 2.04 (dd, 1H, J = 14.2, 14.1 Hz); HRMS–ESI (m/z): 
[M+H]+ calcd for C26H30N3O9, 516.1977; found, 516.2011. 
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Michael–Claisen cyclization product 32. A freshly prepared solution of lithium 
diisopropylamide (1.0 M, 7.86 mL, 7.86 mmol, 3.6 equiv) was added dropwise via 
syringe to a solution of phenyl ester 31 (2.84 g, 7.86 mmol, 3.6 equiv) and TMEDA (2.27 
mL, 15.1 mmol, 7.0 equiv) in tetrahydrofuran (60 mL) at –78 °C, forming a bright red 
solution. After stirring at  –78 °C for 40 min, a solution of the ȕ-methoxymethoxymethyl 
AB enone 26 (1.20 g, 2.16 mmol, 1 equiv) in tetrahydrofuran (15 mL) was added to the 
reaction solution dropwise via syringe. The resulting mixture was allowed to warm 
slowly to –10 °C over 80 min, then was partitioned between aqueous potassium 
phosphate buffer solution (pH 7.0, 0.2 M, 100 mL) and dichloromethane (100 mL). The 
phases were separated and the aqueous phase was further extracted with dichloromethane 
(2 x 75 mL). The organic extracts were combined and the combined solution was dried 
over anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated, affording an orange-yellow oil. The product was purified by flash-column 
chromatography (3.5% ethyl acetate-dichloromethane), providing the Michael–Claisen 
cyclization product 32 as a yellow solid (1.29 g, 72%). 
Rf = 0.31 (30% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 16.77 (s, 1H), 7.51 
(d, 4H, J = 8.0 Hz), 7.41-7.28 (m, 6H), 7.21 (d, 1H, J = 9.0 Hz), 6.90 (d, 1H, J = 9.0 Hz), 
5.38 (s, 2H), 5.17 (AB quartet, 2H), 4.47 (d, 1H, J = 6.5 Hz), 4.34 (d, 1H, J = 6.5 Hz), 
4.15 (d, 1H, J = 9.5 Hz), 3.78 (d, 1H, J = 16.5 Hz), 3.38 (d, 1H, J = 9.0 Hz), 3.27 (d, 1H, 
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J = 9.5 Hz), 3.12 (s, 3H), 2.63 (s, 6H), 2.65-2.58 (m, 1H), 2.51 (s, 6H), 2.51-2.41 (m, 
2H), 2.32 (dd, 1H, J = 14.5, 2.0 Hz), 0.93 (s, 9H), 0.29 (s, 3H), 0.20 (s, 3H); 13C NMR 
(125 MHz, CDCl3) į 186.9, 184.6, 183.0, 181.6, 167.7, 154.7, 145.7, 136.8, 136.1, 135.1, 
128.5, 128.4, 128.4, 128.3, 127.7, 127.0, 125.0, 120.7, 113.7, 108.1, 107.2, 96.1, 82.3, 
72.9, 72.4, 71.4, 61.1, 54.6, 46.4, 44.4, 41.9, 35.8, 34.7, 28.4, 26.5, 19.3, –2.0, –2.1; FTIR 
(neat film), 2932 (w), 1721 (s), 1611 (w), 1510 (m), 1472 (m), 1452 (m), 1269 (w), 1148 
(w), 1107 (w), 1040 (s), 1020 (s), 922 (w), 831 (s), 733 (s) cm–1; HRMS–ESI (m/z): 
[M+H]+ calcd for C46H58N3O9Si, 824.3937; found, 824.3885. 
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Substituted neopentyl alcohol 36. Perchloric acid76 (13.0 mL, 70% solution) was added 
dropwise over 5 min to a solution of the Michael–Claisen cyclization product 32 (1.04 g, 
1.26 mmol, 1 equiv) in tetrahydrofuran (130 mL) at 23 °C. After stirring at this 
temperature for 10 min, the reaction solution was slowly and carefully poured into ice-
cold saturated aqueous sodium bicarbonate solution (300 mL). The resulting mixture was 
extracted with dichloromethane (2 x 250 mL, then 50 mL). The organic extracts were 
combined and the combined solution was dried over anhydrous sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated, providing an orange-yellow oil. 
The product was purified by flash-column chromatography (55% ethyl acetate-hexanes, 
grading to 75% ethyl acetate-hexanes), affording the substituted neopentyl alcohol 36 as 
a yellow solid (720 mg, 73%). 
Rf = 0.26 (65% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 16.76 (s, 1H), 
7.53-7.49 (m, 4H), 7.41-7.28 (m, 6H), 7.22 (d, 1H, J = 9.0 Hz), 6.90 (d, 1H, J = 9.0 Hz), 
5.38 (s, 2H), 5.17 (AB quartet, 2H), 4.11 (d, 1H, J = 9.5 Hz), 3.66 (d, 1H, J = 16.0 Hz), 
3.48 (d, 1H, J = 11.0 Hz), 3.32 (d, 1H, J = 11.0 Hz), 2.64 (s, 6H), 2.68-2.59 (m, 1H), 
2.56-2.48 (m, 1H), 2.51 (s, 6H), 2.38 (dd, 1H, J = 14.5, 4.5 Hz), 2.23 (brd, 1H, J = 14.0 
Hz), 0.92 (s, 9H), 0.25 (s, 3H), 0.18 (s, 3H); 13C NMR (125 MHz, CDCl3) į 186.7, 184.7, 
182.7, 181.4, 167.7, 154.9, 145.7, 136.8, 135.9, 135.1, 128.5, 128.5, 128.5, 128.3, 127.8, 
126.9, 125.3, 120.7, 113.7, 108.2, 107.3, 82.3, 72.4, 71.4, 68.2, 61.3, 46.2, 44.7, 42.0, 
36.8, 34.5, 28.2, 26.5, 19.3, –1.8, –2.0; FTIR (neat film), 2938 (w), 1719 (m), 1609 (w), 
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1510 (s), 1452 (s), 1265 (m), 1020 (m), 829 (s), 733 (s) cm–1; HRMS–ESI (m/z): [M+H]+ 
calcd for C44H54N3O8Si, 780.3675; found,780.3654. 
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C5a–C11a-Bridged cyclopropane tetracycline precursor 37. 4Å molecular sieves (2.4 
g, small chunks) were added to a solution of the substituted neopentyl alcohol 36 (720 
mg, 0.923 mmol, 1 equiv) in dichloromethane (72 mL) and pyridine (7.2 mL) at 23 °C. 
The resulting mixture was stirred at 23 °C for 1 h, then was cooled to 0 °C. A solution of 
phosgene in toluene (20 wt%, 537 µL, 1.02 mmol, 1.1 equiv) was added dropwise to the 
cooled mixture. The resulting solution was stirred at 0 °C for 1 h, whereupon aqueous 
potassium phosphate buffer solution (pH 7.0, 0.2 M, 20 mL) was added. The resulting 
mixture was allowed to warm to 23 °C, then was filtered to remove the molecular sieves. 
Dichloromethane (60 mL) and aqueous potassium phosphate buffer solution (pH 7.0, 
0.2M, 60 mL) were added and the phases were separated. The aqueous phase was further 
extracted with dichloromethane (2 x 60 mL). The organic extracts were combined and the 
combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated, providing an orange-yellow oil. The product 
was purified by flash-column chromatography (20% ethyl acetate-hexanes, grading to 
30% ethyl acetate-hexanes), affording the C5a–C11a-bridged cyclopropane tetracycline 
precursor 37 as a white solid (572 mg, 81%). 
Rf = 0.25 (30% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.52 (d, 2H, J = 
7.3 Hz), 7.44-7.24 (m, 8H), 7.13 (d, 1H, J = 9.0 Hz), 6.86 (d, 1H, J = 9.0 Hz), 5.35 (s, 
2H), 5.05 (AB quartet, 2H), 4.01 (d, 1H, J = 10.5 Hz), 3.85 (d, 1H, J = 17.4 Hz), 2.77 (d, 
1H, J = 17.4 Hz), 2.68-2.57 (m, 3H), 2.62 (s, 6H), 2.49 (s, 6H), 2.25 (d, 1H, J = 5.0 Hz), 
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1.71 (d, 1H, J = 5.0 Hz), 0.89 (s. 9H), 0.28, (s, 3H), 0.12 (s, 3H); 13C NMR (125 MHz, 
CDCl3) į 194.4, 191.8, 185.3, 180.9, 167.6, 152.6, 144.8, 136.7, 135.0, 132.2, 128.6, 
128.5, 128.5, 128.4, 127.6, 127.1, 123.3, 123.2, 113.5, 107.9, 84.0, 72.6, 71.2, 58.8, 49.0, 
44.8, 43.1, 41.8, 32.1, 31.1, 30.9, 26.6, 26.3, 19.5, –2.0, –2.6; FTIR (neat film), 2938 (w), 
1728 (s), 1711 (m), 1670 (w), 1510 (m), 1474 (m), 1452 (m), 1362 (w), 1258 (m), 916 
(m), 827 (s), 733 (s) cm–1; HRMS–ESI (m/z): [M+H]+ calcd for C44H52N3O7Si, 762.3569; 
found,762.3569. 
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C5a-Pyrrolidinomethylminocycline (39). Anhydrous magnesium bromide (8.2 mg, 
0.045 mmol, 2.0 equiv) was added to a solution of the C5a-C11a-bridged cyclopropane 
37 (17.0 mg, 0.022 mmol, 1 equiv) and pyrrolidine (18 µL, 0.223 mmol, 10 equiv) in 
tetrahydrofuran (0.5 mL) at 23 °C. The reaction mixture was stirred at 23 °C for 16 h, 
then was partitioned between dichloromethane and saturated aqueous sodium bicarbonate 
solution (10 mL each). The phases were separated and the aqueous phase was extracted 
with dichloromethane (10 mL). The organic extracts were combined and the combined 
solution was dried over anhydrous sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The crude ring-opened product (38) was dissolved in 
acetonitrile (1.2 mL). The resulting solution was transferred to a polypropylene reaction 
vessel and concentrated aqueous hydrofluoric acid solution (48 wt%, 0.8 mL) was added. 
The reaction mixture was stirred vigorously at 23 °C for 20 h, then was poured into water 
(30 mL) containing dipotassium hydrogenphosphate (8.0 g). The resulting mixture was 
extracted with ethyl acetate (3 x 40 mL). The organic extracts were combined and the 
combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. Palladium black (5.0 mg, 0.047 mmol, 2.8 
equiv) was added in one portion to a solution of the crude product in methanol (1.0 mL) 
and dioxane (1.0 mL) at 23 °C. An atmosphere of hydrogen was introduced by briefly 
evacuating the flask, then flushing with pure hydrogen (1 atm). The reaction mixture was 
stirred at 23 °C for 1 ¼ h, then was filtered through a plug of Celite. The filtrate was 
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concentrated. The product was purified by preparative HPLC on an Agilent Prep C18 
column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, Solvent A: 0.1% trifluoroacetic 
acid in water, Solvent B: acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% 
trifluoroacetic acid in water, 1.0 mL acetonitrile), gradient elution with 5o35% B over 
50 min, flow rate: 7.5 mL/min]. Fractions eluting at 39-43 min were collected and 
concentrated, affording C5a-pyrrolidinomethylminocycline bistrifluoroacetate 39 as a 
yellow solid (12.5 mg, 74%, three steps). 
1H NMR (600 MHz, CD3OD, bistrifluoroacetate) G 7.55 (d, 1H, J = 9.0 Hz), 6.95 (d, 1H, 
J = 9.0 Hz), 4.05 (s, 1H), 3.84 (brs, 1H), 3.75-3.71 (brs, 1H), 3.73 (d, 1H, J = 14.4 Hz), 
3.62 (d, 1H, J = 16.8 Hz), 3.20 (d, 1H, J = 13.2 Hz), 3.14 (d, 1H, J = 15.0 Hz), 3.13-3.03 
(brs, 1H), 3.10 (s, 6H), 2.70 (s, 6H), 2.67 (d, 1H, J = 16.8 Hz), 2.59 (dd, 1H, J = 15.0, 3.0 
Hz), 2.50 (brs, 1H), 2.02-1.90 (m, 5H); HRMS–ESI (m/z): [M+H]+ calcd for C28H37N4O7, 
541.2657; found, 541.2684. 
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C5a-Morpholinomethylminocycline (41). Anhydrous magnesium bromide (6.3 mg, 
0.034 mmol, 2.0 equiv) was added to a solution of the C5a-C11a-bridged cyclopropane 
37 (13.0 mg, 0.017 mmol, 1 equiv) and morpholine (15 µL, 0.17 mmol, 10 equiv) in 
tetrahydrofuran (0.5 mL) at 23 °C. The reaction flask was sealed and the reaction mixture 
was heated to 55 °C. After stirring at 55 °C for 14 h, the reaction mixture was allowed to 
cool to 23 °C. The cooled mixture was partitioned between dichloromethane and 
saturated aqueous sodium bicarbonate solution (10 mL each). The phases were separated 
and the aqueous phase was further extracted with dichloromethane (10 mL). The organic 
extracts were combined and the combined solution was dried over anhydrous sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The crude ring-
opened product was dissolved in acetonitrile (1.2 mL). The resulting solution was 
transferred to a polypropylene reaction vessel and concentrated aqueous hydrofluoric acid 
solution (48 wt%, 0.8 mL) was added. The reaction mixture was stirred vigorously at 23 
°C for 16 ½ h, then was poured into water (30 mL) containing dipotassium 
hydrogenphosphate (8.0 g). The resulting mixture was extracted with ethyl acetate (3 x 
40 mL). The organic extracts were combined and the combined solution was dried over 
anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. Palladium black (5.0 mg, 0.047 mmol, 2.8 equiv) was added in one portion 
to a solution of the crude product in methanol (1.0 mL) and dioxane (1.0 mL) at 23 °C. 
An atmosphere of hydrogen was introduced by briefly evacuating the flask, then flushing 
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with pure hydrogen (1 atm). The reaction mixture was stirred at 23 °C for 1 ¾ h, then was 
filtered through a plug of Celite. The filtrate was concentrated. The product was purified 
by preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV 
detection at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: 
acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL 
acetonitrile), gradient elution with 5o25% B over 50 min, then 25o100% B over 20 
min, flow rate: 7.5 mL/min]. Fractions eluting at 49-52 min were collected and 
concentrated, affording C5a-morpholinomethylminocycline bistrifluoroacetate 41 as an 
orange-yellow solid (7.5 mg, 56%, three steps). 
1H NMR (600 MHz, CD3OD, bistrifluoroacetate) G 7.56 (d, 1H, J = 9.0 Hz), 6.95 (d, 1H, 
J = 9.0 Hz), 4.04 (s, 1H), 3.77-3.69 (m, 4H), 3.53 (d, 1H, J = 16.8 Hz), 3.24 (d, 1H, J = 
13.2 Hz), 3.18-3.14 (m, 1H), 3.08 (s, 6H), 2.99-2.94 (m, 2H), 2.88 (d, 1H, J = 15.0 Hz), 
2.81-2.72 (m, 2H), 2.74 (s, 6H), 2.62 (d, 1H, J = 16.8 Hz), 2.53 (brd, 1H, J = 14.4 Hz), 
1.92 (dd, 1H, J = 14.2, 14.0 Hz); HRMS–ESI (m/z): [M+H]+ calcd for C28H37N4O8, 
557.2606; found, 557.2611. 
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C5a-Piperidinylmethylminocycline (40). Anhydrous magnesium bromide (8.2 mg, 
0.045 mmol, 2.0 equiv) was added to a solution of the C5a–C11a-bridged cyclopropane 
37 (17.0 mg, 0.022 mmol, 1 equiv) and piperidine (22 µL, 0.223 mmol, 10 equiv) in 
tetrahydrofuran (0.5 mL) at 23 °C. The reaction mixture was stirred at 23 °C for 21 h, 
then was heated to 45 °C. After stirring at this temperature for 14 h, the reaction mixture 
was allowed to cool to 23 °C. The cooled mixture was partitioned between 
dichloromethane (15 mL) and saturated aqueous sodium bicarbonate solution (10 mL). 
The phases were separated and the aqueous phase was extracted with dichloromethane 
(10 mL). The organic extracts were combined and the combined solution was dried over 
anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. The crude ring-opened product was dissolved in acetonitrile (1.2 mL). The 
resulting solution was transferred to a polypropylene reaction vessel and concentrated 
aqueous hydrofluoric acid solution (48 wt%, 0.8 mL) was added. The reaction mixture 
was stirred vigorously at 23 °C for 13 h, then was poured into water (30 mL) containing 
dipotassium hydrogenphosphate (8.0 g). The resulting mixture was extracted with ethyl 
acetate (3 x 40 mL). The organic extracts were combined and the combined solution was 
dried over anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. Palladium black (5.0 mg, 0.047 mmol, 2.8 equiv) was added in one portion 
to a solution of the crude product in methanol (1.0 mL) and dioxane (1.0 mL) at 23 °C. 
An atmosphere of hydrogen was introduced by briefly evacuating the flask, then flushing 
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with pure hydrogen (1 atm). The reaction mixture was stirred at 23 °C for 1 ½ h, then was 
filtered through a plug of Celite. The filtrate was concentrated. The product was purified 
by preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV 
detection at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: 
acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL 
acetonitrile), gradient elution with 5o35% B over 50 min, flow rate: 7.5 mL/min]. 
Fractions eluting at 40-44 min were collected and concentrated, affording C5a-
piperidinylmethylminocycline bistrifluoroacetate 40 as a yellow solid (12.0 mg, 70%, 
three steps). 
1H NMR (600 MHz, CD3OD, bistrifluoroacetate) G 7.56 (d, 1H, J = 9.0 Hz), 6.96 (d, 1H, 
J = 9.0 Hz), 4.10 (d, 1H, J = 2.4 Hz), 3.66 (d, 1H, J = 16.8 Hz), 3.46 (d, 1H, J = 14.4 Hz), 
3.40-3.35 (brm, 1H), 3.27-3.23 (m, 1H), 3.23-3.18 (m, 1H), 3.10 (s, 6H), 3.10-3.00 (m, 
2H), 2.71 (s, 6H), 2.71-2.62 (m, 2H), 2.59 (dd, 1H, J = 15.0, 3.0 Hz), 2.02 (dd, 1H, J = 
15.1, 12.7 Hz), 1.95-1.88 (brm, 1H), 1.85-1.78 (brm, 2H), 1.72-1.61 (brm, 2H), 1.43-1.36 
(brm, 1H); HRMS–ESI (m/z): [M+H]+ calcd for C29H39N4O7, 555.2813; found, 555.2788. 
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C5a-Diethylaminomethylminocycline (42). Anhydrous magnesium bromide (7.2 mg, 
0.039 mmol, 2.0 equiv) was added to a solution of the C5a-C11a-bridged cyclopropane 
37 (15.0 mg, 0.020 mmol, 1 equiv) and diethylamine (102 µL, 0.987 mmol, 50 equiv) in 
tetrahydrofuran (0.5 mL) at 23 °C. The reaction flask was sealed and the reaction mixture 
was heated to 45 °C. After stirring at this temperature for 20 h, the reaction mixture was 
allowed to cool to room temperature. The reaction flask was opened briefly and a second 
portion of diethylamine (204 µL, 1.97 mmol, 100 equiv) was added. The flask was re-
sealed and the reaction mixture was heated to 45 °C. After stirring at this temperature for 
a further 55 h, the reaction mixture was allowed to cool to 23 °C. The cooled mixture was 
partitioned between dichloromethane and saturated aqueous sodium bicarbonate solution 
(10 mL each). The phases were separated and the aqueous phase was extracted with 
dichloromethane (10 mL). The organic extracts were combined and the combined 
solution was dried over anhydrous sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The crude ring-opened product was dissolved in acetonitrile 
(1.2 mL). The resulting solution was transferred to a polypropylene reaction vessel and 
concentrated aqueous hydrofluoric acid solution (48 wt%, 0.8 mL) was added. The 
reaction mixture was stirred vigorously at 23 °C for 10 ½ h, then was poured into water 
(30 mL) containing dipotassium hydrogenphosphate (8.0 g). The resulting mixture was 
extracted with ethyl acetate (3 x 40 mL). The organic extracts were combined and the 
combined solution was dried over anhydrous sodium sulfate. The dried solution was 
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filtered and the filtrate was concentrated. Palladium black (5.0 mg, 0.047 mmol, 2.8 
equiv) was added in one portion to a solution of the crude product in methanol (1.0 mL) 
and dioxane (1.0 mL) at 23 °C. An atmosphere of hydrogen was introduced by briefly 
evacuating the flask, then flushing with pure hydrogen (1 atm). The reaction mixture was 
stirred at 23 °C for 1 ¾ h, then was filtered through a plug of Celite. The filtrate was 
concentrated. The product was purified by preparative HPLC on an Agilent Prep C18 
column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, Solvent A: 0.1% trifluoroacetic 
acid in water, Solvent B: acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% 
trifluoroacetic acid in water, 1.0 mL acetonitrile), gradient elution with 5o40% B over 
50 min, flow rate: 7.5 mL/min]. Fractions eluting at 36-39 min were collected and 
concentrated, affording C5a-diethylaminomethylminocycline bistrifluoroacetate 42 as a 
yellow solid (12.0 mg, 79%, three steps). 
1H NMR (600 MHz, CD3OD, bistrifluoroacetate) G 7.54 (d, 1H, J = 9.0 Hz), 6.95 (d, 1H, 
J = 9.0 Hz), 4.10 (d, 1H, J = 3.0 Hz), 3.61 (d, 1H, J = 16.8 Hz), 3.42 (d, 1H, J = 15.0 Hz), 
3.25-3.20 (m, 2H), 3.16-3.02 (brm, 3H), 3.10 (s, 6H), 2.93 (brs, 1H), 2.73-2.69 (m, 1H), 
2.70 (s, 6H), 2.52 (dd, 1H, J = 15.0, 3.0 Hz), 2.07 (dd, 1H, J = 14.1, 13.3 Hz), 1.28 (brs, 
3H), 1.04 (brs, 3H); HRMS–ESI (m/z): [M+H]+ calcd for C28H39N4O7, 543.2813; found, 
543.2821. 
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C5a-N-Imidazolylmethylminocycline (43). Anhydrous magnesium bromide (7.2 mg, 
0.039 mmol, 3.0 equiv) was added to a solution of the C5a-C11a-bridged cyclopropane 
37 (10.0 mg, 0.013 mmol, 1 equiv) and imidazole (6.2 mg, 0.091 mmol, 7.0 equiv) in 
tetrahydrofuran (0.5 mL) at 23 °C. The reaction flask was sealed and the reaction mixture 
was heated to 60 °C. After stirring at this temperature for 60 h, the reaction mixture was 
allowed to cool to 23 °C. The cooled mixture was partitioned between dichloromethane 
and saturated aqueous sodium bicarbonate solution (15 mL each). The phases were 
separated and the aqueous phase was extracted with dichloromethane (15 mL). The 
organic extracts were combined and the combined solution was dried over anhydrous 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
crude ring-opened product was dissolved in acetonitrile (1.2 mL). The resulting solution 
was transferred to a polypropylene reaction vessel and concentrated aqueous hydrofluoric 
acid solution (48 wt%, 0.8 mL) was added. The reaction mixture was stirred vigorously at 
23 °C for 18 h, then was poured into water (30 mL) containing dipotassium 
hydrogenphosphate (8.0 g). The resulting mixture was extracted with ethyl acetate (3 x 
40 mL). The organic extracts were combined and the combined solution was dried over 
anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. Palladium black (5.0 mg, 0.047 mmol, 3.6 equiv) was added in one portion 
to a solution of the crude product in methanol (1.0 mL) and dioxane (1.0 mL) at 23 °C. 
An atmosphere of hydrogen was introduced by briefly evacuating the flask, then flushing 
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with pure hydrogen (1 atm). The reaction mixture was stirred at 23 °C for 1 ¼ h, then was 
filtered through a plug of Celite. The filtrate was concentrated. The product was purified 
by preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV 
detection at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: 
acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL 
acetonitrile), gradient elution with 5o40% B over 50 min, flow rate: 7.5 mL/min]. 
Fractions eluting at 25-27 min were collected and concentrated, affording C5a-
imidazolylmethylminocycline bistrifluoroacetate 43 as a yellow solid (7.3 mg, 73%, three 
steps). 
1H NMR (600 MHz, CD3OD, bistrifluoroacetate) G 8.42 (t, 1H, J = 1.3 Hz), 7.51 (d, 1H, 
J = 9.0 Hz), 7.40 (dd, 1H, J = 1.8, 1.5 Hz), 7.23 (dd, 1H, J = 1.8, 1.6 Hz), 6.86 (d, 1H, J = 
9.0 Hz), 4.48 (AB quartet, 2H), 4.13 (s, 1H), 3.42 (d, 1H, J = 16.8 Hz), 3.25 (dd, 1H, J = 
13.8, 1.2 Hz), 3.11 (s, 6H), 2.73 (s, 6H), 2.69 (d, 1H, J = 16.2 Hz), 2.14 (dd, 1H, J = 15.0, 
3.0 Hz), 1.98 (dd, 1H, J = 14.5, 14.2 Hz); HRMS–ESI (m/z): [M+H]+ calcd for 
C27H32N5O7, 538.2296; found, 538.2285. 
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C5a-Cyclopropylaminomethylminocycline (44). Anhydrous magnesium bromide (8.2 
mg, 0.045 mmol, 2.0 equiv) was added to a solution of the C5a-C11a-bridged 
cyclopropane 37 (17.0 mg, 0.022 mmol, 1 equiv) and cyclopropylamine (15 µL, 0.223 
mmol, 10 equiv) in tetrahydrofuran (0.5 mL) at 23 °C. The reaction mixture was stirred at 
23 °C for 16 h, then was heated to 40 °C. After stirring at this temperature for 22 h, the 
reaction mixture was allowed to cool to room temperature. The reaction flask was opened 
briefly and a second portion of cyclopropylamine (15 µL, 0.223 mmol, 10 equiv) was 
added. The flask was sealed and the reaction mixture was heated to 40 °C. After stirring 
at this temperature for a further 13 h, the reaction mixture was allowed to cool to 23 °C. 
The cooled mixture was partitioned between dichloromethane (15 mL) and saturated 
aqueous sodium bicarbonate solution (10 mL). The phases were separated and the 
aqueous phase was extracted with dichloromethane (10 mL). The organic extracts were 
combined and the combined solution was dried over anhydrous sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated. The crude ring-opened product 
was dissolved in acetonitrile (1.2 mL). The resulting solution was transferred to a 
polypropylene reaction vessel and concentrated aqueous hydrofluoric acid solution (48 
wt%, 0.8 mL) was added. The reaction mixture was stirred vigorously at 23 °C for 12 h, 
then was poured into water (30 mL) containing dipotassium hydrogenphosphate (8.0 g). 
The resulting mixture was extracted with ethyl acetate (3 x 40 mL). The organic extracts 
were combined and the combined solution was dried over anhydrous sodium sulfate. The 
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dried solution was filtered and the filtrate was concentrated. Palladium black (5.0 mg, 
0.047 mmol, 2.8 equiv) was added in one portion to a solution of the crude product in 
methanol (1.0 mL) and dioxane (1.0 mL) at 23 °C. An atmosphere of hydrogen was 
introduced by briefly evacuating the flask, then flushing with pure hydrogen (1 atm). The 
reaction mixture was stirred at 23 °C for 3 ½ h, then was filtered through a plug of Celite. 
The filtrate was concentrated. The product was purified by preparative HPLC on an 
Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, Solvent A: 
0.1% trifluoroacetic acid in water, Solvent B: acetonitrile, injection volume: 5.0 mL (4.0 
mL 0.1% trifluoroacetic acid in water, 1.0 mL acetonitrile), gradient elution with 5o35% 
B over 50 min, flow rate: 7.5 mL/min]. Fractions eluting at 35-36 min were collected and 
concentrated, affording C5a-cyclopropylaminomethylminocycline bistrifluoroacetate 44 
as a yellow solid (3.0 mg, 18%, three steps). 
1H NMR (600 MHz, CD3OD, bistrifluoroacetate) G 7.58 (d, 1H, J = 9.0 Hz), 6.96 (d, 1H, 
J = 9.0 Hz), 4.00 (d, 1H, J = 2.4 Hz), 3.60 (d, 1H, J = 14.4 Hz), 3.55 (d, 1H, J = 16.8 Hz), 
3.19-3.10 (m, 1H), 3.13 (s, 6H), 3.03 (d, 1H, J = 14.4 Hz), 2.76 (s, 6H), 2.76-2.70 (m, 
1H), 2.62-2.58 (m, 1H), 2.25 (dd, 1H, J = 14.8, 2.8 Hz), 1.98 (dd, 1H, J = 14.2, 13.8 Hz), 
0.89-0.82 (m, 1H), 0.77-0.69 (m, 3H); HRMS–ESI (m/z): [M+H]+ calcd for C27H35N4O7, 
527.2500; found, 527.2502. 
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C5a-Methoxymethylminocycline (45). Anhydrous magnesium bromide (9.1 mg, 0.049 
mmol, 2.5 equiv) was added to a solution of the C5a-C11a-bridged cyclopropane 37 (15.0 
mg, 0.020 mmol, 1 equiv) in methanol (1.5 mL) at 23 °C. The reaction flask was sealed 
and the reaction mixture was heated to 65 °C. After stirring at 65 °C for 24 h, the reaction 
mixture was allowed to cool to 23 °C. The cooled mixture was partitioned between 
aqueous potassium phosphate buffer solution (pH 7.0, 0.2 M, 10 mL) and 
dichloromethane (10 mL). The phases were separated and the aqueous phase was 
extracted with dichloromethane (10 mL). The organic extracts were combined and the 
combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The crude ring-opened product was dissolved in 
acetonitrile (1.2 mL). The resulting solution was transferred to a polypropylene reaction 
vessel and concentrated aqueous hydrofluoric acid solution (48 wt%, 0.8 mL) was added. 
The reaction mixture was stirred vigorously at 23 °C for 15 h, then was poured into water 
(30 mL) containing dipotassium hydrogenphosphate trihydrate (10.0 g). The resulting 
mixture was extracted with ethyl acetate (3 x 30 mL). The organic extracts were 
combined and the combined solution was dried over anhydrous sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated. Palladium black (6.0 mg, 0.057 
mmol, 2.8 equiv) was added in one portion to a solution of the crude product in methanol 
(1.0 mL) and dioxane (1.0 mL) at 23 °C. An atmosphere of hydrogen was introduced by 
briefly evacuating the flask, then flushing with pure hydrogen (1 atm). The reaction 
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mixture was stirred at 23 °C for 2 ½ h, then was filtered through a plug of Celite. The 
filtrate was concentrated. The product was purified by preparative HPLC on an Agilent 
Prep C18 column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, Solvent A: 0.1% 
trifluoroacetic acid in water, Solvent B: acetonitrile, injection volume: 7.0 mL (6.0 mL 
0.1% trifluoroacetic acid in water, 1.0 mL acetonitrile), gradient elution with 5o40% B 
over 50 min, flow rate: 7.5 mL/min]. Fractions eluting at 29-33 min were collected and 
concentrated, affording C5a-methoxymethylminocycline trifluoroacetate 45 as a yellow 
solid (7.1 mg, 58%, three steps). 
1H NMR (600 MHz, CD3OD, hydrochloride) G 7.82 (d, 1H, J = 9.4 Hz), 7.05 (d, 1H, J = 
9.2 Hz), 4.15 (s, 1H), 3.49 (d, 1H, J = 10.3 Hz), 3.36 (d, 1H, J = 15.6 Hz), 3.25 (s, 3H), 
3.14 (s, 6H), 3.12 (d, 1H, J = 10.3 Hz), 3.08-3.04 (m, 1H), 2.99 (s, 6H), 2.56 (d, 1H, J = 
15.6 Hz), 2.41 (dd, 1H, J = 14.1, 2.9 Hz), 1.69 (dd, 1H, J = 14.1, 13.9 Hz); HRMS–ESI 
(m/z): [M+H]+ calcd for C25H32N3O8, 502.2184; found, 502.2186.  
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C5a-n-Butoxymethylminocycline (46). Anhydrous magnesium bromide (7.2 mg, 0.039 
mmol, 2.0 equiv) was added to a solution of the C5a-C11a-bridged cyclopropane 37 (15.0 
mg, 0.020 mmol, 1 equiv) in n-butanol (1.0 mL) at 23 °C. The resulting mixture was 
heated to 75 °C. After stirring at 75 °C for 14 h, the reaction mixture was allowed to cool 
to 23 °C. The cooled mixture was partitioned between aqueous potassium phosphate 
buffer solution (pH 7.0, 0.2 M, 10 mL) and dichloromethane (10 mL). The phases were 
separated and the aqueous phase was extracted with dichloromethane (10 mL). The 
organic extracts were combined and the combined solution was dried over anhydrous 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
crude ring-opened product was dissolved in acetonitrile (1.2 mL). The resulting solution 
was transferred to a polypropylene reaction vessel and concentrated aqueous hydrofluoric 
acid solution (48 wt%, 0.8 mL) was added. The reaction mixture was stirred vigorously at 
23 °C for 13 ½ h, then was poured into water (30 mL) containing dipotassium 
hydrogenphosphate (8.0 g). The resulting mixture was extracted with ethyl acetate (3 x 
40 mL). The organic extracts were combined and the combined solution was dried over 
anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. Palladium black (5.0 mg, 0.047 mmol, 2.4 equiv) was added in one portion 
to a solution of the crude product in methanol (1.0 mL) and dioxane (1.0 mL) at 23 °C. 
An atmosphere of hydrogen was introduced by briefly evacuating the flask, then flushing 
with pure hydrogen (1 atm). The reaction mixture was stirred at 23 °C for 3 ¾ h, then was 
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filtered through a plug of Celite. The filtrate was concentrated. The product was purified 
by preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV 
detection at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: 
acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL 
acetonitrile), gradient elution with 5o40% B over 50 min, flow rate: 7.5 mL/min]. 
Fractions eluting at 41-44 min were collected and concentrated, affording C5a-n-
butoxymethylminocycline trifluoroacetate 46 as a yellow solid (7.3 mg, 56%, three 
steps). 
1H NMR (600 MHz, CD3OD, trifluoroacetate) G 7.81 (d, 1H, J = 9.0 Hz), 7.04 (d, 1H, J = 
9.6 Hz), 4.16 (s, 1H), 3.50 (d, 1H, J = 10.2 Hz), 3.38-3.30 (m, 3H), 3.21 (d, 1H, J = 9.6 
Hz), 3.13 (s, 6H), 3.11-3.06 (m, 1H), 2.98 (s, 6H), 2.58 (d, 1H, J = 15.6 Hz), 2.42 (dd, 
1H, J = 13.8, 3.0 Hz), 1.71 (dd, 1H, J = 13.9, 13.8 Hz), 1.50-1.39 (m, 2H), 1.34-1.24 (m, 
2H), 0.87 (t, 3H, J = 7.2 Hz); HRMS–ESI (m/z): [M+H]+ calcd for C28H38N3O8, 
544.2653; found, 544.2655. 
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C5a-Methoxyethoxymethylminocycline (47). Anhydrous magnesium bromide (6.2 mg, 
0.034 mmol, 2.0 equiv) was added to a solution of the C5a-C11a-bridged cyclopropane 
37 (13.0 mg, 0.017 mmol, 1 equiv) in 2-methoxyethanol (0.5 mL) at 23 °C. The resulting 
mixture was heated to 60 °C. After stirring at 60 °C for 26 h, the reaction mixture was 
allowed to cool to 23 °C. The cooled mixture was partitioned between aqueous potassium 
phosphate buffer solution (pH 7.0, 0.2 M, 10 mL) and dichloromethane (10 mL). The 
phases were separated and the aqueous phase was further extracted with dichloromethane 
(10 mL). The organic extracts were combined and the combined solution was dried over 
anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. The crude ring-opened product was dissolved in acetonitrile (1.2 mL). The 
resulting solution was transferred to a polypropylene reaction vessel and concentrated 
aqueous hydrofluoric acid solution (48 wt%, 0.8 mL) was added. The reaction mixture 
was stirred vigorously at 23 °C for 10 ½ h, then was poured into water (30 mL) 
containing dipotassium hydrogenphosphate (8.0 g). The resulting mixture was extracted 
with ethyl acetate (3 x 40 mL). The organic extracts were combined and the combined 
solution was dried over anhydrous sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. Palladium black (5.0 mg, 0.047 mmol, 2.8 equiv) was added in 
one portion to a solution of the crude product in methanol (1.0 mL) and dioxane (1.0 mL) 
at 23 °C. An atmosphere of hydrogen was introduced by briefly evacuating the flask, then 
flushing with pure hydrogen (1 atm). The reaction mixture was stirred at 23 °C for 1 ¾ h, 
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then was filtered through a plug of Celite. The filtrate was concentrated. The product was 
purified by preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, 
UV detection at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: 
acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL 
acetonitrile), gradient elution with 5o40% B over 50 min, flow rate: 7.5 mL/min]. 
Fractions eluting at 32-34 min were collected and concentrated, affording C5a-
methoxyethoxymethylminocycline trifluoroacetate 47 as a yellow solid (5.8 mg, 52%, 
three steps). 
1H NMR (600 MHz, CD3OD, trifluoroacetate) G 7.83 (d, 1h, J = 9.0 Hz), 7.05 (d, 1H, J = 
9.0 Hz), 4.13 (s, 1H), 3.54-3.45 (m, 4H), 3.44-3.40 (m, 1H), 3.34 (d, 1H, J = 15.6 Hz), 
3.27-3.25 (m, 1H), 3.26 (s, 3H), 3.18 (s, 6H), 3.11 (brd, 1H, J = 14.4. Hz), 2.99 (s, 6H), 
2.61 (d, 1H, J = 16.2 Hz), 2.45 (dd, 1H, J = 14.4, 3.0 Hz), 1.71 (t, 1H, J = 14.4 Hz); 
HRMS–ESI (m/z): [M+H]+ calcd for C27H36N3O9, 546.2446; found, 546.2459. 
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Azido ring-opened product 48. Sodium azide (50.0 mg, 0.763 mmol, 3.0 equiv) was 
added to a solution of the C5a-C11a-bridged cyclopropane 37 (194 mg, 0.255 mmol, 1 
equiv) in dimethylformamide (7.5 mL) at 23 °C. The resulting solution was stirred at this 
temperature for 14 h, then was partitioned between saturated aqueous sodium chloride 
solution and diethyl ether (60 mL each). The phases were separated and the aqueous 
phase was further extracted with diethyl ether (60 mL). The organic extracts were 
combined and the combined solution was dried over anhydrous sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated. The product was purified by flash-
column chromatography (12% ethyl acetate-hexanes), providing the azido-substituted 
ring-opened product 48 as a yellow solid (160 mg, 78%).  
= 0.41 (30% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 16.72 (s, 1H), 7.51 
(brd, 4H, J = 8.0 Hz), 7.41-7.26 (m, 7H), 6.95 (d, 1H, 8.5 Hz), 5.38 (s, 2H), 5.18 (AB 
quartet, 2H), 4.11 (d, 1H, J = 10.5 Hz), 3.72 (d, 1H, J = 16.5 Hz), 3.30 (d, 1H, J = 11.5 
Hz), 3.13 (d, 1H, J = 11.5 Hz), 2.65 (s, 6H), 2.65-2.45 (m, 2H), 2.51 (s, 6H), 2.35-2.25 
(m, 2H), 0.92 (s, 9H), 0.27 (s, 3H), 0.19 (s, 3H); 13C NMR (125 MHz, CDCl3) į 186.5, 
184.0, 183.6, 181.5, 167.7, 154.9, 145.9, 136.7, 135.3, 135.0, 128.5, 128.5, 128.5, 128.4, 
127.9, 127.0, 125.8, 120.2, 114.0, 108.3, 107.3, 82.3, 72.5, 71.5, 61.1, 59.1, 46.6, 44.6, 
41.9, 36.4, 35.2, 28.3, 26.5, 19.3, -1.9, -2.1; FTIR (neat film), 2099 (s), 1721 (s), 1609 
(m), 1510 (s), 1258 (m), 829 (s) cm–1; HRMS–ESI (m/z): [M+H]+ calcd for 
C44H53N6O7Si, 805.3740; found, 805.3722. 
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C5a-Aminomethylminocycline (49).80 A solution of trimethylphospine in 
tetrahydrofuran (1.0 M, 398 µL, 0.398 mmol, 2.0 equiv) was added dropwise via syringe 
to a solution of the azido-substituted ring-opened product 48 (160 mg, 0.199 mmol, 1 
equiv) and 2-(tert-butoxycarbonyloxyimino)-2-phenylacetonitrile (98.0 mg, 0.398 mmol, 
2.0 equiv) in tetrahydrofuran at –10 °C. The reaction mixture was allowed to warm to 23 
°C over 15 min. After stirring at this temperature for 15 h, the product solution was 
partitioned between dichloromethane and water (60 mL each). The phases were separated 
and the organic phase was washed sequentially with water (60 mL) and saturated aqueous 
sodium chloride solution (2 x 60 mL). The organic solution was then dried over 
anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. The product was purified by flash-column chromatography (25% ethyl 
acetate-hexanes), providing the desired tert-butyl carbamate as a yellow solid (90 mg, 
51%). Methanol (2.5 mL) and dioxane (2.5 mL) were added to this product, forming a 
yellow solution. Palladium black (25 mg, 0.235 mmol, 2.3 equiv) was added in one 
portion at 23 °C. An atmosphere of hydrogen was introduced by briefly evacuating the 
flask, then flushing with pure hydrogen (1 atm). The reaction mixture was stirred at 23 °C 
for 1 h, whereupon more palladium black (25 mg) was added. The resulting mixture was 
stirred at 23 °C for a further 2 h, then was filtered through a plug of Celite. The filtrate 
was concentrated, providing an orange solid. Concentrated aqueous hydrofluoric acid (48 
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wt%, 1.4 mL) was added to a solution of the crude product in acetonitrile (2.0 mL) in a 
polypropylene reaction vessel at 23 °C. The reaction mixture was stirred vigorously at 23 
°C for 15 h. Excess hydrofluoric acid was quenched by the careful addition of 
methoxytrimethylsilane (9.0 mL). The resulting mixture was concentrated. The product 
was purified by preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 
mm, UV detection at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: 
acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL 
acetonitrile), gradient elution with 5o40% B over 50 min, flow rate: 7.5 mL/min]. 
Fractions eluting at 22-27 min were collected and concentrated, affording C5a-
aminomethylminocycline bistrifluoroacetate 49 as a yellow solid (50 mg, 69%, two 
steps). 
1H NMR (500 MHz, CD3OD, bistrifluoroacetate) G 7.88 (d, 1H, J = 9.0 Hz), 7.10 (d, 1H, 
J = 9.0 Hz), 4.09 (d, 1H, J = 2.5 Hz), 3.60 (d, 1H, J = 17.0 Hz), 3.34 (d, 1H, J = 14.5 Hz), 
3.18 (s, 6H), 3.16 (s, 6H), 3.20-3.14 (m, 1H), 3.02 (d, 1H, J = 14.5 Hz), 2.95 (d, 1H, J = 
17.0 Hz), 2.33 (dd, 1H, J = 15.0, 3.0 Hz), 1.96 (dd, 1H, J = 14.6, 13.7 Hz); HRMS–ESI 
(m/z): [M+H]+ calcd for C24H31N4O7, 487.2187; found 487.2181. 
  
121 
 
 
C5a-Piperazinylmethylminocycline (51). Anhydrous magnesium bromide (51.0 mg, 
0.276 mmol, 2.0 equiv) was added to a solution of the C5a-C11a-bridged cyclopropane 
37 (105 mg, 0.138 mmol, 1 equiv) and tert-butyl 1-piperazine carboxylate (186 mg, 1.00 
mmol, 7.2 equiv) in tetrahydrofuran (2.0 mL) at 23 °C. The reaction flask was sealed and 
the reaction mixture was heated to 45°C. After stirring at 45 °C for 36 h, the reaction 
mixture was allowed to cool to 23 °C. The cooled mixture was partitioned between 
dichloromethane and saturated aqueous sodium bicarbonate solution (25 mL each). The 
phases were separated and the aqueous phase was extracted with dichloromethane (25 
mL). The organic extracts were combined and the combined solution was dried over 
anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. The product mixture was filtered through a short pad of silica gel (eluting 
with 40% ethyl acetate-hexanes) and the filtrate was concentrated, affording an orange-
yellow oil. Methanol (2.5 mL) and dioxane (2.5 mL) were added to the crude ring-opened 
product (50), forming an orange-yellow solution. Palladium black (25 mg, 0.235 mmol, 
1.7 equiv) was added in one portion at 23 °C. An atmosphere of hydrogen was introduced 
by briefly evacuating the flask, then flushing with pure hydrogen (1 atm). The reaction 
mixture was stirred at 23 °C for 2 h, then was filtered through a plug of Celite. The 
filtrate was concentrated, providing an orange solid. Concentrated aqueous hydrofluoric 
acid (48 wt%, 1.5 mL) was added to a solution of the crude product in acetonitrile (2.0 
mL) in a polypropylene reaction vessel at 23 °C. The reaction mixture was stirred 
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vigorously at 23 °C for 14 h. Excess hydrofluoric acid was quenched by the careful 
addition of methoxytrimethylsilane (10.0 mL). The resulting mixture was concentrated. 
The product was purified by preparative HPLC on an Agilent Prep C18 column [10 µm, 
250 x 21.2 mm, UV detection at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, 
Solvent B: acetonitrile, 2 batches, injection volume (for each batch): 5.0 mL (4.0 mL 
0.1% trifluoroacetic acid in water, 1.0 mL acetonitrile), gradient elution with 5o35% B 
over 50 min, flow rate: 7.5 mL/min]. Fractions eluting at 22-29 min were collected and 
concentrated, affording C5a-piperazinylmethylminocycline bistrifluoroacetate 51 as a 
yellow solid (63 mg, 58%, three steps). 
1H NMR (600 MHz, CD3OD, bistrifluoroacetate) G 7.58 (d, 1H, J = 9.6 Hz), 6.93 (d, 1H, 
J = 9.0 Hz), 4.06 (s, 1H), 3.44 (d, 1H, J = 16.2 Hz), 3.11 (brd, 1H, J = 12.6 Hz), 3.08-
3.02 (m, 2H), 3.05 (s, 6H), 3.01-2.95 (m, 2H), 2.82 (s, 6H), 2.61-2.56 (m, 3H), 2.50 (d, 
1H, J = 16.2 Hz), 2.48-2.42 (m, 3H), 2.20 (dd, 1H, J = 13.8, 3.0 Hz), 1.74 (dd, 1H, J = 
14.1, 13.9 Hz); HRMS–ESI (m/z): [M+H]+ calcd for C28H38N5O7, 556.2766; found, 
556.2771. 
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C5a-N-Acetylaminomethylminocycline (52). Acetyl chloride (0.9 µL, 0.013 mmol, 2.3 
equiv) was added to a solution of C5a-aminomethylminocycline bistrifluoroacetate (49, 
4.0 mg, 0.0056 mmol, 1 equiv) and N,N-diisopropylethylamine (4.6 µL, 0.027 mmol, 4.8 
equiv) in methanol (200 µL) at 0 °C. The resulting solution was allowed to warm to 23 
°C over 5 min. The reaction mixture was stirred at this temperature for 1 h, then was 
concentrated. The product was purified by preparative HPLC on an Agilent Prep C18 
column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, Solvent A: 0.1% trifluoroacetic 
acid in water, Solvent B: acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% 
trifluoroacetic acid in water, 1.0 mL acetonitrile), gradient elution with 5o40% B over 
50 min, flow rate: 7.5 mL/min]. Fractions eluting at 25-28 min were collected and 
concentrated, affording C5a-N-acetylaminomethylminocycline trifluoroacetate 52 as a 
yellow solid (3.2 mg, 89%). 
1H NMR (600 MHz, CD3OD, trifluoroacetate) G 7.80 (d, 1H, J = 9.0 Hz), 7.03 (d, 1H, J = 
9.0 Hz), 3.89 (s, 1H), 3.46 (d, 1H, J = 14.4 Hz), 3.27 (d, 1H, J = 13.8 Hz), 3.23 (d, 1H, J 
= 16.8 Hz), 3.15-3.08 (m, 13H), 2.63 (d, 1H, J = 16.2 Hz), 2.11 (dd, 1H, J = 14.4, 2.4 
Hz), 1.91 (s, 3H), 1.69 (t, 1H, J = 14.4 Hz); HRMS–ESI (m/z): [M+H]+ calcd for 
C26H33N4O8, 529.2293; found 529.2299. 
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C5a-N-Methanesulfonylaminomethylminocycline (55). Methanesulfonic anhydride 
(2.3 mg, 0.013 mmol, 2.3 equiv) was added to a solution of C5a-
aminomethylminocycline bistrifluoroacetate (49, 4.0 mg, 0.0056 mmol, 1 equiv) and 
N,N-diisopropylethylamine (4.6 µL, 0.027 mmol, 4.8 equiv) in methanol (200 µL) at 23 
°C. The reaction mixture was stirred at this temperature for 2 h, then was concentrated. 
The product was purified by preparative HPLC on an Agilent Prep C18 column [10 µm, 
250 x 21.2 mm, UV detection at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, 
Solvent B: acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in 
water, 1.0 mL acetonitrile), gradient elution with 5o40% B over 50 min, flow rate: 7.5 
mL/min]. Fractions eluting at 28-30 min were collected and concentrated, affording C5a-
N-methanesulfonylaminomethyl-minocycline trifluoroacetate 55 as a yellow solid (1.5 
mg, 39%). 
1H NMR (600 MHz, CD3OD, trifluoroacetate) G 7.77 (d, 1H, J = 9.0 Hz), 7.01 (d, 1H, J = 
9.0 Hz), 3.91 (s, 1H), 3.34 (d, 1H, J = 16.2 Hz), 3.26-3.21 (m, 2H), 3.08 (s, 6H), 3.03 (s, 
6H), 2.99 (d, 1H, J = 13.8 Hz), 2.86 (s, 3H), 2.60 (d, 1H, J = 16.2 Hz), 2.35 (dd, 1H, J = 
14.4, 3.0 Hz), 1.70 (t, 1H, J = 14.4 Hz); HRMS–ESI (m/z): [M+H]+ calcd for 
C25H32N4O9S, 565.1963; found 565.1973. 
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C5a-N-Methoxyacetylaminomethylminocycline (56). Methoxyacetyl chloride (1.2 µL, 
0.013 mmol, 2.3 equiv) was added to a solution of C5a-aminomethylminocycline 
bistrifluoroacetate (49, 4.0 mg, 0.0056 mmol, 1 equiv) and N,N-diisopropylethylamine 
(4.6 µL, 0.027 mmol, 4.8 equiv) in methanol (200 µL) at 23 °C. The reaction mixture was 
stirred at this temperature for 2 h, then was concentrated. The product was purified by 
preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV detection 
at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: acetonitrile, injection 
volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL acetonitrile), gradient 
elution with 5o40% B over 50 min, flow rate: 7.5 mL/min]. Fractions eluting at 28-30 
min were collected and concentrated, affording C5a-N-methoxyacetylaminomethyl-
minocycline trifluoroacetate 56 as a yellow solid (2.0 mg, 53%). 
1H NMR (600 MHz, CD3OD, trifluoroacetate) G 7.75 (d, 1H, J = 9.0 Hz), 7.00 (d, 1H, J = 
9.0 Hz), 3.92 (s, 1H), 3.84 (AB quartet, 2H, J = 15.0 Hz, ǻȞ = 10.2 Hz), 3.59 (d, 1H, J = 
14.4 Hz), 3.40 (s, 3H), 3.32-3.28 (m, 1H), 3.27 (d, 1H, J = 15.6 Hz), 3.10 (s, 6H), 3.10-
3.07 (m, 1H), 3.03 (s, 6H), 2.58 (d, 1H, J = 16.2 Hz), 2.09 (dd, 1H, J = 14.4, 3.0 Hz), 
1.69 (t, 1H, J = 13.8 Hz); HRMS–ESI (m/z): [M+H]+ calcd for C27H34N4O9, 559.2399; 
found 559.2435. 
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C5a-N-Trimethylacetylaminomethylminocycline (57). Trimethylacetyl chloride (1.6 
µL, 0.013 mmol, 2.3 equiv) was added to a solution of C5a-aminomethylminocycline 
bistrifluoroacetate (49, 4.0 mg, 0.0056 mmol, 1 equiv) and N,N-diisopropylethylamine 
(4.6 µL, 0.027 mmol, 4.8 equiv) in methanol (200 µL) at 23 °C. The reaction mixture was 
stirred at this temperature for 1 ½ h, then was concentrated. The product was purified by 
preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV detection 
at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: acetonitrile, injection 
volume: 5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL acetonitrile), gradient 
elution with 5o40% B over 50 min, flow rate: 7.5 mL/min]. Fractions eluting at 38-40 
min were collected and concentrated, affording C5a-N-
trimethylacetylaminomethylminocycline trifluoroacetate 57 as a yellow solid (3.0 mg, 
78%). 
1H NMR (600 MHz, CD3OD, trifluoroacetate) G 7.73 (d, 1H, J = 9.0 Hz), 6.99 (d, 1H, J = 
9.6 Hz), 3.92 (s, 1H), 3.54 (d, 1H, J = 14.4 Hz), 3.30-3.25 (m, 2H), 3.11 (s, 6H), 3.06-
3.00 (m, 1H), 3.03 (s, 6H), 2.59 (d, 1H, J = 16.2 Hz), 2.03 (dd, 1H, J = 14.4, 3.0 Hz), 
1.71 (t, 1H, J = 14.4 Hz), 1.11 (s, 9H); HRMS–ESI (m/z): [M+H]+ calcd for C29H39N4O8, 
571.2762; found 571.2771. 
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C5a-N-Benzoylaminomethylminocycline (58). Benzoyl chloride (1.5 µL, 0.013 mmol, 
2.3 equiv) was added to a solution of C5a-aminomethylminocycline bistrifluoroacetate 
(49, 4.0 mg, 0.0056 mmol, 1 equiv) and N,N-diisopropylethylamine (4.6 µL, 0.027 mmol, 
4.8 equiv) in methanol (200 µL) at 23 °C. The reaction mixture was stirred at this 
temperature for 1 ½ h, then was concentrated. The product was purified by preparative 
HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, 
Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: acetonitrile, injection volume: 
5.0 mL (4.0 mL 0.1% trifluoroacetic acid in water, 1.0 mL acetonitrile), gradient elution 
with 5o40% B over 50 min, flow rate: 7.5 mL/min]. Fractions eluting at 38-40 min were 
collected and concentrated, affording C5a-N-benzoylaminomethylminocycline 
trifluoroacetate 58 as a yellow solid (1.6 mg, 41%). 
1H NMR (600 MHz, CD3OD, trifluoroacetate) G 7.75 (d, 2H, J = 7.2 Hz), 7.70 (d, 1H, J = 
9.6 Hz), 7.54 (t, 1H, J = 7.8 Hz), 7.45 (t, 2H, J = 7.8 Hz), 6.95 (d, 1H, J = 9.0 Hz), 3.94 
(s, 1H), 3.74 (d, 1H, J = 14.4 Hz), 3.37 (d, 1H, J = 15.6 Hz), 3.36-3.27 (m, 2H), 3.13 (s, 
6H), 3.02 (s, 6H), 2.63 (d, 1H, J = 16.2 Hz), 2.21 (dd, 1H, J = 14.4, 2.4 Hz), 1.76 (t, 1H, J 
= 14.4 Hz); HRMS–ESI (m/z): [M+H]+ calcd for C31H35N4O8, 591.2449; found 591.2459. 
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Chapter 3 
Synthesis of C5-Substituted Tetracyclines 
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Introduction 
Oxytetracycline (2, Scheme 3.1) is the only naturally-occurring tetracycline with 
substitution at C5.86 Methacycline (65) and doxycycline (7), semisynthetic tetracycline 
antibiotics which are derived from oxytetracycline, retain the C5 hydroxyl substituent 
found in the natural product. The synthesis of methacycline is presented in Scheme 3.1 
below. Treatment of oxytetracycline with N-chlorosuccinimide (NCS) in 50% aqueous 
1,2-dimethoxyethane in the presence of triethylamine affords chlorinated product 63.87 
The 11a-chloro substituent prevents formation of anhydrotetracyclines (which contain an 
aromatic C ring) in subsequent steps. Exocyclic dehydration of 63 in the presence of 
anhydrous hydrogen fluoride provides exo-methylene 64, which is then converted into 
methacycline (65) upon reductive removal of the 11a-chloro substituent with sodium 
hydrosulfite. Doxycycline (7) was originally isolated from the mixture of products 
obtained by palladium-catalyzed hydrogenolysis of oxytetracycline. It is now prepared on 
an industrial scale by hydrogenation of methacycline (65) in the presence of a rhodium 
metal complex (Scheme 3.2 below).88 Following its approval in 1967, doxycycline 
became Pfizer’s first once-a-day, broad-spectrum antibiotic. The utility of doxycycline 
has declined due to increasingly widespread bacterial resistance, but it is still used 
frequently to treat acne, rosacea, chlamydia, syphilis and rickettsial infections. 
                                                 
86 Tetracyclines in Biology, Chemistry and Medicine; Nelson, M., Hillen, W., Greenwald, R. A., Eds.; 
Birkhauser: Boston, 2001.  
87 (a) Blackwood, R. K.; Beereboom, J. J.; Rennhard, H. H.; Schach Von Wittenau, M.; Stephen, C. R. J. 
Am. Chem. Soc. 1961, 83, 2773–2775. (b) Blackwood, R. K.; Beereboom, J. J.; Rennhard, H. H.; Schach 
Von Wittenau, M.; Stephen, C. R. J. Am. Chem. Soc. 1963, 85, 3943–3953. 
88 Villax, I.; Page, P. U.S. Patent 4,500,458, 1985. 
155 
 
O
H
N(CH3)2
HO
OH
NH2
OOHOH O
H
OHCH3 OH
O
H
N(CH3)2
HO
OH
NH2
OOHOH O
H
OH
Oxytetracycline (2)
Methacycline (65)
5
5
O
H
N(CH3)2
HO
OH
NH2
OOHOH O
H
OH3C OH
Cl
O
H
N(CH3)2
O
OH
NH2
OOHOH O
H
OH
Cl
liquid HF
11a
63
64
NCS, Et3N
H2O–DME (1:1)
50%
47%
62%
Na2S2O4
H2O–CH3OH (1:1)
 
Scheme 3.1. Synthesis of methacycline (65) from oxytetracycline (2). 
 
 
Scheme 3.2. Synthesis of doxycycline (7) from methacycline (65). 
 
A limited range of tetracyclines with modified C5 substituents has been prepared 
by semisynthesis.89 The C5 hydroxyl group of doxycycline can be oxidized using 
dimethyl sulfoxide and acetic anhydride to provide the corresponding ketone (5-deoxy-5-
oxo-doxycycline), which was found to be inactive. In addition, selective esterification of 
                                                 
89 Cunha, B. A. Clinical Uses of Tetracyclines. In Handbook of Experimental Pharmacology; Hlavka, J. J. 
and Boothe, J. H., Eds.; Springer-Verlag: New York, 1985; pp 393–403. 
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the C5 secondary carbinol can be achieved by treatment of tetracyclines with carboxylic 
acids in the presence of strong acids such as HF and CH3SO3H (esterification of the C12a 
tertiary carbinol does not occur under these conditions). Tetracyclines with ester 
substituents at C5 were generally found to be less active than the corresponding C5-
hydroxy compounds, although certain C5-esters exhibited notable activity against 
tetracycline-resistant Gram-positive organisms. The 5-formyl derivatives of methacycline 
and doxycycline were reported to be more active than their parent compounds. 
The first-generation synthesis of the AB enone 10 also provided access to an AB 
precursor with a protected hydroxyl group at the Ȗ-position (enone 66, Scheme 3.3).90 Dr. 
Qui Wang, a postdoctoral researcher in the Myers laboratory, converted oxygenated AB 
enone 66 to 5-hydroxyminocycline (67). This fully synthetic tetracycline was found to be 
2- to 4-fold less active than minocycline against most bacterial strains tested (and 
significantly less active against others). 
 
Scheme 3.3. Synthesis of 5-hydroxyminocycline (67) from oxygenated AB enone 66. 
 
The lack of knowledge of structure-activity relationships at position C5 led us to 
consider expansion of our fully synthetic platform to enable a thorough analysis of this 
                                                 
90 Charest, M. G.; Lerner, C. D.; Brubaker, J. D.; Siegel, D. R.; Myers, A. G. Science 2005, 308, 395–398. 
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chemical space. The availability of large quantities of the AB enone 10 meant that this 
compound could be used as starting material for these investigations. We envisioned 
preparing fully synthetic tetracyclines with unprecedented modifications at C5 by 
Michael–Claisen cyclizations of diverse Ȗ-substituted AB precursors with D-ring 
precursors, followed by deprotection (Scheme 3.4). In this chapter, the development of 
chemical pathways for transformation of the AB enone 10 into a range of Ȗ-substituted 
AB enones and then C5-substituted tetracyclines will be described. 
 
Scheme 3.4. Synthesis of fully synthetic C5-substituted tetracyclines from Ȗ-substituted 
AB enones. 
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Results 
The chemical reactivity that has formed the foundation of our efforts to prepare Ȗ-
substituted AB precursors was discovered by Dr. Evan Hecker, a post-doctoral researcher 
in the Myers laboratory. The AB enone 10 was first converted to tert-butyldimethylsilyl 
dienol ether 68 in 78% yield by heating a solution of 10, tert-butyldimethylsilyl 
trifluoromethanesulfonate (1.5 equiv) and triethylamine (3 equiv) in 1,2-dichloroethane at 
reflux for 18 h (Scheme 3.5). Treatment of a solution of tert-butyldimethylsilyl dienol 
ether 68 in the solvent mixture 4:1 tetrahydrofuran–water with N-bromosuccinimide 
(NBS) at 23 °C then afforded Ȗ-(Į)-bromo AB precursor 69 as a single diastereomer in 
92% yield. This stereochemical assignment was supported by NOE studies and confirmed 
by X-ray crystallography (Figure 3.1). The regio- and stereo-selectivity of this 
bromination reaction are striking. The Ȗ-selectivity of electrophilic addition may be 
governed by electronic effects,91 but could also be augmented by significant steric 
hindrance on both faces of the silyl dienol ether 68 at the Į-position (presumably 68 
adopts a similar conformation to the AB enone 10). The (Į)-stereochemistry of the bromo 
substituent results from selective electrophilic addition to the “lower” convex face of silyl 
dienol ether 68. 
 
                                                 
91 For a discussion of the factors governing the regioselectivity of vinylogous aldol reactions of silyl dienol 
ether nucleophiles, see: Denmark, S. E.; Heemstra Jr., J, R.; Beutner, G. L. Angew. Chem. Int. Ed. 2005, 44, 
4682–4698. 
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Scheme 3.5. Two-step synthesis of Ȗ-(Į)-bromo AB precursor 69 from the AB enone 10. 
 
 
Figure 3.1. X-ray crystal structure of Ȗ-(Į)-bromo AB precursor 69. 
 
 Building upon this result, I chose to pursue the synthesis of an intermediate which 
could be more easily diversified than Ȗ-bromo enone 69. Addition of N-iodosuccinimide 
to a solution of silyl dienol ether 68 in acetonitrile and water (19:1 mixture) at –10 °C, 
followed by warming to 0 °C afforded Ȗ-(Į)-iodo AB enone 70 (Scheme 3.6). Exclusion 
of light during reaction, work-up and purification enabled isolation of Ȗ-iodo enone 70 in 
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93% yield (11-g batch). Crucially, treatment of a solution of Ȗ-iodo enone 70 in dioxane 
and water (5:1 mixture) with silver (I) trifluoroacetate (1 equiv) and heating of this 
mixture at 45 °C provided Ȗ-(ȕ)-hydroxy AB enone 71 in 51% yield. 
 
Scheme 3.6. Two-step synthesis of Ȗ-(ȕ)-hydroxy AB enone 71 from tert-
butyldimethylsilyl dienol ether 68. 
 
 Ȗ-(ȕ)-Hydroxy enone 71 was then transformed into a diverse range of Ȗ-
substituted AB precursors (Scheme 3.7). Activation of the Ȗ-hydroxy group of 71 
followed by nucleophilic displacement provided enone products with various substituents 
on the “lower” face at the Ȗ-position. Treatment of a solution of 71 in dichloromethane 
with diethylamino sulfur trifluoride (DAST) at 0 °C following by warming to 23 °C 
afforded Ȗ-fluoro AB enone 72 in 67% yield. Similarly, sequential addition of 
triphenylphosphine, diethyl azodicarboxylate (DEAD) and diphenyl phosphoryl azide 
(DPPA) to a solution of 71 in THF at 23 °C provided Ȗ-azido AB enone 73 (72% yield). 
Furthermore, the Ȗ-hydroxy substituent of enone 71 could be straightforwardly inverted 
by Mitsunobu reaction with formic acid followed by deformylation of the formate ester 
intermediate upon treatment with ammonium hydroxide in methanol at 0 °C, providing Ȗ-
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(Į)-hydroxy AB enone 74. The hydroxyl group of 74 was then straightforwardly 
alkylated and acylated to provide new AB precursors 75 and 76 (Scheme 3.7). 
 
Scheme 3.7. Synthesis of diverse Ȗ-substituted AB precursors from Ȗ-(ȕ)-hydroxy enone 
71. 
 
 tert-Butyldimethylsilyl dienol ether 68 also served as a precursor to AB enones 
with one-carbon extensions at the Ȗ-position (Scheme 3.8). Addition of N,N-
dimethylmethyleneiminium chloride (Eschenmoser’s salt, 1.2 equiv) to a solution of silyl 
dienol ether 68 in 1,2-dichloroethane and heating of this mixture at reflux for 14 h 
afforded a mixture of Ȗ-dimethylaminomethyl AB enone 77 (40%) and Ȗ-exo-methylene 
enone 78 (48%). This useful reactivity was then harnessed to provide an enone with a 
protected aminomethyl substituent at the Ȗ-position (80). In this case, aminoalkylation 
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was achieved using a diallylimmonium trifluoroacetate salt (79) developed by Knochel.92 
Formation of the Ȗ-exo-methylene enone by-product (78) in this reaction was minimized 
by: (1) adding electrophile 79 (4 equiv) in a portionwise manner, and (2) employing a 
lower reaction temperature (60–65 °C). These procedural modifications enabled isolation 
of Ȗ-diallylaminomethyl AB precursor 80 in 70% yield. 
 
Scheme 3.8. Aminoalkylation reactions of tert-butyldimethylsilyl dienol ether 68. 
 
 With a diverse collection of modified AB precursors in hand, the next task was to 
transform these substrates into the corresponding fully synthetic tetracyclines. The D-ring 
precursors corresponding to minocycline and 7-fluorotetracyclines (28 and 81, 
respectively) were chosen as suitable substrates for these investigations.93 AB enones 
                                                 
92 Millot, N.; Piazza, C.; Avolio, S.; Knochel, P. Synthesis 2000, 7, 941–948. 
93 7-Fluorotetracyclines were discovered and developed by Tetraphase Pharmaceuticals using the fully 
synthetic platform developed in the Myers laboratory. The synthesis and utility of fluorinated D-ring 
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with “lower” face Ȗ-substituents were found to undergo highly efficient Michael–Claisen 
cyclizations with benzylic anions formed by LDA deprotonation of 28 and 81 in the 
presence of TMEDA, affording tetracycline precursors with a range of substituents at C5. 
A selection of these cyclization reactions is presented in Scheme 3.9. 
N
O
O O OBn
H
N(CH3)2
OTBS
CH3O
N
O
O
H
N(CH3)2
OTBS
OBnO HOBocO
H
N(CH3)2 O
CH3
CO2Ph
BocO
LDA, TMEDA, THF
–78 –10 °C
N(CH3)2
87%
CH3
CH3
CO2Ph
BocO
N
O
O
H
N(CH3)2
OTBS
OBnO HOBocO
HLDA, TMEDA, THF
–78 –10 °C
N
O
O O OBn
H
N(CH3)2
OTBS
F N(CH3)2N(CH3)2 F
66%
N
O
O
H
N(CH3)2
OTBS
OBnO HOBocO
H
F O
N
O
O O OBn
H
N(CH3)2
OTBS
O
CH3O
O
CH3O
O
CH3
CO2Ph
BocO
LDA, TMEDA, THF
–78 –10 °C
F
77%
28
28
81
72
76
75
82
83
84  
Scheme 3.9. Michael–Claisen cyclizations of o-toluate ester anions with AB precursors 
possessing fluoro (72), methoxy (76) and methyl carbonate (75) substituents at the Ȗ-
position. 
 
 Two-step deprotection of the Michael–Claisen cyclization products shown in 
Scheme 3.9 under typical conditions provided fully synthetic tetracyclines with 
                                                                                                                                                 
precursor 81 is described here: C7-Fluoro Substituted Tetracycline Compounds. PCT International 
Application Serial No. US2009/053142. 
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unprecedented modifications at C5.54b For example, treatment of 5-methoxy cycloadduct 
83 with hydrofluoric acid in acetonitrile at 23 °C, followed by hydrogenolysis of the 
crude reaction product (85) in the presence of palladium black under an atmosphere of 
hydrogen in methanol–dioxane at 23 °C and subsequent purification by rp-HPLC 
afforded 5-methoxyminocycline (86, 100% over two steps, Scheme 3.10). 
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Scheme 3.10. Synthesis of 5-methoxyminocycline (86) by two-step deprotection of 
Michael–Claisen product 83 and transformation of 86 into 5-methoxytigecycline (89). 
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The goal of multiplicatively expanding the pool of fully synthetic tetracyclines 
was then efficiently advanced by employing “semisynthetic” strategies.94 Selective 
nitration at C9 of 5-methoxyminocycline (86) was achieved by addition of potassium 
nitrate (1.1 equiv) to an ice-cold solution of 86 in concentrated sulfuric acid, affording 9-
nitro-5-methoxyminocycline (87) in 63% yield after purification by rp-HPLC (Scheme 
3.10 above). Reduction of the nitro group of 87 by palladium-catalyzed hydrogenation 
followed by treatment of a solution of the crude aniline product (88) in 
dimethylformamide and acetonitrile (1:1 mixture) with 2-(tert-butylamino)acetyl chloride 
hydrochloride afforded 5-methoxytigecycline (89, 49% yield over two steps). 
A number of glycylcyclines with different C9 side chains were straightforwardly 
prepared by reaction of 9-amino “branch points” such as 88 with various different 
electrophiles (Scheme 3.11 below). Furthermore, the three-step sequence described above 
for transformation of a C5-substituted minocycline analog into the corresponding 
tigecycline compound (nitration–nitro reduction–side chain attachment) was also 
effective for the synthesis of 9-glycylamido derivatives of 7-fluorotetracyclines from the 
corresponding C9-unsubstituted compounds.93 For example, numerous 5,7-
difluorotetracyclines (compounds 93–96) with different substitution patterns at C9 were 
conveniently prepared from a single Michael–Claisen cycloadduct (92) by deprotection 
followed by C9 functionalization (Scheme 3.12). 
 
                                                 
94 (a) Sum, P.-E.; Lee, V. J.; Testa, R. T.; Hlavka, J. J.; Ellestad, G. A.; Bloom, J. D.; Gluzman, Y.; Tally, 
F. P. J. Med. Chem. 1994, 37, 184–188. (b) Sum, P.-E.; Petersen, P. Bioorg. Med. Chem. Lett. 1999, 9, 
1459–1462. 
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Scheme 3.11. Synthesis of diverse glycylcyclines by final step diversification of 9-
amino-5-methoxyminocycline (88). 
 
 
Scheme 3.12. 5,7-Difluorotetracyclines (93–96) prepared from a single Michael–Claisen 
cyclization product (92) by deprotection followed by C9 functionalization (nitration–nitro 
reduction–side chain attachment). 
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Fully synthetic tetracyclines possessing amino and aminomethyl substituents at 
C5 were also targeted for synthesis. We anticipated that these compounds could serve as 
substrates for late-stage diversification, thus allowing maximally expedient exploration of 
chemical space at C5. 5-Aminominocycline (99) was prepared in five synthetic 
operations from Ȗ-azido AB enone 73 (Scheme 3.13). C-ring-forming cyclization of 73 
with D-ring precursor 31 afforded the desired Michael–Claisen product (97) in 50% 
yield. Staudinger reduction was achieved by treatment of a solution of azide 97 in THF 
with trimethylphosphine followed by hydrolysis of the iminophosphorane intermediate 
with 1M aqueous sodium hydroxide solution. The resulting primary amine was then 
protected by treatment with di-tert-butyl dicarbonate and triethylamine, providing tert-
butyl carbamate 98 in 60% yield from azide 97.95 Two-step deprotection using the 
inverted sequence afforded 5-aminominocycline (99) after purification by rp-HPLC 
(100% yield over two steps). Fully synthetic 5-amido derivatives of 5-aminominocycline 
(99) are presented in Scheme 3.14 below. 
                                                 
95 Prior research had shown that the hydrogenolysis deprotection step is slow and low-yielding in the 
presence of free primary amines. For this reason, the hydrogenolysis reaction was performed on a substrate 
in which the primary amine was protected as a tert-butyl carbamate. 
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Scheme 3.13. Synthesis of 5-aminominocycline (99) from Ȗ-azido AB enone 73. 
 
 
Scheme 3.14. Fully synthetic 5-amido derivatives of 5-aminominocycline (99). 
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5-Aminomethylminocycline (103) was prepared in five steps from Ȗ-
diallylaminomethyl AB enone 80 (Scheme 3.15). Michael–Claisen reaction of 80 and the 
minocycline D-ring precursor 28 provided the cyclization product 101 in 70% yield. Bis-
deallylation of 101 was achieved by treatment with a catalytic amount of palladium 
tetrakis-(triphenylphosphine) and an excess of dimethylbarbituric acid (DCE, 35 °C). The 
resulting primary amine (102) was protected as a tert-butyl carbamate prior to two-step 
deprotection (hydrogenolysis followed by hydrofluoric acid treatment), affording 5-
aminomethylminocycline (103). With this fully synthetic tetracycline in hand, it was 
straightforward to rapidly synthesize a collection of related analogs possessing extended 
substituents at C5 (Scheme 3.16). 
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Scheme 3.15. Synthesis of 5-aminomethylminocycline (103) from Ȗ-diallylaminomethyl 
AB enone 80. 
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Scheme 3.16. Fully synthetic 5-amido derivatives of 5-aminomethylminocycline (103). 
 
 Finally, it is worth noting that the C-ring-forming Michael–Claisen cyclization of 
an AB precursor possessing an “upper” face (or ȕ-face) substituent at the Ȗ-position can 
also be stereoselective, albeit to a lesser extent (Scheme 3.17). Michael–Claisen reaction 
of enone 104 (with a protected hydroxy substituent on the upper face at the Ȗ-position) 
with minocycline D-ring precursor 31 afforded the desired cyclization product 105 in 
40% yield. The stereochemistry of 105 was confirmed by X-ray crystallography (Figure 
3.2 below). A minor diastereomer, believed to be epimeric at C5a, was isolated separately 
(15% yield). Two-step deprotection of Michael–Claisen product 105 provided 5-(ȕ)-
hydroxyminocycline (106, 58% over two steps). 
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Scheme 3.17. Three-step synthesis of 5-(ȕ)-hydroxyminocycline (106) from an AB enone 
with a protected hydroxy substituent on the upper face at the Ȗ-position (104). 
 
 
Figure 3.2. X-ray crystal structure of Michael–Claisen cyclization product 105. 
 
Antibacterial Activities 
 Minimum inhibitory concentrations (MIC) values were determined for all C5-
substituted tetracyclines against a broad panel of tetracycline-sensitive and tetracycline-
resistant Gram-positive and Gram-negative bacteria. In summary, numerous fully 
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synthetic C5-modified tetracyclines exhibited good activity against Gram-positive 
bacteria (including tetracycline-resistant organisms) and weak activity against some 
Gram-negative organisms, however C5 substitution provided compounds which were less 
active (to greater and lesser extents) than the corresponding C5-unsubstituted compounds 
(e.g. minocycline, tigecycline). Specific examples are discussed here and complete 
antibacterial activity data for all C5-substituted analogs is presented in the tables below 
(pages 176–184). 
MIC assays for tigecycline (9), 5-fluoro-TP-434 (96)96 and 5-methoxytigecycline 
(89) against tetracycline-susceptible E. coli and leaky E. coli strains are depicted in 
Figure 3.3 below. As discussed in Chapter 2, leaky E. coli has a more permeable outer 
membrane than E. coli (due to knockout of a lipopolysaccharide gene) and so provides 
some insight as to the effect of outer membrane penetration on antibacterial activity. The 
results of these MIC assays revealed that both synthetic analogs possess antibacterial 
activity and that 5-fluoro-glycylcycline 96 has similar activity to tigecycline (9) in this E. 
coli strain and is 16-fold more active than tigecycline in leaky E. coli. Thus, fully 
synthetic C5-fluoro-substituted tetracycline 96 was found to exhibit significantly greater 
potency than tigecycline against a tetracycline-susceptible strain with a permeabilized 
outer membrane. Unfortunately this improvement in activity (vs. tigecycline) was not 
common to other bacteria. Determination of antibacterial activities against a broad panel 
of Gram-positive and Gram-negative bacteria (including tetracycline-resistant organisms) 
                                                 
96 TP-434 is a fully synthetic tetracycline antibiotic discovered and developed by Tetraphase 
Pharmaceuticals that is currently undergoing a Phase 2 clinical trial. 
173 
 
showed that 96 is significantly less active than tigecycline against most bacterial strains 
(see tables below for complete data). 
 
 E. coli Leaky E. coli 
Tigecycline (9, rows 1 & 2) 1 1 
5-Fluoro-TP-434 (96, rows 3 & 4) 1 0.063 
5-Methoxytigecycline (89, rows 5 & 6) 4 1 
 
Figure 3.3. Minimum inhibitory concentration (MIC) assays and values in µg / mL for 
tigecycline (9), 5-fluoro-TP-434 (96) and 5-methoxytigecycline (89) against E. coli and 
leaky E. coli strains. 
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Chart 3.1. MIC values in µg/mL for minocycline and C5-substituted minocycline 
analogs. Abbreviations: GP, Gram-positive; GN, Gram-negative; SA, S. aureus; EF, E. 
faecalis; SP, S. pneumoniae; EC, E. coli; KP, K. pneumoniae; PA, P. aeruginosa; tetM, 
ribosomal protection proteins; tetA, tetK, tetracycline efflux proteins; tolC, multiple 
efflux pump knockout. 
 
Antibacterial activities for selected C5-substituted variants of minocycline are 
displayed in Chart 3.1 above. 5-Fluorominocycline and minocycline exhibited identical 
activity in many bacterial strains, while 5-fluorominocycline was found to be 2-fold less 
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active in others. 5-Methoxyminocycline and 5-aminominocycline were substantially less 
active against Gram-positive bacteria such as S. aureus and slightly less active than 
minocycline against Gram-negative organisms. 5-Aminomethylminocycline and its 
derivatives were found to be almost completely inactive as antibiotics, indicating that the 
introduction of extended substituents at C5 is not a promising strategy for the discovery 
of new tetracycline antibiotics. The discovery that 5-fluorominocycline has similar 
antibacterial activity to minocycline led to optimism regarding the activity of 5-
fluorotigecycline. Unfortunately this compound was found to be significantly less potent 
than tigecycline (the corresponding 5-unsubstituted compound, Chart 3.2 below). The 
finding that fluoro-substitution has different effects on the activity of minocycline and 
tigecycline is one of many “non-linear” effects we have observed. In the case of 
tigecycline, 5-methoxy and 5-fluoro substitution were found to be similarly detrimental to 
antibacterial activity. 
 
Chart 3.2. MIC values in µg/mL for tigecycline and selected C5-substituted tigecycline 
analogs (see Chart 3.1 for abbreviations). 
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Conclusion 
 In conclusion, we have developed new chemical pathways for the synthesis of 
diverse Ȗ-substituted AB enones from the Ȗ-unsubstituted AB enone 10. These modified 
AB precursors were then transformed into more than 40 fully synthetic tetracyclines with 
unprecedented substitutions at C5 by coupling with various D-ring precursors followed 
by deprotection and late-stage “branch point” diversification. Many of the modified AB 
precursors served as precursors to small libraries of tetracyclines with a given substituent 
at C5 and different D-ring portions, thereby multiplicatively expanding the pool of fully 
synthetic tetracyclines. Many fully synthetic C5-substituted tetracyclines demonstrated 
good activity against Gram-positive bacteria (including tetracycline-resistant organisms), 
however most compounds were significantly less active than the corresponding C5-
unsubstituted tetracyclines against both Gram-positive and Gram-negative bacteria. 
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C5–Substituted Tetracyclines: Experimental Section 
 
tert–Butyldimethylsilyl dienol ether 68. Triethylamine (13.0 mL, 93.0 mmol, 3.0 equiv) 
and tert–butyldimethylsilyl trifluoromethanesulfonate (10.7 mL, 46.6 mmol, 1.5 equiv) 
were added sequentially to a stirring solution of AB enone 10 (15.0 g, 31.1 mmol, 1 
equiv) in 1,2-dichloroethane (120 mL) at 23 °C. The reaction mixture was heated to 
reflux and stirred at this temperature for 18 h. The reaction solution was allowed to cool, 
then was poured into saturated aqueous sodium bicarbonate solution (350 mL). The 
resulting mixture was extracted with ethyl acetate (2 x 350 mL). The organic extracts 
were combined and the combined extracts were dried over anhydrous sodium sulfate. The 
dried solution was filtered and the filtrate was concentrated. The crude product was 
purified by flash-column chromatography (4% ethyl acetate–hexanes, grading to 6%), 
affording tert-butyldimethylsilyl dienol ether 68 as an off-white solid (14.5 g, 78%). 
Rf  = 0.68 (20% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 7.48 (d, 2H, J = 
7.8 Hz), 7.35 (m, 3H), 5.98 (dd, 1H, J = 9.3, 5.9 Hz), 5.87 (dd, 1H, J = 9.3, 5.9 Hz), 5.32 
(m, 2H), 5.25 (d, 1H, J = 5.8 Hz), 3.78 (d, 1H, J = 10.3 Hz), 2.83 (dd, 1H, J = 9.8, 5.9 
Hz), 2.48 (s, 6H), 0.82 (s, 9H), 0.77 (s, 9H), 0.15 (s, 6H), 0.13 (s, 3H), –0.04 (s, 3H); 13C 
NMR (500 MHz, CDCl3) į 188.7, 181.8, 167.7, 151.0, 139.3, 135.1, 128.9, 128.5, 128.4, 
123.0, 122.9, 107.9, 103.4, 94.7, 81.7, 72.3, 64.2, 48.1, 42.4, 25.8, 25.4, 18.9, 17.8, –2.8, 
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–3.4, –4.5, –5.3; FTIR (neat film) 2929, 1716, 1510, 1247 cm–1; HRMS–ESI (m/z) calcd 
for C32H49N2O5Si2, 597.3175; found, 596.3179. 
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Ȗ-(Į)-Iodo AB enone 70. Light was excluded throughout the synthesis, work-up and 
purification of Ȗ-(Į)-iodo AB enone 70. N-Iodosuccinimide (4.83 g, 20.4 mmol, 1.05 
equiv) was added in one portion to a stirring solution of tert-butyldimethylsilyl dienol 
ether 68 (11.6 g, 19.4 mmol, 1 equiv) in acetonitrile (171 mL) and water (9.0 mL) at –10 
°C. The resulting mixture was stirred at this temperature for 5 min, then was allowed to 
warm to 0 °C. After stirring at 0 °C for 4 h, the reaction solution was partitioned between 
saturated aqueous sodium thiosulfate solution and ethyl acetate (300 mL each). The 
phases were separated and the aqueous phase was extracted with ethyl acetate (300 mL). 
The organic extracts were combined and the combined solution was dried over anhydrous 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
crude product was purified by flash-column chromatography (12% ethyl acetate–hexanes, 
grading to 15%), providing the Ȗ-(Į)-iodo AB enone 70 as a yellow solid (11.0 g, 93%). 
Rf = 0.59 (30% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 7.49 (d, 2H, J = 
7.3 Hz), 7.40–7.34 (m, 3H), 6.91 (ddd, 1H, J = 10.1, 4.6, 1.4 Hz), 6.03 (d, 1H, J = 10.1 
Hz), 5.74 (d, 1H, J = 4.6 Hz), 5.36 (AB quartet, 2H), 3.52 (d, 1H, J = 11.0 Hz), 3.23 (d, 
1H, J = 11.0 Hz), 2.50 (s, 6H), 0.99 (s, 9H), 0.20 (s, 3H), 0.11 (s, 3H); 13C NMR (125 
MHz, CDCl3) į 193.1, 186.4, 179.0, 167.4, 147.7, 134.9, 128.6, 128.5, 128.4, 126.1, 
108.3, 83.1, 72.6, 60.8, 53.9, 41.9, 26.8, 19.5, 11.9, –2.2, –2.2; HRMS–ESI (m/z): 
[M+H]+ calcd for C26H34IN2O5Si, 609.1276; found, 609.1304. 
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Ȗ-(ȕ)-Hydroxy AB enone 71. Light was excluded throughout the reaction and work–up 
in this procedure. Silver (I) trifluoroacetate (2.59 g, 11.5 mmol, 1 equiv) was added in 
one portion to a solution of the Ȗ-(Į)-iodo AB enone 70 (7.0 g, 11.5 mmol, 1 equiv) in 
dioxane (85 mL) and water (17 mL) at 23 °C. The resulting mixture was heated to 45 °C 
and stirred at this temperature for 14 h. The reaction mixture was allowed to cool to 23 
°C, then was partitioned between saturated aqueous sodium thiosulfate solution and ethyl 
acetate (250 mL each). The phases were separated and the organic phase was washed 
with saturated aqueous sodium bicarbonate solution (100 mL). The aqueous phases were 
combined and the combined aqueous mixture was extracted with ethyl acetate (250 mL, 
then 100 mL). The organic extracts were combined and the combined solution was dried 
over anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. The crude product was purified by flash-column chromatography (20% 
ethyl acetate–hexanes, grading to 25%), affording the Ȗ-(ȕ)-hydroxy AB enone 71 as an 
off–white solid (2.90 g, 51%). 
Rf = 0.40 (30% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 7.48 (d, 2H, J = 
7.3 Hz), 7.39–7.34 (m, 3H), 7.07 (d, 1H, J = 10.5 Hz), 6.05 (dd, 1H, J = 10.5, 2.3 Hz), 
5.35 (AB quartet, 2H), 5.20 (brs, 1H), 4.37 (d, 1H, J = 11.0 Hz), 3.26–3.24 (m, 1H), 2.53 
(brs, 6H), 0.83 (s, 9H), 0.26 (s, 3H), 0.03 (s, 3H); 13C NMR (125 MHz, CDCl3) į 191.9, 
186.0, 178.7, 167.4, 154.2, 134.7, 128.6, 128.5, 128.4, 126.4, 108.6, 83.8, 72.7, 68.3, 
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59.0, 50.7, 25.9, 19.0, –2.5, –4.1; FTIR (neat film), 2930 (w), 2857 (w), 1722 (s), 1684 
(m), 1613 (w), 1512 (m), 1022 (s), 837 (s) cm–1; HRMS–ESI (m/z): [M+H]+ calcd for 
C26H35N2O6Si, 499.2259; found, 499.2278. 
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Ȗ-(Į)-Fluoro AB enone 72. Diethylaminosulfur trifluoride (74 µL, 0.562 mmol, 1.1 
equiv) was added dropwise to a solution of the Ȗ-(ȕ)-hydroxy enone 71 (255 mg, 0.511 
mmol, 1 equiv) in dichloromethane (10 mL) at 0 °C. The resulting orange solution was 
allowed to warm to 23 °C. After stirring at this temperature for 10 min, the reaction 
mixture was diluted with dichloromethane (10 mL) and washed with saturated aqueous 
sodium bicarbonate solution (20 mL). The phases were separated and the aqueous phase 
was extracted with dichloromethane (20 mL). The organic extracts were combined and 
the combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and filtrate was concentrated. The product was purified by flash-column 
chromatography (15% ethyl acetate–hexanes), providing the Ȗ-(Į)-fluoro AB enone 72 as 
a yellow solid (171 mg, 67%). 
Rf = 0.40 (25% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 7.51 (d, 2H, J = 
7.0 Hz), 7.41–7.35 (m, 3H), 6.95–6.91 (m, 1H), 6.18 (dd, 1H, J = 10.5, 2.0 Hz), 5.43 (dd, 
1H, J = 43.5, 4.0 Hz), 5.37 (AB quartet, 2H), 3.47 (dd, 1H, J = 11.0, 1.5 Hz), 3.08–3.01 
(m, 1H), 2.51 (s, 6H), 0.85 (s, 9H), 0.25 (s, 3H), 0.04 (s, 3H); 13C NMR (125 MHz, 
CDCl3) į 193.9 (d, J = 2.7 Hz), 186.6, 180.0 (d, J = 3.7 Hz), 167.4, 141.0 (d, J = 17.4 
Hz), 134.8, 129.7 (d, J = 8.2 Hz), 128.6, 128.5, 128.5, 108.3, 83.8, 82.1 (d, J = 73.2 Hz), 
72.7, 59.1 (d, J = 7.3 Hz), 50.4 (d, J = 17.4 Hz), 42.0, 25.9, 19.1, –2.4, –3.9; 19F NMR 
(300 MHz, CDCl3) į –170.1; FTIR (neat film), 2930 (w), 1721 (s), 1692 (m), 1512 (m), 
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1474 (m), 1188 (w), 1051 (m), 936 (s), 839 (s) cm–1; HRMS–ESI (m/z): [M+H]+ calcd for 
C26H34FN2O5Si, 501.2216; found, 501.2245. 
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Ȗ-(Į)-Azido AB enone 73. Triphenylphosphine (631 mg, 2.41 mmol, 1.2 equiv), a  
solution of diethyl azodicarboxylate (40% in toluene, 1.10 mL, 2.41 mmol, 1.2 equiv) 
and diphenyl phosphoryl azide (535 µL, 2.41 mmol, 1.2 equiv) were added sequentially 
to a solution of Ȗ-(ȕ)-hydroxy AB enone 71 (1.00 g, 2.01 mmol, 1 equiv) in 
dichloromethane (25 mL) at 23 °C. After stirring at this temperature for 1 h, the reaction 
mixture was concentrated. The crude product was purified by flash-column 
chromatography (7% acetone–hexanes), affording the Ȗ-(Į)-azido AB enone 73 as an off-
white solid (802 mg, 76%). 
Rf = 0.08 (8% acetone–hexanes); 1H NMR (500 MHz, CDCl3) į 7.50 (d, 2H, J = 7.8 Hz), 
7.40–7.34 (m, 3H), 6.74 (dd, 1H, J = 9.8, 3.9 Hz), 6.14 (d, 1H, J = 9.8 Hz), 5.37 (AB 
quartet, 2H), 4.83 (d, 1H, J = 3.9 Hz), 3.54 (d, 1H, J = 11.7 Hz), 2.86 (d, 1H, J = 10.7 
Hz), 2.50 (s, 6H), 0.89 (s, 9H), 0.27 (s, 3H), 0.03 (s, 3H); 13C NMR (125 MHz, CDCl3) į 
193.4, 186.5, 179.9, 167.3, 142.4, 134.8, 128.8, 128.6, 128.5, 128.4, 108.3, 81.9, 72.6, 
59.7, 55.0, 49.4, 41.8, 25.8, 19.1, –2.5, –3.6; FTIR (neat film), 2099 (s), 1722 (s), 1688 
(m), 1611 (w), 1506 (m), 1248 (m), 839 (s), 737 (s) cm–1; HRMS–ESI (m/z): [M+H]+ 
calcd for C26H34N5O5Si, 524.2324; found, 524.2324. 
 
194 
 
 
Ȗ-(Į)-Hydroxy AB enone 74. A solution of diethyl azodicarboxylate (40% in toluene, 
396 µL, 1.01 mmol, 1.4 equiv) was added dropwise via syringe to a stirred solution of the 
Ȗ-(ȕ)-hydroxy AB enone 71 (360 mg, 0.722 mmol, 1 equiv), triphenylphosphine (265 mg, 
1.01 mmol, 1.4 equiv) and formic acid (38.1 µL, 1.01 mmol, 1.4 equiv) in 
tetrahydrofuran (2.0 mL) at 23 °C. After stirring at this temperature for 5 h, the reaction 
mixture was diluted with dichloromethane (20 mL) and washed with saturated aqueous 
sodium bicarbonate solution (20 mL). The phases were separated and the aqueous phase 
was extracted with dichloromethane (20 mL). The organic extracts were combined and 
the combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and filtrate was concentrated, providing a green oil. The crude formate ester 
product was dissolved in methanol (15 mL) and the resulting solution was cooled to 0 °C. 
Aqueous ammonia (30% solution, 127 µL, 0.978 mmol, 1.35 equiv) was added to the 
cooled solution. The reaction was stirred at 0 °C for 25 min, then was diluted with 
dichloromethane (80 mL) and washed with saturated aqueous sodium bicarbonate 
solution (60 mL). The phases were separated and the aqueous phase was extracted with 
dichloromethane (80 mL). The organic extracts were combined and the combined 
solution was dried over anhydrous sodium sulfate. The dried solution was filtered and 
filtrate was concentrated, affording a brown-red oil. The product was purified by flash-
column chromatography (17% ethyl acetate–hexanes), providing the Ȗ-(Į)-hydroxy AB 
enone 74 as a white solid (302 mg, 84%, two steps). 
195 
 
Rf = 0.23 (25% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 7.51–7.50 (m, 
2H), 7.41–7.35 (m, 3H), 7.02–6.98 (m, 1H), 6.11 (d, 1H, J = 10.2 Hz), 5.37 (AB quartet, 
2H), 4.71–4.67 (m, 1H), 3.63 (d, 1H, J = 11.2 Hz), 3.57 (d, 1H, J = 11.2 Hz), 2.93–2.91 
(m, 1H), 2.49 (s, 6H), 0.88 (s, 9H), 0.32 (s, 3H), 0.08 (s, 3H); 13C NMR (125 MHz, 
CDCl3) į 193.2, 186.5, 180.7, 167.3, 146.9, 134.9, 128.6, 128.5, 128.5, 127.2, 108.2, 
84.3, 72.7, 64.5, 59.6, 51.8, 41.9, 26.2, 19.1, –2.3, –3.6; HRMS–ESI (m/z): [M+H]+ calcd 
for C26H35N2O6Si, 499.2259; found, 499.2270. 
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Ȗ-(Į)-Methoxy AB enone 76. Trimethylsilyldiazomethane (320 µL, 0.64 mmol, 2.5 
equiv) was added dropwise in three portions (2 x 120 µL, then 80 µL) over 10 min to a 
solution of the Ȗ-(Į)-hydroxy AB enone 74 (127 mg, 0.255 mmol, 1 equiv) and 
tetrafluoroboric acid (60 µL, 0.458 mmol, 1.8 mmol) in dichloromethane (3.0 mL) at 0 
°C. The resulting mixture was allowed to warm to 23 °C. After stirring at this 
temperature for 3 h, more trimethylsilyldiazomethane (120 µL) was added to the reaction 
mixture. The resulting solution was stirred at 23 °C for a further 1 h, then was diluted 
with dichloromethane (20 mL) and poured into water (20 mL). Saturated aqueous sodium 
bicarbonate solution (10 mL) was added and the phases were separated. The aqueous 
phase was then extracted with dichloromethane (20 mL). The organic extracts were 
combined and the combined solution was dried over anhydrous sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated. The crude product was purified by 
flash-column chromatography (13% ethyl acetate–hexanes), affording the Ȗ-(Į)-methoxy 
AB enone 76 as a white solid (43 mg, 33%). 
Rf = 0.32 (25% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 7.50 (d, 2H, J = 
7.3 Hz), 7.40–7.34 (m, 3H), 6.91 (dd, 1H, J = 10.1, 4.1 Hz), 6.08 (d, J = 10.1 Hz), 5.37 
(AB quartet, 2H), 4.21 (s, 1H), 3.47 (d, 1H, J = 10.5 Hz), 3.41 (s, 3H), 2.88 (d, 1H, J = 
9.6 Hz), 2.50 (s, 6H), 0.84 (s, 9H), 0.22 (s, 3H), 0.03 (s, 3H); 13C NMR (125 MHz, 
CDCl3) į 194.5, 187.5, 180.4, 167.4, 144.7, 135.0, 128.5, 128.5, 128.4, 127.8, 108.2, 
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82.3, 73.9, 72.6, 59.6, 57.0, 48.3, 42.2, 25.8, 19.1, –2.4, –3.7; HRMS–ESI (m/z): [M+H]+ 
calcd for C27H37N2O6Si, 513.2415; found, 513.2414. 
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Ȗ-(Į)-Oxycarbonyloxymethyl AB Enone 75. Methyl chloroformate (233 µL, 3.00 
mmol, 2.2 equiv) and 4-dimethylaminopyridine (367 mg, 3.00 mmol, 2.2 equiv) were 
added sequentially to a solution of the Ȗ-(Į)-hydroxy AB enone 74 (680 mg, 1.36 mmol, 
1 equiv) in dichloromethane (15 mL) at 23 °C. The reaction mixture was stirred at this 
temperature for 13 h, then was diluted with dichloromethane (50 mL) and poured into 
saturated aqueous sodium bicarbonate solution (50 mL). The phases were separated and 
the aqueous phase was extracted with dichloromethane (50 mL). The organic extracts 
were combined and the combined solution was dried over anhydrous sodium sulfate. The 
dried solution was filtered and the filtrate was concentrated. The crude product was 
purified by flash-column chromatography, providing methyl carbonate 75 (517 mg, 
68%). 
Rf = 0.18 (20% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 7.51–7.50 (m, 
2H), 7.41–7.35 (m, 3H), 6.93 (ddd, 1H, J = 10.3, 4.7, 1.8 Hz), 6.19 (dd, 1H, J = 10.3, 1.0 
Hz), 5.71 (m, 1H), 5.37 (AB quartet, 2H), 3.82 (s, 3H), 3.57 (d, 1H, J = 11.3 Hz), 3.02–
2.99 (m, 1H), 2.51 (s, 6H), 0.86 (s, 9H), 0.26 (s, 3H), 0.02 (s, 3H); 13C NMR (125 MHz, 
CDCl3) į 193.8, 186.6, 180.3, 167.4, 155.4, 141.4, 134.9, 129.7, 128.6, 128.5, 128.5, 
108.3, 82.0, 72.7, 69.1, 59.7, 55.0, 49.9, 42.0, 25.9, 19.1, –2.4, –3.7. 
 
199 
 
 
Ȗ-(Į)-N,N-Diallylaminomethyl-substituted AB enone 80. A freshly prepared solution 
of immonium trifluoroacetate salt 79 in anhydrous 1,2-dichloroethane (0.6 M, 4.3 mL, 
2.58 mmol, 1.5 equiv)92 was added dropwise to a solution of tert-butyldimethylsilyl 
dienol ether 68 (1.01 g, 1.69 mmol, 1 equiv) in anhydrous 1,2-dichloroethane (10 mL) at 
23 °C. The reaction mixture was heated to 60–65 °C. After stirring at this temperature for 
1 h, a second portion of immonium trifluoroacetate solution (0.6 M, 4.3 mL, 2.58 mmol, 
1.5 equiv) was added dropwise to the reaction solution. The resulting solution was stirred 
at 60–65 °C for 1 h, whereupon a final portion of immonium trifluoroacetate solution (0.6 
M, 2.8 mL, 1.68 mmol, 1 equiv) was added dropwise.  After stirring at 60–65 °C for a 
further 30 min, the reaction solution was allowed to cool to 23 °C. The cooled solution 
was poured into saturated aqueous sodium bicarbonate solution (60 mL). 
Dichloromethane (60 mL) was added and the phases were separated. The aqueous phase 
was extracted with dichloromethane (60 mL). The organic extracts were combined and 
the combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated, affording a brown oil. The crude product was 
purified by flash-column chromatography (dichloromethane flush, then 1% ether–
dichloromethane, grading to 3% ether–dichloromethane), affording the Ȗ-(Į)-N,N-
diallylaminomethyl-substituted AB enone 80 as a pale yellow solid (699 mg, 70%). 
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1H NMR (500 MHz, CDCl3) į 7.50 (d, 2H, J = 6.8 Hz), 7.40–7.34 (m, 3H), 6.94 (ddd, 
1H, J = 10.3, 4.9, 1.5 Hz), 6.06 (dd, 1H, J = 10.3, 2.0 Hz), 5.87–5.79 (m, 2H), 5.36 (2H, 
AB quartet), 5.18–5.13 (m, 4H), 3.57 (d, 1H, J = 11.2 Hz), 3.21–3.16 (m, 5H), 2.89 (dd, 
1H, J = 12.7, 7.3 Hz), 2.83 (dd, 12.7, 7.3 Hz), 2.76 (d, 1H, J = 11.2 Hz), 2.48 (s, 9H), 
0.86 (s, 9H), 0.24 (s, 3H), 0.01 (s, 3H); HRMS–ESI (m/z): [M+H]+ calcd for 
C33H46N3O5Si, 592.3201; found, 592.3212. 
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Michael–Claisen cyclization product 82. A freshly prepared solution of lithium 
diisopropylamide (1.0 M, 3.30 mL, 3.30 mmol, 3.0 equiv) was added dropwise via 
syringe to a solution of minocycline D-ring precursor 28 (1.22 g, 3.30 mmol, 3.0 equiv) 
and N,N,N’,N’-tetramethylethylenediamine (TMEDA, 995 µL, 6.59 mmol, 6.0 equiv) in 
tetrahydrofuran (40 mL) at –78 °C, forming a dark red solution. After stirring at –78 °C 
for 35 min, a solution of Ȗ-(Į)-fluoro AB enone 72 (550 mg, 1.10 mmol, 1 equiv) in 
tetrahydrofuran (5 mL) was added dropwise via syringe to the reaction solution. The 
resulting mixture was allowed to warm slowly to –10 °C over 100 min, then was 
partitioned between aqueous potassium phosphate buffer solution (pH 7.0, 0.2 M, 100 
mL) and dichloromethane (100 mL). The phases were separated and the aqueous phase 
was further extracted with dichloromethane (2 x 50 mL). The organic extracts were 
combined and the combined solution was dried over anhydrous sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated, affording a dark green oil. The 
product was purified by flash-column chromatography (13% ethyl acetate–hexanes), 
providing the Michael–Claisen cyclization product 82 as a yellow solid (560 mg, 66%). 
Rf = 0.43 (25% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 15.70 (s, 1H), 7.51 
(d, 2H, J = 6.8 Hz), 7.41–7.35 (m, 3H), 7.28 (d, 1H, J = 8.8 Hz), 7.05 (d, 1H, J = 8.8 Hz), 
5.38 (AB quartet, 2H), 5.07 (dd, 1H, J = 47.9, 2.0 Hz), 3.83 (dd, 1H, J = 15.6, 5.9 Hz), 
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3.69 (d, 1H, J = 11.7 Hz), 3.37 (ddd, 1H, J = 30.3, 15.7, 4.9, 3.9 Hz), 2.94 (dd, 1H, J = 
20.5, 10.8 Hz), 2.68 (s, 6H), 2.52 (s, 6H), 2.34 (dd, 1H, J = 15.7, 14.7 Hz), 1.54 (s, 9H), 
0.83 (s, 9H), 0.24 (s, 3H), 0.09 (s, 3H); 13C NMR (125 MHz, CDCl3) į 186.4, 185.8, 
180.8, 180.1 (d, J = 3.7 Hz), 167.5, 152.1, 149.7, 145.3, 135.8, 135.0, 128.6, 128.5, 
128.5, 124.7, 123.1, 122.5, 108.4, 104.4 (d, J = 7.3 Hz), 92.4 (d, J = 179.4 Hz), 83.8, 
81.8, 72.6, 59.5 (d, J = 10.1 Hz), 52.5 (d, J = 19.2 Hz), 44.3, 41.9, 37.5 (d, J = 28.4 Hz), 
31.4 (d, J = 1.8 Hz), 27.7, 25.9, 19.0, –2.4, –3.4; FTIR (neat film), 1759 (m), 1722 (m), 
1614 (w), 1512 (m), 1234 (s), 1148 (w), 735 (w) cm–1; HRMS–ESI (m/z): [M+H]+ calcd 
for C41H53FN3O9Si, 778.3530; found, 778.3533. 
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5-(Į)-Fluorominocycline (107). Concentrated aqueous hydrofluoric acid solution (48 
wt%, 3.0 mL) was added to a solution of the Michael–Claisen cyclization product 82 
(522 mg, 0.671 mmol, 1 equiv) in acetonitrile (4.5 mL) in a polypropylene reaction vessel 
at 23 °C. The reaction solution was stirred vigorously at 23 °C for 13 ½ h, then was 
poured into water (150 mL) containing dipotassium hydrogenphosphate trihydrate (30 g). 
The resulting mixture was extracted with ethyl acetate (150 mL, then 2 x 100 mL). The 
organic extracts were combined and the combined solution was dried over anhydrous 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated, 
affording a brownish yellow solid. Methanol (4.0 mL) and dioxane (4.0 mL) were added 
to the crude product. Palladium black (28.6 mg, 0.268 mmol, 0.4 equiv) was added in one 
portion to the resulting solution at 23 °C. An atmosphere of hydrogen was introduced by 
briefly evacuating the flask, then flushing with pure hydrogen (1 atm). The reaction 
mixture was stirred at 23 °C for 75 min, then was filtered through a plug of Celite. The 
filtrate was concentrated. The product was purified by preparative HPLC on an Agilent 
Prep C18 column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, Solvent A: 0.1% 
trifluoroacetic acid in water, Solvent B: acetonitrile, 2 batches, injection volume: 8.0 mL 
(6.0 mL 0.1% trifluoroacetic acid in water, 2.0 mL acetonitrile), gradient elution with 
20o40% B over 40 min, flow rate: 15 mL/min]. Fractions eluting at 6–13 min were 
collected and concentrated, then re–purified by preparative HPLC [10 µm, 250 x 21.2 
mm, UV detection at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: 
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acetonitrile, 2 batches, injection volume: 8.0 mL (7.0 mL 0.1% trifluoroacetic acid in 
water, 1.0 mL acetonitrile), gradient elution with 5o40% B over 50 min, flow rate: 7.5 
mL/min]. Fractions eluting 23–30 min were collected and concentrated, affording 5-(Į)-
fluorominocycline trifluoroacetate (107) as a yellow solid (321 mg, 81%, two steps). 
1H NMR (500 MHz, CD3OD, trifluoroacetate) G 7.83 (d, 1H, J = 9.3 Hz), 7.03 (d, 1H, J = 
9.3 Hz), 4.59 (ddd, 1H, J = 48.8, 11.7, 9.3 Hz), 4.57 (d, 1H, J = 1.0 Hz), 3.66 (dd, 1H, J = 
15.6, 4.4 Hz), 3.36–3.26 (m, 2H), 3.13 (s, 6H), 2.94 (s, 6H), 2.65 (dd, 1H, J = 14.6, 14.2 
Hz); HRMS–ESI (m/z): [M+H]+ calcd for C23H27FN3O7, 476.1828; found, 476.1843. 
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Michael–Claisen cyclization product 83. A freshly prepared solution of lithium 
diisopropylamide (1.0 M, 2.06 mL, 2.06 mmol, 3.0 equiv) was added dropwise via 
syringe to a solution of the minocycline D-ring precursor 28 (765 mg, 2.06 mmol, 3.0 
equiv) and TMEDA (622 µL, 4.12 mmol, 6.0 equiv) in tetrahydrofuran (17 mL) at –78 
°C, forming a dark red solution. After stirring at –78 °C for 45 min, a solution of Ȗ-(Į)-
methoxy AB enone 76 (352 mg, 0.687 mmol, 1 equiv) in tetrahydrofuran (2.5 mL) was 
added dropwise via syringe to the reaction solution. The resulting mixture was allowed to 
warm slowly to –10 °C over 100 min, then was partitioned between aqueous potassium 
phosphate buffer solution (pH 7.0, 0.2 M, 70 mL) and dichloromethane (70 mL). The 
phases were separated and the aqueous phase was further extracted with dichloromethane 
(70 mL). The organic extracts were combined and the combined solution was dried over 
anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. The product was purified by flash-column chromatography (15% ethyl 
acetate–hexanes), providing the Michael–Claisen cyclization product 83 as a yellow solid 
(473 mg, 87%). 
Rf = 0.24 (20% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 15.70 (s, 1H), 
7.52–7.50 (m, 2H), 7.41–7.34 (m, 3H), 7.26 (d, 1H, J = 8.8 Hz), 7.02 (d, 1H, J = 8.3 Hz), 
5.37 (AB quartet, 2H), 3.80 (d, 1H, J = 3.9 Hz), 3.72 (dd, 1H, J = 15.6, 5.4 Hz), 3.64 (d, 
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1H, J = 10.7 Hz), 3.38 (s, 3H), 3.17 (ddd, 1H, J = 14.6, 5.4, 4.4 Hz), 2.79 (d, 1H, J = 10.3 
Hz), 2.67 (s, 6H), 2.51 (s, 6H), 2.34 (dd, 1H, J = 15.1, 14.6 Hz), 1.53 (s, 9H), 0.83 (s, 
9H), 0.23 (s, 3H), 0.05 (s, 3H); 13C NMR (125 MHz, CDCl3) į 187.3, 186.3, 180.6, 
180.5, 167.4, 152.1, 149.6, 145.2, 136.4, 135.0, 128.5, 128.5, 128.4, 124.4, 123.2, 122.2, 
108.5, 106.0, 83.6, 82.5, 81.7, 72.5, 60.4, 56.2, 50.1, 44.4, 41.9, 37.5, 32.4, 27.7, 25.9, 
19.0, –2.4, –3.4; HRMS–ESI (m/z): [M+H]+ calcd for C42H56N3O10Si, 790.3730; found, 
790.3736. 
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5-(Į)-Methoxyminocycline (86). Concentrated aqueous hydrofluoric acid solution (48 
wt%, 3.0 mL) was added to a solution of the Michael–Claisen cyclization product 83 
(472 mg, 0.597 mmol, 1 equiv) in acetonitrile (4.5 mL) in a polypropylene reaction vessel 
at 23 °C. The reaction solution was stirred vigorously at 23 °C for 14 h, then was poured 
into water (150 mL) containing dipotassium hydrogenphosphate trihydrate (30 g). The 
resulting mixture was extracted with ethyl acetate (150 mL, then 2 x 100 mL). The 
organic extracts were combined and the combined solution was dried over anhydrous 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated, 
affording an orange-brown solid. Methanol (4.0 mL) and dioxane (4.0 mL) were added to 
the crude product. Palladium black (25.4 mg, 0.239 mmol, 0.4 equiv) was added in one 
portion to the resulting solution at 23 °C. An atmosphere of hydrogen was introduced by 
briefly evacuating the flask, then flushing with pure hydrogen (1 atm). The reaction 
mixture was stirred at 23 °C for 75 min, then was filtered through a plug of Celite. The 
filtrate was concentrated. The crude product was purified by preparative HPLC on an 
Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, Solvent A: 
0.1% trifluoroacetic acid in water, Solvent B: acetonitrile, 2 batches, injection volume: 
8.0 mL (6.0 mL 0.1% trifluoroacetic acid in water, 2.0 mL acetonitrile), gradient elution 
with 20o40% B over 40 min, flow rate: 15 mL/min]. Fractions eluting at 4–9 min were 
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collected and concentrated, affording 5-(Į)-methoxyminocycline trifluoroacetate (86) as a 
yellow solid (359 mg, 100%, 2 steps). 
1H NMR (600 MHz, CD3OD, trifluoroacetate) į 7.83 (d, 1H, J = 9.4 Hz), 7.03 (dd, 1H, J 
= 9.2, 0.7 Hz), 4.25 (d, 1H, J = 1.2 Hz), 3.67 (s, 3H), 3.62 (dd, 1H, J = 15.2, 4.4 Hz), 3.22 
(dd, 1H, J = 11.4, 9.1 Hz), 3.16 (s, 6H), 3.07–3.02 (m, 1H), 2.99 (dd, 1H, J = 11.4, 9.3 
Hz), 2.94 (s, 6H), 2.66 (dd, 1H, J = 14.5, 14.4 Hz); HRMS–ESI (m/z): [M+H]+ calcd for 
C24H30N3O8, 488.2027; found, 488.2052. 
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9-Nitro-5-(Į)-methoxyminocycline (87). Potassium nitrate (46.6 mg, 0.461 mmol, 1.1 
equiv) was added in one portion to a cooled orange solution of 5-(Į)-
methoxyminocycline trifluoroacetate (86, 252 mg, 0.419 mmol, 1 equiv) in concentrated 
sulfuric acid (2.0 mL) at 0 °C. The reaction mixture was stirred at this temperature for 2 
h, then was added portionwise and dropwise over 5 min to ice-cold diethyl ether (20 mL), 
leading to formation of a yellow precipitate. The resulting suspension was transferred 
using a wide-bore pipette to a Celite pad contained in a sintered glass funnel. The Celite 
pad was washed thoroughly with ice-cold diethyl ether (100 mL). The crude nitration 
product was then eluted with methanol (100 mL). The orange-yellow filtrate from elution 
with methanol was concentrated. The crude product was purified by preparative HPLC 
on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, 
Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: acetonitrile, 2 batches, injection 
volume: 8.0 mL (6.0 mL 0.1% trifluoroacetic acid in water, 2.0 mL acetonitrile), gradient 
elution with 20o40% B over 40 min, flow rate: 15 mL/min]. Fractions eluting at 18-28 
min were collected and concentrated, affording 9-nitro-5-(Į)-methoxyminocycline 
trifluoroacetate (87) as a brownish yellow solid (171 mg, 63%). 
1H NMR (600 MHz, CD3OD, trifluoroacetate) į 8.01 (s, 1H), 4.26 (d, 1H, J = 1.2 Hz), 
3.80 (dd, 1H, J = 15.8, 4.5 Hz), 3.69 (s, 3H), 3.27 (dd, 1H, J = 11.6, 9.1 Hz), 2.99–2.92 
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(m, 2H), 2.94 (brs, 6H), 2.73 (s, 6H), 2.55 (dd, 1H, J = 15.7, 13.6 Hz); HRMS–ESI (m/z): 
[M+H]+ calcd for C24H29N4O10, 533.1878; found, 533.1881. 
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5-(Į)-Methoxytigecycline (89). Palladium black (14.8 mg, 0.139 mmol, 0.4 equiv) was 
added in one portion to a solution of 9-nitro-5-(Į)-methoxyminocycline trifluoroacetate 
(87, 225 mg, 0.348 mmol, 1 equiv) in methanol (8.0 mL) at 23 °C. An atmosphere of 
hydrogen was introduced by briefly evacuating the flask, then flushing with pure 
hydrogen (1 atm). The reaction mixture was stirred at 23 °C for 1 ½ h, then was filtered 
through a plug of Celite. The filtrate was concentrated. The crude aniline product (88) 
was then divided into 8 equal portions (0.0435 mmol each, assuming 100% yield for nitro 
reduction) and used in diversifying steps without further purification. 
2-(tert-Butylamino)acetyl chloride hydrochloride (16.2 mg, 0.087 mmol, 2.0 equiv) was 
added in one portion to a solution of crude 9-amino-5-(Į)-methoxyminocycline 
trifluoroacetate (0.0435 mmol, 1 equiv) in N,N-dimethylformamide (200 µL) and 
acetonitrile (200 µL) at 23 °C. The reaction mixture was stirred at this temperature for 2 
h, whereupon 0.1% aqueous trifluoroacetic acid solution was added (6.0 mL). The 
resulting crude product solution was filtered and then purified by preparative HPLC by 
loading directly onto an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV detection 
at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: acetonitrile, gradient 
elution with 5o40% B over 50 min, flow rate: 7.5 mL/min]. Fractions eluting 21-24 min 
were collected and concentrated, affording 5-(Į)-methoxytigecycline bistrifluoroacetate 
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(89) as a yellow solid (18.0 mg, 49% over 2 steps from 9-nitro-5-(Į)-
methoxyminocycline). 
1H NMR (600 MHz, CD3OD, bistrifluoroacetate) į 8.48 (s, 1H), 4.26 (d, 1H, J = 1.2 Hz), 
4.09 (s, 2H), 3.71 (dd, 1H, J = 15.2, 4.5 Hz), 3.68 (s, 3H), 3.23 (dd, 1H, J = 11.6, 8.9 Hz), 
3.00–2.94 (m, 2H), 2.94 (brs, 6H), 2.88 (s, 6H), 2.51 (dd, 1H, J = 15.2, 13.6 Hz), 1.43 (s, 
9H); HRMS–ESI (m/z): [M+H]+ calcd for C30H42N5O9, 616.2977; found, 616.2969. 
213 
 
 
9-(N,N-dimethylglycylamido)-5-(Į)-methoxyminocycline (90). 2-(Dimethylamino)-
acetyl chloride hydrochloride (13.7 mg, 0.087 mmol, 2.0 equiv) was added in one portion 
to a solution of crude 9-amino-5-(Į)-methoxyminocycline trifluoroacetate (88, 0.0435 
mmol, 1 equiv) in N,N-dimethylformamide (200 µL) and acetonitrile (200 µL) at 23 °C. 
The reaction mixture was stirred at this temperature for 3 h, whereupon 0.1% aqueous 
trifluoroacetic acid solution was added (6.0 mL). The resulting crude product solution 
was filtered and then purified by preparative HPLC by loading directly onto an Agilent 
Prep C18 column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, Solvent A: 0.1% 
trifluoroacetic acid in water, Solvent B: acetonitrile, gradient elution with 5o40% B over 
50 min, flow rate: 7.5 mL/min]. Fractions eluting 18-20 min were collected and 
concentrated, affording 9-(N,N-dimethylglycylamido)-5-(Į)-methoxyminocycline 
bistrifluoroacetate (90) as a yellow solid (15.0 mg, 42% over 2 steps from 9-nitro-5-(Į)-
methoxyminocycline). 
1H NMR (600 MHz, CD3OD, bistrifluoroacetate) į 8.49 (s, 1H), 4.25 (d, 1H, J = 1.0 Hz), 
4.25 (s, 2H), 3.71–3.68 (m, 1H), 3.68 (s, 3H), 3.23 (dd, 1H, J = 11.4, 9.1 Hz), 3.02 (s, 
6H), 3.02–2.94 (m, 2H), 2.94 (s, 6H), 2.92 (s, 6H), 2.53 (dd, 1H, J = 15.1, 13.6 Hz); 
HRMS–ESI (m/z): [M+H]+ calcd for C28H38N5O9, 588.2664; found, 588.2663. 
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9-(Pyrollidinoglycylamido)-5-(Į)-methoxyminocycline (91). Bromoacetyl bromide (4.5 
µL, 0.052 mmol, 1.2 equiv) was added dropwise to a mixture of crude 9-amino-5-(Į)-
methoxyminocycline trifluoroacetate (88, 0.0435 mmol, 1 equiv) and sodium carbonate 
(23 mg, 0.22 mmol, 5.0 equiv) in N,N-dimethylformamide (300 µL) and acetonitrile (100 
µL) at 23 °C. The resulting mixture was stirred at this temperature for 15 min, whereupon 
pyrrolidine (36.0 µL, 0.435 mmol, 10.0 equiv) was added. The reaction mixture was 
stirred at 23 °C for a further 2 h, then 0.1% aqueous trifluoroacetic acid solution was 
added (6.0 mL). The resulting crude product solution was filtered and then purified by 
preparative HPLC by loading directly onto an Agilent Prep C18 column [10 µm, 250 x 
21.2 mm, UV detection at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent 
B: acetonitrile, gradient elution with 5o40% B over 50 min, flow rate: 7.5 mL/min]. 
Fractions eluting 20–23 min were collected and concentrated, providing 9-
(pyrrolidino)acetamido-5-(Į)-methoxyminocycline bistrifluoroacetate (91) as a yellow 
solid (14.5 mg, 40% yield over 2 steps from 9-nitro-5-(Į)-methoxyminocycline). 
1H NMR (600 MHz, CD3OD, bistrifluoroacetate) į 8.56 (s, 1H), 4.34 (s, 2H), 4.25 (d, 
1H, J = 1.2 Hz), 3.80 (brs, 2H), 3.68 (s, 3H), 3.69–3.65 (m, 1H), 3.24–3.18 (brm, 2H), 
3.23 (dd, 1H, J = 11.5, 9.0 Hz), 3.03–2.94 (m, 2H), 3.00 (s, 6H), 2.94 (s, 6H), 2.57 (dd, 
1H, J = 15.1, 13.6 Hz), 2.18 (brs, 2H), 2.09 (brs, 2H); HRMS–ESI (m/z): [M+H]+ calcd 
for C30H40N5O9, 614.2821; found, 614.2823. 
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Michael–Claisen cyclization product 92. A freshly prepared solution of lithium 
diisopropylamide (1.0 M, 3.45 mL, 3.45 mmol, 3.0 equiv) was added dropwise via 
syringe to a solution of phenyl ester 81 (1.19 g, 3.45 mmol, 3.0 equiv) and TMEDA (1.04 
mL, 6.89 mmol, 6.0 equiv) in tetrahydrofuran (40 mL) at –78 °C, forming a dark red 
solution. After stirring at –78 °C for 45 min, a solution of Ȗ-(Į)-fluoro AB enone 72 (575 
mg, 1.15 mmol, 1 equiv) in tetrahydrofuran (5 mL) was added dropwise via syringe to the 
reaction solution. The resulting mixture was allowed to warm slowly to –10 °C over 100 
min, then was partitioned between aqueous potassium phosphate buffer solution (pH 7.0, 
0.2 M, 125 mL) and dichloromethane (125 mL). The phases were separated and the 
aqueous phase was further extracted with dichloromethane (2 x 50 mL). The organic 
extracts were combined and the combined solution was dried over anhydrous sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated, affording a 
brown oil. The product was purified by flash-column chromatography (8% ethyl acetate–
hexanes), providing the Michael–Claisen cyclization product 92 as a greenish-yellow 
solid (523 mg, 61%). 
Rf = 0.48 (25% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 15.64 (s, 1H), 
7.52–7.50 (m, 2H), 7.41–7.35 (m, 3H), 7.25 (dd, 1H, J = 8.3, 8.3 Hz), 7.07 (dd, 1H, J = 
9.0, 4.5 Hz), 5.38 (AB quartet, 2H), 5.03 (ddd, 1H, J = 47.8, 3.5, 1.0 Hz), 3.67 (dd, 1H, J 
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= 15.6, 5.4 Hz), 3.62 (d, 1H, J = 11.2 Hz), 3.56–3.45 (m, 1H), 2.93 (ddd, 1H, J = 22.0, 
10.8, 1.0 Hz), 2.52 (s, 6H), 2.48 (dd, 1H, J = 15.6, 15.6 Hz), 1.53 (s, 9H), 0.83 (s, 9H), 
0.24 (s, 3H), 0.09 (s, 3H); 13C NMR (125 MHz, CDCl3) į 188.0, 186.0, 180.1 (d, J = 4.7 
Hz), 178.1, 167.4, 156.6 (d, J = 244.4 Hz), 151.6, 146.1 (d, J = 2.7 Hz), 134.9, 128.6, 
128.5, 128.5, 127.8 (d, J = 19.2 Hz), 123.6 (d, J = 8.2 Hz), 123.5 (d, J = 3.7 Hz), 120.6 
(d, J = 23.8 Hz), 108.4, 104.0 (d, J = 8.2 Hz), 92.4 (d, J = 180.3 Hz), 84.2, 81.9, 72.7, 
59.6 (d, J = 10.1 Hz), 52.5 (d, J = 20.1 Hz), 41.9, 36.8 (d, J = 28.4 Hz), 27.9, 27.6, 25.9, 
19.0, –2.4, –3.4; 19F NMR (300 MHz, CDCl3) į –115.1, –159.8; FTIR (neat film), 1763 
(w), 1721 (m), 1614 (w), 1508 (m), 1452 (m), 1144 (m), 733 (s) cm–1; HRMS–ESI (m/z): 
[M+H]+ calcd for C39H47F2N2O9Si, 753.3013; found, 753.3023. 
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7-Fluoro-5-(Į)-fluorosancycline (93). Concentrated aqueous hydrofluoric acid solution 
(48 wt%, 3.0 mL) was added to a solution of the Michael–Claisen cyclization product 92 
(416 mg, 0.553 mmol, 1 equiv) in acetonitrile (4.5 mL) in a polypropylene reaction vessel 
at 23 °C. The reaction solution was stirred vigorously at 23 °C for 16 h, then was poured 
into water (150 mL) containing dipotassium hydrogenphosphate trihydrate (30 g). The 
resulting mixture was extracted with ethyl acetate (150 mL, then 2 x 50 mL). The organic 
extracts were combined and the combined solution was dried over anhydrous sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. Methanol (4.0 
mL) and dioxane (4.0 mL) were added to the crude product. Palladium black (23.5 mg, 
0.221 mmol, 0.4 equiv) was added in one portion to the resulting solution at 23 °C. An 
atmosphere of hydrogen was introduced by briefly evacuating the flask, then flushing 
with pure hydrogen (1 atm). The reaction mixture was stirred at 23 °C for 1 h, then was 
filtered through a plug of Celite. The filtrate was concentrated. The product was purified 
by preparative HPLC on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV 
detection at 350 nm, Solvent A: 0.1% trifluoroacetic acid in water, Solvent B: 
acetonitrile, 2 batches, injection volume: 8.0 mL (6.0 mL 0.1% trifluoroacetic acid in 
water, 2.0 mL acetonitrile), gradient elution with 20o40% B over 40 min, flow rate: 15 
mL/min]. Fractions eluting at 15–25 min were collected and concentrated, affording 7-
fluoro-5-(Į)-fluorosancycline trifluoroacetate (93) as a yellow solid (310 mg, 99%, two 
steps). 
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1H NMR (600 MHz, CD3OD, trifluoroacetate) G 7.32 (dd, 1H, J = 9.1, 8.9 Hz), 6.85 (dd, 
1H, J = 9.2, 4.2 Hz), 4.57 (ddd, 1H, J = 48.8, 11.8, 9.0 Hz), 4.56 (s, 1H), 3.49 (dd, 1H, J 
= 15.7, 4.7 Hz), 3.32 (dd, 1H, J = 11.9, 5.5 Hz), 3.28–3.21 (m, 1H), 2.93 (brs, 6H), 2.48 
(dd, 1H, J = 14.8, 14.4 Hz); HRMS–ESI (m/z): [M+H]+ calcd for C21H21F2N2O7, 
451.1311; found, 451.1312. 
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Michael–Claisen cyclization product 97. A freshly prepared solution of lithium 
diisopropylamide (1.0 M, 2.31 mL, 2.31 mmol, 3.1 equiv) was added dropwise via 
syringe to a solution of phenyl ester 31 (808 mg, 2.23 mmol, 3.0 equiv) and TMEDA 
(670 µL, 4.47 mmol, 6.0 equiv) in tetrahydrofuran (20 mL) at –78 °C, forming a dark red 
solution. After stirring at –78 °C for 40 min, a solution of Ȗ-(Į)-azido-substituted AB 
enone 73 (390 mg, 0.745 mmol, 1 equiv) in tetrahydrofuran (4.0 mL) was added 
dropwise via syringe to the reaction solution. The resulting mixture was stirred at –78 °C 
for 10 min, then was allowed to warm slowly to –10 °C over 100 min. Aqueous 
potassium phosphate buffer solution (pH 7.0, 0.2 M, 50 mL) was added and the resulting 
mixture was allowed to warm to 23 °C. Dichloromethane (50 mL) was added to the crude 
product mixture and the phases were separated. The aqueous phase was further extracted 
with dichloromethane (50 mL). The organic extracts were combined and the combined 
solution was dried over anhydrous sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The product was purified first by flash-column chromatography 
(12% ethyl acetate–hexanes), then by preparative HPLC on an Agilent Prep C18 column 
[10 µm, 250 x 21.2 mm, UV detection at 350 nm, Solvent A: water, Solvent B: methanol, 
3 batches, gradient elution with 95o100% B over 50 min, flow rate: 15 mL/min]. 
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Fractions eluting at 16–22 min were collected and concentrated, providing the Michael–
Claisen cyclization product 97 as a yellow solid (294 mg, 50%). 
Rf = 0.28 (20% ethyl acetate–hexanes); 1H NMR (500 MHz, CDCl3) į 15.82 (s, 1H), 7.53 
(d, 2H, J = 6.8 Hz), 7.45 (d, 2H, J = 6.8 Hz), 7.42-7.29 (m, 6H), 7.22 (d, 1H, J = 8.8 Hz), 
6.89 (d, 1H, J = 8.8 Hz), 5.40 (s, 2H), 5.16 (AB quartet, 2H), 4.14 (d, 1H, J = 5.9 Hz), 
3.80 (dd, 1H, J = 15.6, 5.9 Hz), 3.74 (d, 1H, J = 10.7 Hz), 3.07-3.01 (m, 1H), 2.82 (d, 1H, 
J = 11.7 Hz), 2.65 (s, 6H), 2.55 (s, 6H), 2.26 (app t, 1H, J = 15.6, 14.7 Hz), 0.86 (s, 9H), 
0.28 (s, 3H), 0.08 (s, 3H); 13C NMR (125 MHz, CDCl3) į 187.3, 186.7, 180.6, 180.1, 
167.5, 154.9, 145.1, 136.9, 136.5, 135.0, 128.5, 128.5, 128.5, 128.4, 127.7, 126.8, 125.3, 
119.7, 114.0, 108.6, 105.1, 82.6, 72.6, 71.4, 62.7, 61.6, 52.5, 44.8, 41.9, 36.7, 32.3, 26.0, 
19.1, -2.3, -3.1; FTIR (neat film), 2097 (s), 1722 (m), 1611 (m), 1512 (s), 1250 (s), 833 
(s) cm–1; HRMS–ESI (m/z): [M+H]+ calcd for C43H51N6O7Si, 791.3583; found, 791.3605. 
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tert-Butyl carbamate 98. A solution of trimethylphosphine in tetrahydrofuran (1.0 M, 50 
µL, 0.050 mmol, 1.4 equiv) was added dropwise to a solution of the Michael–Claisen 
cyclization product 97 (27.9 mg, 0.035 mmol, 1 equiv) in tetrahydrofuran (2.5 mL) and 
water (2.5 µL) at 23 °C. The resulting mixture was stirred at this temperature for 90 min, 
whereupon an additional portion of trimethylphosphine solution (10 µL, 0.010 mmol, 0.3 
equiv) was added. After stirring at 23 °C for a further 30 min, the reaction mixture was 
concentrated. The crude iminophosphorane product was dissolved in tetrahydrofuran (0.5 
mL) and water (0.25 mL), and aqueous sodium hydroxide solution (2.0 M, 0.25 mL) was 
added dropwise to the resulting solution. The reaction mixture was stirred at 23 °C for 1 
h, whereupon aqueous hydrochloric acid solution (2.0 M, 0.25 mL) was added. Saturated 
aqueous sodium bicarbonate solution (10 mL) and ethyl acetate (10 ml) were added in 
sequence and the phases were separated. The aqueous phase was extracted with ethyl 
acetate (10 mL). The organic extracts were combined and the combined solution was 
dried. The dried solution as filtered and the filtrate was concentrated. The crude 
Staudinger reduction product was dissolved in dichloromethane (1.0 mL), and 
triethylamine (9.8 µL, 0.071 mmol, 2.0 equiv) and di-tert-butyl dicarbonate (12.3 µL, 
0.053 mmol, 1.5 equiv) were added in sequence. The reaction mixture was stirred at 23 
°C for 9 h, then was concentrated. The crude product was purified by preparative HPLC 
on an Agilent Prep C18 column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, 
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Solvent A: water, Solvent B: methanol, gradient elution with 95o100% B over 50 min, 
flow rate: 15 mL/min]. Fractions eluting at 14–18 min were collected and concentrated, 
affording tert-butyl carbamate 98 as a yellow solid (18.4 mg, 60%). 
1H NMR (500 MHz, CDCl3) į 16.28, 7.51 (d, 2H, J = 7.3 Hz), 7.47 (d, 2H, J = 7.3 Hz), 
7.41-7.29 (m, 6H), 7.19 (d, 1H, J = 8.8 Hz), 6.87 (d, 1H, J = 8.8 Hz), 5.38 (s, 2H), 5.18 
(AB quartet, 2H), 4.55 (d, 1H, J = 9.8 Hz), 3.95 (dd, 1H, J = 15.7, 4.9 Hz), 3.94 (d, 1H, J 
= 10.8 Hz), 2.83-2.79 (m, 1H), 2.67-2.63 (m, 1H), 2.63 (s, 6H), 2.52 (s, 6H), 2.35 (appt, 
1H, J = 15.1, 15.1 Hz), 1.41 (s, 9H), 0.93 (s, 9H), 0.36 (s, 3H), 0.08 (s, 3H); 13C NMR 
(125 MHz, CDCl3) į 186.5, 184.4, 181.2, 181.1, 167.4, 155.2, 154.8, 145.3, 138.0, 136.9, 
135.0, 128.5, 128.5, 128.5, 128.4, 127.7, 126.8, 125.2, 120.6, 113.6, 108.4, 106.7, 83.1, 
79.1, 72.6, 71.3, 60.8, 52.7, 48.5, 44.7, 41.8, 40.2, 33.2, 28.3, 26.3, 19.1, -2.5, -2.6; FTIR 
(neat film), 1717 (s), 1611 (w), 1512 (m), 1474 (m), 1171 (m) cm–1; HRMS–ESI (m/z): 
[M+H]+ calcd for C48H61N4O9Si, 865.4202; found, 865.4246. 
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5-Aminominocycline (99). Palladium black (23.6 mg, 0.222 mmol, 2.0 equiv) was added 
in one portion to a solution of tert-butyl carbamate 98 (96 mg, 0.111 mmol, 1 equiv) in 
methanol–dioxane (4 mL, 1:1 mixture) at 23 °C. An atmosphere of hydrogen was 
introduced by briefly evacuating the flask, then flushing with pure hydrogen (1 atm). The 
reaction mixture was stirred at 23 °C for 2 ½ h, then was filtered through a plug of Celite. 
The filtrate was concentrated, affording an orange solid. Concentrated aqueous 
hydrofluoric acid (48 wt%, 0.8 mL) was added to a solution of the crude product in 
acetonitrile (1.6 mL) in a polypropylene reaction vessel at 23 °C. The reaction mixture 
was stirred vigorously at 23 °C for 12 h. Excess hydrofluoric acid was quenched by the 
careful addition of methoxytrimethylsilane (6.0 mL). The resulting mixture was 
concentrated. The product was purified by preparative HPLC on an Agilent Prep C18 
column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, Solvent A: 0.1% trifluoroacetic 
acid in water, Solvent B: acetonitrile, gradient elution with 5o40% B over 50 min, flow 
rate: 7.5 mL/min]. Fractions eluting at 30–35 min were collected and concentrated, 
affording C5-aminominocycline trifluoroacetate (99) as a yellow solid (65 mg, 100%, 
two steps). 
1H NMR (600 MHz, CD3OD, trifluoroacetate) į 7.90 (d, 1H, J = 9.2 Hz), 7.07 (d, 1H, J = 
9.2 Hz), 4.10 (d, 1H, J = 8.6 Hz), 3.96 (brs, 1H), 3.81 (dd, 1H, J = 15.4, 4.4 Hz), 3.29-
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3.26 (m, 1H), 3.27 (s, 6H), 3.09 (brs, 1H), 2.92 (s, 6H), 2.92-2.90 (m, 1H); HRMS–ESI 
(m/z): [M+H]+ calcd for C23H29N4O7, 473.2031; found, 473.2052. 
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5-N-Acetylaminominocycline (100). N,N-Diisopropylethylamine (6.0 µL, 0.034 mmol, 
5.0 equiv) and acetyl chloride (1.9 µL, 0.027 mmol, 4.0 equiv) were added sequentially 
to solution of 5-aminominocycline trifluoroacetate (99, 4.0 mg, 0.0068 mmol, 1 equiv) in 
methanol (200 µL) at 0 °C. The resulting solution was allowed to warm to 23 °C over 5 
min. The reaction mixture was stirred at this temperature for 40 min, then was 
concentrated. The product was purified by preparative HPLC on an Agilent Prep C18 
column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, Solvent A: 0.1% trifluoroacetic 
acid in water, Solvent B: acetonitrile, injection volume: 5.0 mL (4.0 mL 0.1% 
trifluoroacetic acid in water, 1.0 mL acetonitrile), gradient elution with 5o40% B over 
50 min, flow rate: 7.5 mL/min]. Fractions eluting at 24-27 min were collected and 
concentrated, affording 5-N-acetylaminominocycline trifluoroacetate (100) as a yellow 
solid (3.1 mg, 73%). 
1H NMR (600 MHz, CD3OD, trifluoroacetate) G 7.69 (d, 1H, J = 9.2 Hz), 6.97 (d, 1H, J = 
9.2 Hz), 4.00 (brs, 1H), 3.92 (s, 1H), 3.41 (dd, 1H, J = 15.4, 4.1 Hz), 3.03-2.92 (m, 2H), 
2.98 (s, 6H), 2.95 (s, 6H), 2.38 (appt, 1H, J = 14.8, 14.3 Hz), 2.13 (s, 3H); HRMS–ESI 
(m/z): [M+H]+ calcd for C25H31N4O8, 515.2136; found 515.2128. 
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5-Aminomethylminocycline precursor 102. Michael–Claisen cyclization product 101 
(815 mg, 0.938 mmol, 1 equiv) was dissolved in 1,2-dichloroethane (10 mL) and argon 
was bubbled through the resulting solution for 2 min. The solution was then transferred to 
a round–bottomed flask containing tetrakis(triphenylphosphine)palladium (108 mg, 0.094 
mmol, 0.1 equiv) and 1,3-dimethylbarbituric acid (878 mg, 5.63 mmol, 6.0 equiv). The 
yellow homogeneous reaction solution was heated to 35 °C. After stirring at this 
temperature for 80 min, the reaction solution was allowed to cool to 23 °C. The cooled 
solution was diluted with ethyl acetate (50 mL) and the resulting solution was poured into 
saturated aqueous sodium bicarbonate solution (50 mL). The phases were separated and 
the aqueous phase was further extracted with ethyl acetate (2 x 50 mL). The organic 
extracts were combined and the combined solution was dried over anhydrous sodium 
sulfate. The dried solution was filtered and the filtrate was concentrated. The crude 
product was purified by flash-column chromatography (1.5% methanol–dichloromethane, 
grading to 5%), affording amine 102 as a golden brown solid (571 mg, 77%). 
Rf = 0.26 (5% methanol–dichloromethane); 1H NMR (500 MHz, CDCl3) į 7.50 (d, 2H, J 
= 6.8 Hz), 7.39–7.32 (m, 3H), 7.23 (d, 1H, J = 8.8 Hz), 7.01 (d, 1H, J = 8.3 Hz), 5.37 
(AB quartet, 2H), 3.71 (d, 1H, J = 10.7 Hz), 3.60 (dd, 1H, J = 15.4, 5.2 Hz), 3.09–3.00 
(m, 2H), 2.77 (d, 1H, J = 10.3 Hz), 2.75–2.70 (m, 1H), 2.66 (s, 6H), 2.50 (s, 6H), 2.29 
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(dd, 1H, J = 15.2, 15.1 Hz), 2.22–2.18 (m, 1H), 1.52 (s, 9H), 0.87 (s, 9H), 0.24 (s, 3H), –
0.03 (s, 3H); 13C NMR (125 MHz, CDCl3) į 187.3, 187.2, 181.0, 180.1, 167.3, 152.0, 
149.4, 145.1, 136.3, 135.0, 128.4, 128.4, 128.3, 124.1, 123.2, 122.1, 108.5, 107.4, 83.6, 
83.5, 72.4, 62.6, 53.4, 48.4, 47.7, 44.4, 43.0, 41.8, 33.7, 33.5, 27.6, 26.4, 19.1, –2.5, –2.6; 
HRMS–ESI (m/z): [M+H]+ calcd for C42H57N4O9Si, 789.3889; found, 789.3920. 
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X-Ray Crystallography (Michael–Claisen cyclization product 105):  A crystal 
mounted on a diffractometer was collected data at 100 K. The intensities of the 
reflections were collected by means of a Bruker APEX II CCD along with the D8 
Diffractometer (30 KeV, O= 0.413280 Å), and equipped with an Oxford Cryosystems 
nitrogen open flow apparatus.  The collection method involved 0.5q scans in Phi at -5q in 
2T.  Data integration down to 0.82 Å resolution was carried out using SAINT V7.46 A 
(Bruker diffractometer, 2009) with reflection spot size optimisation.  Absorption 
corrections were made with the program SADABS (Bruker diffractometer, 2009).  The 
structure was solved by the direct methods procedure and refined by least-squares 
methods again F2 using SHELXS-97 and SHELXL-97 (Sheldrick, 2008).  Non-hydrogen 
atoms were refined anisotropically, and hydrogen atoms were allowed to ride on the 
respective atoms.  Crystal data as well as details of data collection and refinement are 
summarized in Table 3.10, geometric parameters are shown in Tables 3.11, and 
hydrogen-bond parameters are listed in Table 3.12. The Ortep plots produced with 
SHELXL-97 program, and the other drawings were produced with Accelrys DS 
Visualizer 2.0 (Accelrys, 2007). 
Acknowledgement: We thank Dr. Yu-Sheng Chen at ChemMatCARS, APS, for his 
assistance with single-crystal data. ChemMatCARS Sector 15 is principally supported by 
the National Science Foundation/Department of Energy under grant number NSF/CHE-
0822838. Use of the Advanced Photon Source was supported by the U. S. Department of 
Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-
AC02-06CH11357. 
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Table 3.10. Experimental details 
 IV-PMW-117 
Crystal data 
Chemical formula C90H110N6O18Si2 
Mr 1620.02 
Crystal system, space group Triclinic, P1 
Temperature (K) 100 
a, b, c (Å) 8.5526 (8), 13.1550 (12), 20.6010 (19) 
D, E, J (°) 106.209 (2), 90.871 (2), 105.015 (2) 
V (Å3) 2140.1 (3) 
Z 1 
Radiation type Synchrotron, O = 0.41328 Å 
P (mm-1) 0.07 
Crystal size (mm) 0.03 × 0.03 × 0.02 
Data collection 
Diffractometer Bruker D8 goniometer with CCD area detector diffractometer 
Absorption correction Multi-scan  
SADABS 
 Tmin, Tmax 0.998, 0.999 
No. of measured, independent and 
observed [I > 2V(I)] reflections 
34033, 12277, 9207   
Rint 0.042 
Refinement 
R[F2 > 2V(F2)], wR(F2), S 0.096,  0.211,  1.10 
No. of reflections 12277 
No. of parameters 1169 
No. of restraints 499 
H-atom treatment H-atom parameters constrained 
'Umax, 'Umin (e Å-3) 0.94, -0.51 
Absolute structure Flack H D (1983), Acta Cryst. A39, 876-881 
Flack parameter -0.4 (12) 
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Computer programs: APEX2 v2009.3.0 (Bruker-AXS, 2009), SAINT 7.46A (Bruker-AXS, 2009), 
SHELXS97 (Sheldrick, 2008), SHELXL97 (Sheldrick, 2008), Bruker SHELXTL (Sheldrick, 2008). 
 
 
Table 3.11. Geometric parameters (Å, º) 
O1—C1 1.369 (7) O16—H16 0.8400 
O1—N1 1.422 (9) O17—C66 1.418 (10) 
O2—C22 1.398 (9) O17—Si2B 1.651 (10) 
O2—C4 1.443 (8) O17—Si2 1.723 (8) 
O4—C26 1.305 (11) O18—C67 1.200 (9) 
O4—C11 1.346 (10) O19—C69 1.315 (10) 
O5—C13 1.288 (9) O19—C89 1.530 (16) 
O6—C15 1.286 (9) O19—C89B 1.550 (12) 
O6—H6 0.8400 N11—C69 1.256 (10) 
O7—C16 1.419 (9) N12—C58 1.420 (11) 
O7—Si1B 1.655 (9) N12—C74 1.460 (12) 
O7—Si1 1.674 (9) N12—C75 1.467 (13) 
O8—C17 1.179 (8) C51—C68 1.282 (11) 
O9—C19 1.290 (9) C51—C52 1.512 (11) 
O9—C39B 1.518 (18) C52—N13 1.409 (11) 
O9—C39 1.520 (9) C52—C53 1.580 (9) 
N1—C19 1.304 (10) C52—H52 1.0000 
N2—C2 1.451 (9) C53—C54 1.509 (11) 
N2—C20 1.453 (10) C53—C66 1.524 (11) 
N2—C21 1.467 (10) C53—H53 1.0000 
N3—C25 1.292 (14) C54—C55 1.523 (9) 
N3—C25B 1.35 (2) C54—H54 1.0000 
N3—C8 1.403 (12) C55—C64 1.462 (10) 
N3—C24B 1.42 (2) C55—C56 1.529 (11) 
N3—C24 1.453 (14) C55—H55 1.0000 
C1—C18 1.313 (10) C56—C57 1.511 (10) 
C1—C2 1.459 (10) C56—H56A 0.9900 
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Table 3.11. (Continued)    
C2—C3 1.566 (8) C56—H56B 0.9900 
C2—H2 1.0000 C57—C62 1.353 (11) 
C3—C16 1.513 (10) C57—C58 1.416 (11) 
C3—C4 1.541 (9) N13—C70 1.449 (10) 
C3—H3 1.0000 N13—C71 1.462 (11) 
C4—C5 1.512 (9) C58—C59 1.424 (12) 
C4—H4 1.0000 C59—C60 1.359 (13) 
C5—C14 1.523 (10) C59—H59 0.9500 
C5—C6 1.543 (9) C60—C61 1.389 (12) 
C5—H5 1.0000 C60—H60 0.9500 
C6—C7 1.500 (9) C61—O14 1.335 (10) 
C6—H6A 0.9900 C61—C62 1.424 (10) 
C6—H6B 0.9900 C62—C63 1.487 (11) 
C7—C8 1.392 (11) C63—C64 1.420 (9) 
C7—C12 1.396 (11) C64—C65 1.390 (10) 
C8—C9 1.367 (11) C65—C66 1.520 (9) 
C9—C10 1.364 (12) C66—C67 1.559 (11) 
C9—H9 0.9500 C67—C68 1.471 (10) 
C10—C11 1.367 (11) C68—C69 1.439 (10) 
C10—H10 0.9500 C70—H70A 0.9800 
C11—C12 1.403 (9) C70—H70B 0.9800 
C12—C13 1.455 (10) C70—H70C 0.9800 
C13—C14 1.412 (9) C71—H71A 0.9800 
C14—C15 1.340 (10) C71—H71B 0.9800 
C15—C16 1.537 (9) C71—H71C 0.9800 
C16—C17 1.520 (10) C72—O13 1.366 (12) 
C17—C18 1.491 (9) C72—H72A 0.9900 
C18—C19 1.434 (10) C72—H72B 0.9900 
C20—H20A 0.9800 O13—C73 1.439 (12) 
C20—H20B 0.9800 C73—H73A 0.9800 
C20—H20C 0.9800 C73—H73B 0.9800 
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Table 3.11. (Continued)    
C21—H21A 0.9800 C73—H73C 0.9800 
C21—H21B 0.9800 C72B—O13B 1.36 (2) 
C21—H21C 0.9800 C72B—H72C 0.9900 
C22—O3 1.347 (10) C72B—H72D 0.9900 
C22—H22A 0.9900 O13B—C73B 1.44 (2) 
C22—H22B 0.9900 C73B—H73D 0.9800 
O3—C23 1.382 (12) C73B—H73E 0.9800 
C23—H23A 0.9800 C73B—H73F 0.9800 
C23—H23B 0.9800 C74—H74A 0.9800 
C23—H23C 0.9800 C74—H74B 0.9800 
C24—H24A 0.9800 C74—H74C 0.9800 
C24—H24B 0.9800 C75—H75A 0.9800 
C24—H24C 0.9800 C75—H75B 0.9800 
C25—H25A 0.9800 C75—H75C 0.9800 
C25—H25B 0.9800 O14—C76 1.449 (10) 
C25—H25C 0.9800 C76—C77 1.471 (11) 
C24B—H24D 0.9800 C76—C77B 1.475 (18) 
C24B—H24E 0.9800 C76—H76A 0.9900 
C24B—H24F 0.9800 C76—H76B 0.9900 
C25B—H25D 0.9800 C76—H76C 0.9900 
C25B—H25E 0.9800 C76—H76D 0.9900 
C25B—H25F 0.9800 C77—C78 1.3900 
C26—C27 1.508 (10) C77—C82 1.3900 
C26—H26A 0.9900 C78—C79 1.3900 
C26—H26B 0.9900 C78—H78 0.9500 
C27—C28 1.3900 C79—C80 1.3900 
C27—C32 1.3900 C79—H79 0.9500 
C28—C29 1.3900 C80—C81 1.3900 
C28—H28 0.9500 C80—H80 0.9500 
C29—C30 1.3900 C81—C82 1.3900 
C29—H29 0.9500 C81—H81 0.9500 
C30—C31 1.3900 C82—H82 0.9500 
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Table 3.11. (Continued)    
C30—H30 0.9500 C77B—C78B 1.3900 
C31—C32 1.3900 C77B—C82B 1.3900 
C31—H31 0.9500 C78B—C79B 1.3900 
C32—H32 0.9500 C78B—H78A 0.9500 
Si1—C35 1.875 (17) C79B—C80B 1.3900 
Si1—C33 1.918 (19) C79B—H79A 0.9500 
Si1—C34 1.951 (15) C80B—C81B 1.3900 
C33—H33A 0.9800 C80B—H80A 0.9500 
C33—H33B 0.9800 C81B—C82B 1.3900 
C33—H33C 0.9800 C81B—H81A 0.9500 
C34—H34A 0.9800 C82B—H82A 0.9500 
C34—H34B 0.9800 Si2—C85 1.794 (16) 
C34—H34C 0.9800 Si2—C83 1.94 (2) 
C35—C38 1.38 (2) Si2—C84 1.942 (15) 
C35—C37 1.44 (2) C83—H83A 0.9800 
C35—C36 1.53 (2) C83—H83B 0.9800 
C36—H36A 0.9800 C83—H83C 0.9800 
C36—H36B 0.9800 C84—H84A 0.9800 
C36—H36C 0.9800 C84—H84B 0.9800 
C37—H37A 0.9800 C84—H84C 0.9800 
C37—H37B 0.9800 C85—C88 1.476 (19) 
C37—H37C 0.9800 C85—C86 1.490 (19) 
C38—H38A 0.9800 C85—C87 1.69 (2) 
C38—H38B 0.9800 C86—H86A 0.9800 
C38—H38C 0.9800 C86—H86B 0.9800 
Si1B—C35B 1.908 (19) C86—H86C 0.9800 
Si1B—C34B 1.935 (19) C87—H87A 0.9800 
Si1B—C33B 1.965 (18) C87—H87B 0.9800 
Si1B—C38B 2.33 (2) C87—H87C 0.9800 
C34B—H34D 0.9800 C88—H88A 0.9800 
C34B—H34E 0.9800 C88—H88B 0.9800 
C34B—H34F 0.9800 C88—H88C 0.9800 
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Table 3.11. (Continued)    
C33B—H33D 0.9800 Si2B—C85B 1.786 (19) 
C33B—H33E 0.9800 Si2B—C84B 1.918 (19) 
C33B—H33F 0.9800 Si2B—C83B 2.07 (2) 
C35B—C38B 1.38 (2) C83B—H83D 0.9800 
C35B—C37B 1.40 (2) C83B—H83E 0.9800 
C35B—C36B 1.53 (2) C83B—H83F 0.9800 
C36B—H36D 0.9800 C84B—H84D 0.9800 
C36B—H36E 0.9800 C84B—H84E 0.9800 
C36B—H36F 0.9800 C84B—H84F 0.9800 
C37B—H37D 0.9800 C85B—C86B 1.45 (2) 
C37B—H37E 0.9800 C85B—C88B 1.50 (2) 
C37B—H37F 0.9800 C85B—C87B 1.70 (3) 
C38B—H38D 0.9800 C86B—H86D 0.9800 
C38B—H38E 0.9800 C86B—H86E 0.9800 
C38B—H38F 0.9800 C86B—H86F 0.9800 
C39—C40 1.425 (12) C87B—H87D 0.9800 
C39—H39A 0.9900 C87B—H87E 0.9800 
C39—H39B 0.9900 C87B—H87F 0.9800 
C40—C41 1.3900 C88B—H88D 0.9800 
C40—C45 1.3900 C88B—H88E 0.9800 
C41—C42 1.3900 C88B—H88F 0.9800 
C41—H41 0.9500 C89—C90 1.453 (19) 
C42—C43 1.3900 C89—H89A 0.9900 
C42—H42 0.9500 C89—H89B 0.9900 
C43—C44 1.3900 C90—C91 1.3900 
C43—H43 0.9500 C90—C95 1.3900 
C44—C45 1.3900 C91—C92 1.3900 
C44—H44 0.9500 C91—H91 0.9500 
C45—H45 0.9500 C92—C93 1.3900 
C39B—C40B 1.434 (19) C92—H92 0.9500 
C39B—H39C 0.9900 C93—C94 1.3900 
C39B—H39D 0.9900 C93—H93 0.9500 
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Table 3.11. (Continued)    
C40B—C41B 1.3900 C94—C95 1.3900 
C40B—C45B 1.3900 C94—H94 0.9500 
C41B—C42B 1.3900 C95—H95 0.9500 
C41B—H41A 0.9500 C89B—C90B 1.463 (18) 
C42B—C43B 1.3900 C89B—H89C 0.9900 
C42B—H42A 0.9500 C89B—H89D 0.9900 
C43B—C44B 1.3900 C90B—C91B 1.3900 
C43B—H43A 0.9500 C90B—C95B 1.3900 
C44B—C45B 1.3900 C91B—C92B 1.3900 
C44B—H44A 0.9500 C91B—H91A 0.9500 
C45B—H45A 0.9500 C92B—C93B 1.3900 
O11—C51 1.363 (8) C92B—H92A 0.9500 
O11—N11 1.409 (9) C93B—C94B 1.3900 
O12—C54 1.431 (10) C93B—H93A 0.9500 
O12—C72 1.453 (10) C94B—C95B 1.3900 
O12—C72B 1.47 (2) C94B—H94A 0.9500 
O15—C63 1.267 (9) C95B—H95A 0.9500 
O16—C65 1.287 (9)   
 
C1—O1—N1 107.8 (5) C58—N12—C75 110.3 (8) 
C22—O2—C4 114.6 (7) C74—N12—C75 107.7 (9) 
C26—O4—C11 113.4 (7) C68—C51—O11 111.1 (7) 
C15—O6—H6 109.5 C68—C51—C52 131.6 (6) 
C16—O7—Si1B 142.6 (6) O11—C51—C52 116.8 (7) 
C16—O7—Si1 131.4 (6) N13—C52—C51 121.5 (7) 
C19—O9—C39B 119.7 (12) N13—C52—C53 112.2 (6) 
C19—O9—C39 115.5 (7) C51—C52—C53 106.2 (6) 
C19—N1—O1 105.7 (5) N13—C52—H52 105.2 
C2—N2—C20 114.3 (6) C51—C52—H52 105.2 
C2—N2—C21 112.5 (7) C53—C52—H52 105.2 
C20—N2—C21 112.4 (6) C54—C53—C66 112.0 (6) 
C25—N3—C8 111.7 (11) C54—C53—C52 109.6 (6) 
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Table 3.11. (Continued)    
C25B—N3—C8 114 (2) C66—C53—C52 117.5 (6) 
C25—N3—C24B 124 (2) C54—C53—H53 105.6 
C25B—N3—C24B 111 (3) C66—C53—H53 105.6 
C8—N3—C24B 124 (2) C52—C53—H53 105.6 
C25—N3—C24 117.2 (11) O12—C54—C53 106.8 (6) 
C25B—N3—C24 81 (3) O12—C54—C55 110.3 (6) 
C8—N3—C24 112.6 (9) C53—C54—C55 112.1 (6) 
C18—C1—O1 109.8 (6) O12—C54—H54 109.2 
C18—C1—C2 129.9 (6) C53—C54—H54 109.2 
O1—C1—C2 120.0 (6) C55—C54—H54 109.2 
N2—C2—C1 118.3 (6) C64—C55—C54 112.8 (6) 
N2—C2—C3 112.0 (5) C64—C55—C56 108.7 (6) 
C1—C2—C3 109.7 (6) C54—C55—C56 113.7 (6) 
N2—C2—H2 105.2 C64—C55—H55 107.1 
C1—C2—H2 105.2 C54—C55—H55 107.1 
C3—C2—H2 105.2 C56—C55—H55 107.1 
C16—C3—C4 110.9 (6) C57—C56—C55 107.6 (7) 
C16—C3—C2 115.9 (6) C57—C56—H56A 110.2 
C4—C3—C2 108.4 (6) C55—C56—H56A 110.2 
C16—C3—H3 107.1 C57—C56—H56B 110.2 
C4—C3—H3 107.1 C55—C56—H56B 110.2 
C2—C3—H3 107.1 H56A—C56—H56B 108.5 
O2—C4—C5 112.8 (6) C62—C57—C58 122.9 (7) 
O2—C4—C3 107.1 (5) C62—C57—C56 119.4 (7) 
C5—C4—C3 110.7 (6) C58—C57—C56 117.7 (8) 
O2—C4—H4 108.7 C52—N13—C70 114.0 (7) 
C5—C4—H4 108.7 C52—N13—C71 113.0 (7) 
C3—C4—H4 108.7 C70—N13—C71 110.5 (7) 
C4—C5—C14 111.6 (6) C57—C58—N12 121.1 (7) 
C4—C5—C6 112.3 (5) C57—C58—C59 115.0 (9) 
C14—C5—C6 108.0 (5) N12—C58—C59 123.6 (8) 
C4—C5—H5 108.3 C60—C59—C58 122.3 (8) 
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Table 3.11. (Continued)    
C14—C5—H5 108.3 C60—C59—H59 118.8 
C6—C5—H5 108.3 C58—C59—H59 118.8 
C7—C6—C5 109.9 (6) C59—C60—C61 121.5 (8) 
C7—C6—H6A 109.7 C59—C60—H60 119.2 
C5—C6—H6A 109.7 C61—C60—H60 119.2 
C7—C6—H6B 109.7 O14—C61—C60 123.3 (7) 
C5—C6—H6B 109.7 O14—C61—C62 119.2 (7) 
H6A—C6—H6B 108.2 C60—C61—C62 117.6 (9) 
C8—C7—C12 120.3 (7) C57—C62—C61 120.3 (8) 
C8—C7—C6 119.8 (7) C57—C62—C63 119.6 (6) 
C12—C7—C6 119.8 (6) C61—C62—C63 120.0 (8) 
C9—C8—C7 119.3 (9) O15—C63—C64 122.7 (7) 
C9—C8—N3 121.0 (8) O15—C63—C62 121.4 (6) 
C7—C8—N3 119.7 (7) C64—C63—C62 115.9 (7) 
C10—C9—C8 120.8 (8) C65—C64—C63 116.8 (7) 
C10—C9—H9 119.6 C65—C64—C55 123.9 (6) 
C8—C9—H9 119.6 C63—C64—C55 119.2 (7) 
C9—C10—C11 121.1 (8) O16—C65—C64 124.0 (6) 
C9—C10—H10 119.4 O16—C65—C66 114.3 (6) 
C11—C10—H10 119.4 C64—C65—C66 121.7 (7) 
O4—C11—C10 120.5 (7) O17—C66—C65 109.1 (6) 
O4—C11—C12 119.9 (7) O17—C66—C53 109.6 (6) 
C10—C11—C12 119.5 (8) C65—C66—C53 111.5 (6) 
C7—C12—C11 118.7 (7) O17—C66—C67 105.1 (6) 
C7—C12—C13 117.7 (6) C65—C66—C67 110.1 (6) 
C11—C12—C13 123.5 (8) C53—C66—C67 111.3 (6) 
O5—C13—C14 119.8 (6) O18—C67—C68 125.4 (7) 
O5—C13—C12 119.6 (6) O18—C67—C66 125.1 (6) 
C14—C13—C12 120.6 (7) C68—C67—C66 109.3 (7) 
C15—C14—C13 120.5 (7) C51—C68—C69 104.4 (7) 
C15—C14—C5 122.7 (6) C51—C68—C67 121.7 (7) 
C13—C14—C5 116.5 (6) C69—C68—C67 133.9 (8) 
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Table 3.11. (Continued)    
O6—C15—C14 122.7 (6) N11—C69—O19 125.0 (7) 
O6—C15—C16 114.0 (6) N11—C69—C68 111.4 (8) 
C14—C15—C16 123.3 (7) O19—C69—C68 123.4 (7) 
O7—C16—C3 107.4 (6) N13—C70—H70A 109.5 
O7—C16—C17 106.0 (6) N13—C70—H70B 109.5 
C3—C16—C17 114.4 (6) H70A—C70—H70B 109.5 
O7—C16—C15 108.3 (6) N13—C70—H70C 109.5 
C3—C16—C15 111.0 (6) H70A—C70—H70C 109.5 
C17—C16—C15 109.5 (6) H70B—C70—H70C 109.5 
O8—C17—C18 123.9 (6) N13—C71—H71A 109.5 
O8—C17—C16 126.8 (6) N13—C71—H71B 109.5 
C18—C17—C16 109.3 (6) H71A—C71—H71B 109.5 
C1—C18—C19 106.0 (6) N13—C71—H71C 109.5 
C1—C18—C17 121.1 (6) H71A—C71—H71C 109.5 
C19—C18—C17 132.8 (7) H71B—C71—H71C 109.5 
O9—C19—N1 124.1 (7) O13—C72—O12 112.9 (8) 
O9—C19—C18 125.3 (7) O13—C72—H72A 109.0 
N1—C19—C18 110.6 (7) O12—C72—H72A 109.0 
N2—C20—H20A 109.5 O13—C72—H72B 109.0 
N2—C20—H20B 109.5 O12—C72—H72B 109.0 
H20A—C20—H20B 109.5 H72A—C72—H72B 107.8 
N2—C20—H20C 109.5 C72—O13—C73 112.0 (10) 
H20A—C20—H20C 109.5 O13—C73—H73A 109.5 
H20B—C20—H20C 109.5 O13—C73—H73B 109.5 
N2—C21—H21A 109.5 H73A—C73—H73B 109.5 
N2—C21—H21B 109.5 O13—C73—H73C 109.5 
H21A—C21—H21B 109.5 H73A—C73—H73C 109.5 
N2—C21—H21C 109.5 H73B—C73—H73C 109.5 
H21A—C21—H21C 109.5 O13B—C72B—O12 110 (3) 
H21B—C21—H21C 109.5 O13B—C72B—H72C 109.7 
O3—C22—O2 114.7 (7) O12—C72B—H72C 109.7 
O3—C22—H22A 108.6 O13B—C72B—H72D 109.7 
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O2—C22—H22A 108.6 O12—C72B—H72D 109.7 
O3—C22—H22B 108.6 H72C—C72B—H72D 108.2 
O2—C22—H22B 108.6 C72B—O13B—C73B 117 (4) 
H22A—C22—H22B 107.6 O13B—C73B—H73D 109.5 
C22—O3—C23 112.1 (9) O13B—C73B—H73E 109.5 
O3—C23—H23A 109.5 H73D—C73B—H73E 109.5 
O3—C23—H23B 109.5 O13B—C73B—H73F 109.5 
H23A—C23—H23B 109.5 H73D—C73B—H73F 109.5 
O3—C23—H23C 109.5 H73E—C73B—H73F 109.5 
H23A—C23—H23C 109.5 N12—C74—H74A 109.5 
H23B—C23—H23C 109.5 N12—C74—H74B 109.5 
N3—C24—H24A 109.5 H74A—C74—H74B 109.5 
N3—C24—H24B 109.5 N12—C74—H74C 109.5 
H24A—C24—H24B 109.5 H74A—C74—H74C 109.5 
N3—C24—H24C 109.5 H74B—C74—H74C 109.5 
H24A—C24—H24C 109.5 N12—C75—H75A 109.5 
H24B—C24—H24C 109.5 N12—C75—H75B 109.5 
N3—C25—H25A 109.5 H75A—C75—H75B 109.5 
N3—C25—H25B 109.5 N12—C75—H75C 109.5 
H25A—C25—H25B 109.5 H75A—C75—H75C 109.5 
N3—C25—H25C 109.5 H75B—C75—H75C 109.5 
H25A—C25—H25C 109.5 C61—O14—C76 120.1 (6) 
H25B—C25—H25C 109.5 O14—C76—C77 109.3 (7) 
N3—C24B—H24D 109.5 O14—C76—C77B 108.6 (11) 
N3—C24B—H24E 109.5 O14—C76—H76A 109.8 
H24D—C24B—H24E 109.5 C77—C76—H76A 109.8 
N3—C24B—H24F 109.5 C77B—C76—H76A 103.9 
H24D—C24B—H24F 109.5 O14—C76—H76B 109.8 
H24E—C24B—H24F 109.5 C77—C76—H76B 109.8 
N3—C25B—H25D 109.5 C77B—C76—H76B 116.2 
N3—C25B—H25E 109.5 H76A—C76—H76B 108.3 
H25D—C25B—H25E 109.5 O14—C76—H76C 110.0 
240 
 
Table 3.11. (Continued)    
N3—C25B—H25F 109.5 C77—C76—H76C 115.6 
H25D—C25B—H25F 109.5 C77B—C76—H76C 110.0 
H25E—C25B—H25F 109.5 H76B—C76—H76C 102.1 
O4—C26—C27 108.8 (8) O14—C76—H76D 110.0 
O4—C26—H26A 109.9 C77—C76—H76D 103.4 
C27—C26—H26A 109.9 C77B—C76—H76D 110.0 
O4—C26—H26B 109.9 H76A—C76—H76D 114.3 
C27—C26—H26B 109.9 H76C—C76—H76D 108.3 
H26A—C26—H26B 108.3 C78—C77—C82 120.0 
C28—C27—C32 120.0 C78—C77—C76 120.5 (6) 
C28—C27—C26 121.6 (5) C82—C77—C76 119.1 (6) 
C32—C27—C26 118.2 (6) C77—C78—C79 120.0 
C27—C28—C29 120.0 C77—C78—H78 120.0 
C27—C28—H28 120.0 C79—C78—H78 120.0 
C29—C28—H28 120.0 C80—C79—C78 120.0 
C28—C29—C30 120.0 C80—C79—H79 120.0 
C28—C29—H29 120.0 C78—C79—H79 120.0 
C30—C29—H29 120.0 C79—C80—C81 120.0 
C31—C30—C29 120.0 C79—C80—H80 120.0 
C31—C30—H30 120.0 C81—C80—H80 120.0 
C29—C30—H30 120.0 C82—C81—C80 120.0 
C30—C31—C32 120.0 C82—C81—H81 120.0 
C30—C31—H31 120.0 C80—C81—H81 120.0 
C32—C31—H31 120.0 C81—C82—C77 120.0 
C31—C32—C27 120.0 C81—C82—H82 120.0 
C31—C32—H32 120.0 C77—C82—H82 120.0 
C27—C32—H32 120.0 C78B—C77B—C82B 120.0 
O7—Si1—C35 104.6 (7) C78B—C77B—C76 125.3 (16) 
O7—Si1—C33 118.2 (7) C82B—C77B—C76 105.4 (16) 
C35—Si1—C33 115.3 (9) C77B—C78B—C79B 120.0 
O7—Si1—C34 107.0 (7) C77B—C78B—H78A 120.0 
C35—Si1—C34 106.0 (8) C79B—C78B—H78A 120.0 
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C33—Si1—C34 104.8 (9) C78B—C79B—C80B 120.0 
Si1—C33—H33A 109.5 C78B—C79B—H79A 120.0 
Si1—C33—H33B 109.5 C80B—C79B—H79A 120.0 
H33A—C33—H33B 109.5 C81B—C80B—C79B 120.0 
Si1—C33—H33C 109.5 C81B—C80B—H80A 120.0 
H33A—C33—H33C 109.5 C79B—C80B—H80A 120.0 
H33B—C33—H33C 109.5 C82B—C81B—C80B 120.0 
Si1—C34—H34A 109.5 C82B—C81B—H81A 120.0 
Si1—C34—H34B 109.5 C80B—C81B—H81A 120.0 
H34A—C34—H34B 109.5 C81B—C82B—C77B 120.0 
Si1—C34—H34C 109.5 C81B—C82B—H82A 120.0 
H34A—C34—H34C 109.5 C77B—C82B—H82A 120.0 
H34B—C34—H34C 109.5 O17—Si2—C85 108.6 (6) 
C38—C35—C37 113.1 (17) O17—Si2—C83 115.6 (7) 
C38—C35—C36 105.9 (15) C85—Si2—C83 100.4 (8) 
C37—C35—C36 113.0 (15) O17—Si2—C84 107.2 (7) 
C38—C35—Si1 104.3 (14) C85—Si2—C84 106.8 (8) 
C37—C35—Si1 111.9 (13) C83—Si2—C84 117.4 (9) 
C36—C35—Si1 108.1 (13) Si2—C83—H83A 109.5 
C35—C36—H36A 109.5 Si2—C83—H83B 109.5 
C35—C36—H36B 109.5 H83A—C83—H83B 109.5 
H36A—C36—H36B 109.5 Si2—C83—H83C 109.5 
C35—C36—H36C 109.5 H83A—C83—H83C 109.5 
H36A—C36—H36C 109.5 H83B—C83—H83C 109.5 
H36B—C36—H36C 109.5 Si2—C84—H84A 109.5 
C35—C37—H37A 109.5 Si2—C84—H84B 109.5 
C35—C37—H37B 109.5 H84A—C84—H84B 109.5 
H37A—C37—H37B 109.5 Si2—C84—H84C 109.5 
C35—C37—H37C 109.5 H84A—C84—H84C 109.5 
H37A—C37—H37C 109.5 H84B—C84—H84C 109.5 
H37B—C37—H37C 109.5 C88—C85—C86 118.5 (14) 
C35—C38—H38A 109.5 C88—C85—C87 101.3 (14) 
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C35—C38—H38B 109.5 C86—C85—C87 105.7 (14) 
H38A—C38—H38B 109.5 C88—C85—Si2 111.9 (12) 
C35—C38—H38C 109.5 C86—C85—Si2 112.2 (12) 
H38A—C38—H38C 109.5 C87—C85—Si2 105.6 (11) 
H38B—C38—H38C 109.5 C85—C86—H86A 109.5 
O7—Si1B—C35B 122.1 (7) C85—C86—H86B 109.5 
O7—Si1B—C34B 111.3 (8) H86A—C86—H86B 109.5 
C35B—Si1B—C34B 114.7 (10) C85—C86—H86C 109.5 
O7—Si1B—C33B 101.9 (8) H86A—C86—H86C 109.5 
C35B—Si1B—C33B 100.2 (9) H86B—C86—H86C 109.5 
C34B—Si1B—C33B 102.8 (11) C85—C87—H87A 109.5 
O7—Si1B—C38B 101.7 (7) C85—C87—H87B 109.5 
C34B—Si1B—C38B 102.3 (10) H87A—C87—H87B 109.5 
C33B—Si1B—C38B 136.1 (9) C85—C87—H87C 109.5 
Si1B—C34B—H34D 109.5 H87A—C87—H87C 109.5 
Si1B—C34B—H34E 109.5 H87B—C87—H87C 109.5 
H34D—C34B—H34E 109.5 C85—C88—H88A 109.5 
Si1B—C34B—H34F 109.5 C85—C88—H88B 109.5 
H34D—C34B—H34F 109.5 H88A—C88—H88B 109.5 
H34E—C34B—H34F 109.5 C85—C88—H88C 109.5 
Si1B—C33B—H33D 109.5 H88A—C88—H88C 109.5 
Si1B—C33B—H33E 109.5 H88B—C88—H88C 109.5 
H33D—C33B—H33E 109.5 O17—Si2B—C85B 124.3 (8) 
Si1B—C33B—H33F 109.5 O17—Si2B—C84B 116.1 (9) 
H33D—C33B—H33F 109.5 C85B—Si2B—C84B 118.0 (11) 
H33E—C33B—H33F 109.5 O17—Si2B—C83B 90.7 (9) 
C38B—C35B—C37B 113.7 (19) C85B—Si2B—C83B 87.8 (11) 
C38B—C35B—C36B 104.2 (17) C84B—Si2B—C83B 104.5 (12) 
C37B—C35B—C36B 108.5 (15) Si2B—C83B—H83D 109.5 
C38B—C35B—Si1B 89.0 (13) Si2B—C83B—H83E 109.5 
C37B—C35B—Si1B 129.7 (16) H83D—C83B—H83E 109.5 
C36B—C35B—Si1B 108.2 (14) Si2B—C83B—H83F 109.5 
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C35B—C36B—H36D 109.5 H83D—C83B—H83F 109.5 
C35B—C36B—H36E 109.5 H83E—C83B—H83F 109.5 
H36D—C36B—H36E 109.5 Si2B—C84B—H84D 109.5 
C35B—C36B—H36F 109.5 Si2B—C84B—H84E 109.5 
H36D—C36B—H36F 109.5 H84D—C84B—H84E 109.5 
H36E—C36B—H36F 109.5 Si2B—C84B—H84F 109.5 
C35B—C37B—H37D 109.5 H84D—C84B—H84F 109.5 
C35B—C37B—H37E 109.5 H84E—C84B—H84F 109.5 
H37D—C37B—H37E 109.5 C86B—C85B—C88B 114.4 (18) 
C35B—C37B—H37F 109.5 C86B—C85B—C87B 114 (2) 
H37D—C37B—H37F 109.5 C88B—C85B—C87B 96.2 (17) 
H37E—C37B—H37F 109.5 C86B—C85B—Si2B 126.4 (16) 
C35B—C38B—Si1B 54.9 (11) C88B—C85B—Si2B 105.2 (16) 
C35B—C38B—H38D 109.5 C87B—C85B—Si2B 95.4 (14) 
Si1B—C38B—H38D 82.3 C85B—C86B—H86D 109.5 
C35B—C38B—H38E 109.5 C85B—C86B—H86E 109.5 
Si1B—C38B—H38E 163.7 H86D—C86B—H86E 109.5 
H38D—C38B—H38E 109.5 C85B—C86B—H86F 109.5 
C35B—C38B—H38F 109.5 H86D—C86B—H86F 109.5 
Si1B—C38B—H38F 75.4 H86E—C86B—H86F 109.5 
H38D—C38B—H38F 109.5 C85B—C87B—H87D 109.5 
H38E—C38B—H38F 109.5 C85B—C87B—H87E 109.5 
C40—C39—O9 109.0 (8) H87D—C87B—H87E 109.5 
C40—C39—H39A 109.9 C85B—C87B—H87F 109.5 
O9—C39—H39A 109.9 H87D—C87B—H87F 109.5 
C40—C39—H39B 109.9 H87E—C87B—H87F 109.5 
O9—C39—H39B 109.9 C85B—C88B—H88D 109.5 
H39A—C39—H39B 108.3 C85B—C88B—H88E 109.5 
C41—C40—C45 120.0 H88D—C88B—H88E 109.5 
C41—C40—C39 118.1 (9) C85B—C88B—H88F 109.5 
C45—C40—C39 121.9 (9) H88D—C88B—H88F 109.5 
C40—C41—C42 120.0 H88E—C88B—H88F 109.5 
244 
 
Table 3.11. (Continued)    
C40—C41—H41 120.0 C90—C89—O19 97.5 (13) 
C42—C41—H41 120.0 C90—C89—H89A 112.3 
C41—C42—C43 120.0 O19—C89—H89A 112.3 
C41—C42—H42 120.0 C90—C89—H89B 112.3 
C43—C42—H42 120.0 O19—C89—H89B 112.3 
C44—C43—C42 120.0 H89A—C89—H89B 109.9 
C44—C43—H43 120.0 C91—C90—C95 120.0 
C42—C43—H43 120.0 C91—C90—C89 104 (2) 
C43—C44—C45 120.0 C95—C90—C89 136 (2) 
C43—C44—H44 120.0 C92—C91—C90 120.0 
C45—C44—H44 120.0 C92—C91—H91 120.0 
C44—C45—C40 120.0 C90—C91—H91 120.0 
C44—C45—H45 120.0 C91—C92—C93 120.0 
C40—C45—H45 120.0 C91—C92—H92 120.0 
C40B—C39B—O9 107 (2) C93—C92—H92 120.0 
C40B—C39B—H39C 110.3 C94—C93—C92 120.0 
O9—C39B—H39C 110.3 C94—C93—H93 120.0 
C40B—C39B—H39D 110.3 C92—C93—H93 120.0 
O9—C39B—H39D 110.3 C93—C94—C95 120.0 
H39C—C39B—H39D 108.5 C93—C94—H94 120.0 
C41B—C40B—C45B 120.00 (7) C95—C94—H94 120.0 
C41B—C40B—C39B 129 (2) C94—C95—C90 120.0 
C45B—C40B—C39B 110 (3) C94—C95—H95 120.0 
C42B—C41B—C40B 120.0 C90—C95—H95 120.0 
C42B—C41B—H41A 120.0 C90B—C89B—O19 111.0 (13) 
C40B—C41B—H41A 120.0 C90B—C89B—H89C 109.4 
C41B—C42B—C43B 120.0 O19—C89B—H89C 109.4 
C41B—C42B—H42A 120.0 C90B—C89B—H89D 109.4 
C43B—C42B—H42A 120.0 O19—C89B—H89D 109.4 
C42B—C43B—C44B 120.00 (6) H89C—C89B—H89D 108.0 
C42B—C43B—H43A 120.0 C91B—C90B—C95B 120.0 
C44B—C43B—H43A 120.0 C91B—C90B—C89B 125.8 (14) 
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C45B—C44B—C43B 120.0 C95B—C90B—C89B 114.2 (14) 
C45B—C44B—H44A 120.0 C92B—C91B—C90B 120.0 
C43B—C44B—H44A 120.0 C92B—C91B—H91A 120.0 
C44B—C45B—C40B 120.0 C90B—C91B—H91A 120.0 
C44B—C45B—H45A 120.0 C93B—C92B—C91B 120.0 
C40B—C45B—H45A 120.0 C93B—C92B—H92A 120.0 
C51—O11—N11 106.4 (6) C91B—C92B—H92A 120.0 
C54—O12—C72 113.1 (7) C92B—C93B—C94B 120.0 
C54—O12—C72B 139 (3) C92B—C93B—H93A 120.0 
C65—O16—H16 109.5 C94B—C93B—H93A 120.0 
C66—O17—Si2B 135.8 (7) C93B—C94B—C95B 120.0 
C66—O17—Si2 135.7 (7) C93B—C94B—H94A 120.0 
C69—O19—C89 108.4 (12) C95B—C94B—H94A 120.0 
C69—O19—C89B 117.7 (9) C94B—C95B—C90B 120.0 
C69—N11—O11 106.4 (7) C94B—C95B—H95A 120.0 
C58—N12—C74 118.4 (8) C90B—C95B—H95A 120.0 
 
C1—O1—N1—C19 -0.3 (8) O11—C51—C52—N13 47.7 (11) 
N1—O1—C1—C18 2.1 (9) C68—C51—C52—C53 -10.7 (14) 
N1—O1—C1—C2 175.8 (7) O11—C51—C52—C53 177.5 (7) 
C20—N2—C2—C1 -77.7 (9) N13—C52—C53—C54 -114.7 (8) 
C21—N2—C2—C1 52.2 (8) C51—C52—C53—C54 110.3 (8) 
C20—N2—C2—C3 153.2 (7) N13—C52—C53—C66 115.9 (8) 
C21—N2—C2—C3 -76.9 (7) C51—C52—C53—C66 -19.0 (10) 
C18—C1—C2—N2 -143.3 (8) C72—O12—C54—C53 135.4 (7) 
O1—C1—C2—N2 44.4 (10) C72B—O12—C54—C53 156 (3) 
C18—C1—C2—C3 -13.1 (12) C72—O12—C54—C55 -102.5 (8) 
O1—C1—C2—C3 174.6 (6) C72B—O12—C54—C55 -82 (3) 
N2—C2—C3—C16 118.9 (7) C66—C53—C54—O12 61.1 (7) 
C1—C2—C3—C16 -14.6 (9) C52—C53—C54—O12 -71.2 (8) 
N2—C2—C3—C4 -115.7 (7) C66—C53—C54—C55 -59.9 (8) 
C1—C2—C3—C4 110.8 (7) C52—C53—C54—C55 167.9 (7) 
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Table 3.11. (Continued)    
C22—O2—C4—C5 -101.7 (7) O12—C54—C55—C64 -75.7 (8) 
C22—O2—C4—C3 136.3 (6) C53—C54—C55—C64 43.2 (9) 
C16—C3—C4—O2 59.9 (7) O12—C54—C55—C56 48.6 (9) 
C2—C3—C4—O2 -68.3 (7) C53—C54—C55—C56 167.5 (7) 
C16—C3—C4—C5 -63.4 (7) C64—C55—C56—C57 -59.4 (8) 
C2—C3—C4—C5 168.3 (6) C54—C55—C56—C57 174.1 (7) 
O2—C4—C5—C14 -72.7 (7) C55—C56—C57—C62 37.3 (10) 
C3—C4—C5—C14 47.2 (8) C55—C56—C57—C58 -142.4 (8) 
O2—C4—C5—C6 48.8 (8) C51—C52—N13—C70 -78.2 (10) 
C3—C4—C5—C6 168.7 (6) C53—C52—N13—C70 154.7 (7) 
C4—C5—C6—C7 179.4 (6) C51—C52—N13—C71 49.1 (9) 
C14—C5—C6—C7 -57.0 (7) C53—C52—N13—C71 -78.0 (8) 
C5—C6—C7—C8 -143.2 (8) C62—C57—C58—N12 178.9 (8) 
C5—C6—C7—C12 33.9 (10) C56—C57—C58—N12 -1.5 (13) 
C12—C7—C8—C9 -1.3 (15) C62—C57—C58—C59 -7.7 (13) 
C6—C7—C8—C9 175.7 (9) C56—C57—C58—C59 172.0 (8) 
C12—C7—C8—N3 176.6 (9) C74—N12—C58—C57 155.2 (9) 
C6—C7—C8—N3 -6.3 (14) C75—N12—C58—C57 -80.2 (10) 
C25—N3—C8—C9 -84.1 (13) C74—N12—C58—C59 -17.6 (14) 
C25B—N3—C8—C9 -40 (3) C75—N12—C58—C59 106.9 (10) 
C24B—N3—C8—C9 101 (3) C57—C58—C59—C60 3.0 (14) 
C24—N3—C8—C9 50.2 (15) N12—C58—C59—C60 176.2 (9) 
C25—N3—C8—C7 98.0 (13) C58—C59—C60—C61 1.0 (15) 
C25B—N3—C8—C7 142 (3) C59—C60—C61—O14 179.4 (9) 
C24B—N3—C8—C7 -77 (3) C59—C60—C61—C62 -0.7 (13) 
C24—N3—C8—C7 -127.7 (11) C58—C57—C62—C61 8.3 (13) 
C7—C8—C9—C10 -2.1 (16) C56—C57—C62—C61 -171.3 (7) 
N3—C8—C9—C10 -180.0 (11) C58—C57—C62—C63 -175.4 (8) 
C8—C9—C10—C11 5.2 (17) C56—C57—C62—C63 4.9 (12) 
C26—O4—C11—C10 90.5 (11) O14—C61—C62—C57 176.0 (8) 
C26—O4—C11—C12 -87.5 (10) C60—C61—C62—C57 -3.8 (12) 
C9—C10—C11—O4 177.2 (9) O14—C61—C62—C63 -0.2 (12) 
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Table 3.11. (Continued)    
C9—C10—C11—C12 -4.8 (16) C60—C61—C62—C63 179.9 (7) 
C8—C7—C12—C11 1.7 (13) C57—C62—C63—O15 154.4 (8) 
C6—C7—C12—C11 -175.4 (7) C61—C62—C63—O15 -29.3 (11) 
C8—C7—C12—C13 -175.8 (8) C57—C62—C63—C64 -25.2 (11) 
C6—C7—C12—C13 7.1 (11) C61—C62—C63—C64 151.1 (7) 
O4—C11—C12—C7 179.4 (8) O15—C63—C64—C65 4.0 (11) 
C10—C11—C12—C7 1.4 (13) C62—C63—C64—C65 -176.4 (7) 
O4—C11—C12—C13 -3.3 (13) O15—C63—C64—C55 179.3 (7) 
C10—C11—C12—C13 178.7 (9) C62—C63—C64—C55 -1.2 (10) 
C7—C12—C13—O5 154.7 (7) C54—C55—C64—C65 -14.8 (11) 
C11—C12—C13—O5 -22.6 (12) C56—C55—C64—C65 -141.8 (7) 
C7—C12—C13—C14 -24.4 (11) C54—C55—C64—C63 170.3 (7) 
C11—C12—C13—C14 158.2 (8) C56—C55—C64—C63 43.3 (9) 
O5—C13—C14—C15 3.6 (11) C63—C64—C65—O16 -5.5 (11) 
C12—C13—C14—C15 -177.3 (7) C55—C64—C65—O16 179.4 (7) 
O5—C13—C14—C5 177.9 (6) C63—C64—C65—C66 176.7 (7) 
C12—C13—C14—C5 -2.9 (10) C55—C64—C65—C66 1.7 (12) 
C4—C5—C14—C15 -18.7 (9) Si2B—O17—C66—C65 -31.1 (11) 
C6—C5—C14—C15 -142.7 (7) Si2—O17—C66—C65 -81.4 (8) 
C4—C5—C14—C13 167.0 (6) Si2B—O17—C66—C53 -153.4 (8) 
C6—C5—C14—C13 43.1 (8) Si2—O17—C66—C53 156.3 (6) 
C13—C14—C15—O6 -3.4 (11) Si2B—O17—C66—C67 86.9 (9) 
C5—C14—C15—O6 -177.5 (7) Si2—O17—C66—C67 36.6 (9) 
C13—C14—C15—C16 177.7 (6) O16—C65—C66—O17 44.3 (9) 
C5—C14—C15—C16 3.7 (11) C64—C65—C66—O17 -137.7 (8) 
Si1B—O7—C16—C3 -152.6 (8) O16—C65—C66—C53 165.4 (7) 
Si1—O7—C16—C3 159.0 (6) C64—C65—C66—C53 -16.6 (10) 
Si1B—O7—C16—C17 84.7 (10) O16—C65—C66—C67 -70.5 (8) 
Si1—O7—C16—C17 36.3 (8) C64—C65—C66—C67 107.4 (8) 
Si1B—O7—C16—C15 -32.7 (12) C54—C53—C66—O17 165.7 (6) 
Si1—O7—C16—C15 -81.1 (8) C52—C53—C66—O17 -66.0 (8) 
C4—C3—C16—O7 164.5 (5) C54—C53—C66—C65 44.9 (8) 
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Table 3.11. (Continued)    
C2—C3—C16—O7 -71.4 (7) C52—C53—C66—C65 173.1 (7) 
C4—C3—C16—C17 -78.2 (7) C54—C53—C66—C67 -78.5 (7) 
C2—C3—C16—C17 45.9 (8) C52—C53—C66—C67 49.7 (9) 
C4—C3—C16—C15 46.3 (7) O17—C66—C67—O18 -108.5 (8) 
C2—C3—C16—C15 170.4 (6) C65—C66—C67—O18 8.8 (11) 
O6—C15—C16—O7 45.5 (9) C53—C66—C67—O18 133.0 (8) 
C14—C15—C16—O7 -135.5 (7) O17—C66—C67—C68 67.2 (7) 
O6—C15—C16—C3 163.2 (6) C65—C66—C67—C68 -175.5 (6) 
C14—C15—C16—C3 -17.9 (10) C53—C66—C67—C68 -51.3 (8) 
O6—C15—C16—C17 -69.6 (8) O11—C51—C68—C69 -4.1 (10) 
C14—C15—C16—C17 109.3 (8) C52—C51—C68—C69 -176.2 (10) 
O7—C16—C17—O8 -109.7 (9) O11—C51—C68—C67 178.5 (7) 
C3—C16—C17—O8 132.2 (8) C52—C51—C68—C67 6.3 (16) 
C15—C16—C17—O8 6.9 (12) O18—C67—C68—C51 -158.2 (9) 
O7—C16—C17—C18 69.0 (8) C66—C67—C68—C51 26.1 (11) 
C3—C16—C17—C18 -49.2 (8) O18—C67—C68—C69 25.2 (15) 
C15—C16—C17—C18 -174.5 (7) C66—C67—C68—C69 -150.5 (10) 
O1—C1—C18—C19 -2.8 (9) O11—N11—C69—O19 -179.9 (9) 
C2—C1—C18—C19 -175.8 (8) O11—N11—C69—C68 -4.2 (11) 
O1—C1—C18—C17 -179.1 (7) C89—O19—C69—N11 6 (2) 
C2—C1—C18—C17 7.9 (13) C89B—O19—C69—N11 -13.7 (17) 
O8—C17—C18—C1 -157.3 (8) C89—O19—C69—C68 -169.1 (17) 
C16—C17—C18—C1 24.0 (10) C89B—O19—C69—C68 171.1 (12) 
O8—C17—C18—C19 27.6 (14) C51—C68—C69—N11 5.3 (12) 
C16—C17—C18—C19 -151.1 (8) C67—C68—C69—N11 -177.7 (9) 
C39B—O9—C19—N1 18 (2) C51—C68—C69—O19 -178.9 (9) 
C39—O9—C19—N1 -5.4 (13) C67—C68—C69—O19 -1.9 (17) 
C39B—O9—C19—C18 -163.1 (19) C54—O12—C72—O13 -80.9 (9) 
C39—O9—C19—C18 173.7 (9) C72B—O12—C72—O13 126 (4) 
O1—N1—C19—O9 177.9 (8) O12—C72—O13—C73 -79.7 (11) 
O1—N1—C19—C18 -1.4 (9) C54—O12—C72B—O13B -87 (4) 
C1—C18—C19—O9 -176.6 (8) C72—O12—C72B—O13B -47 (3) 
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Table 3.11. (Continued)    
C17—C18—C19—O9 -0.9 (15) O12—C72B—O13B—C73B -99 (6) 
C1—C18—C19—N1 2.7 (10) C60—C61—O14—C76 35.5 (12) 
C17—C18—C19—N1 178.3 (8) C62—C61—O14—C76 -144.4 (8) 
C4—O2—C22—O3 -78.6 (9) C61—O14—C76—C77 162.2 (7) 
O2—C22—O3—C23 -79.8 (10) C61—O14—C76—C77B 154.7 (14) 
C11—O4—C26—C27 -178.9 (6) O14—C76—C77—C78 -49.8 (10) 
O4—C26—C27—C28 104.0 (8) C77B—C76—C77—C78 36 (9) 
O4—C26—C27—C32 -71.8 (8) O14—C76—C77—C82 137.4 (6) 
C32—C27—C28—C29 0.0 C77B—C76—C77—C82 -137 (10) 
C26—C27—C28—C29 -175.7 (8) C82—C77—C78—C79 0.0 
C27—C28—C29—C30 0.0 C76—C77—C78—C79 -172.7 (8) 
C28—C29—C30—C31 0.0 C77—C78—C79—C80 0.0 
C29—C30—C31—C32 0.0 C78—C79—C80—C81 0.0 
C30—C31—C32—C27 0.0 C79—C80—C81—C82 0.0 
C28—C27—C32—C31 0.0 C80—C81—C82—C77 0.0 
C26—C27—C32—C31 175.9 (7) C78—C77—C82—C81 0.0 
C16—O7—Si1—C35 135.3 (8) C76—C77—C82—C81 172.8 (8) 
Si1B—O7—Si1—C35 9.4 (8) O14—C76—C77B—C78B 11 (2) 
C16—O7—Si1—C33 5.5 (10) C77—C76—C77B—C78B -86 (9) 
Si1B—O7—Si1—C33 -120.4 (9) O14—C76—C77B—C82B 156.6 (13) 
C16—O7—Si1—C34 -112.5 (9) C77—C76—C77B—C82B 60 (9) 
Si1B—O7—Si1—C34 121.6 (10) C82B—C77B—C78B—C79B 0.0 
O7—Si1—C35—C38 -62.0 (15) C76—C77B—C78B—C79B 142 (2) 
C33—Si1—C35—C38 69.6 (16) C77B—C78B—C79B—C80B 0.0 
C34—Si1—C35—C38 -174.9 (15) C78B—C79B—C80B—C81B 0.0 
O7—Si1—C35—C37 60.6 (13) C79B—C80B—C81B—C82B 0.0 
C33—Si1—C35—C37 -167.9 (12) C80B—C81B—C82B—C77B 0.0 
C34—Si1—C35—C37 -52.4 (15) C78B—C77B—C82B—C81B 0.0 
O7—Si1—C35—C36 -174.4 (11) C76—C77B—C82B—C81B -148 (2) 
C33—Si1—C35—C36 -42.8 (14) C66—O17—Si2—C85 136.8 (9) 
C34—Si1—C35—C36 72.7 (14) Si2B—O17—Si2—C85 28.0 (9) 
C16—O7—Si1B—C35B -77.6 (12) C66—O17—Si2—C83 24.9 (10) 
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Table 3.11. (Continued)    
Si1—O7—Si1B—C35B 13.0 (8) Si2B—O17—Si2—C83 -83.9 (9) 
C16—O7—Si1B—C34B 63.2 (14) C66—O17—Si2—C84 -108.2 (10) 
Si1—O7—Si1B—C34B 153.8 (12) Si2B—O17—Si2—C84 143.0 (11) 
C16—O7—Si1B—C33B 172.1 (11) O17—Si2—C85—C88 -49.4 (15) 
Si1—O7—Si1B—C33B -97.2 (9) C83—Si2—C85—C88 72.3 (15) 
C16—O7—Si1B—C38B -45.2 (11) C84—Si2—C85—C88 -164.7 (14) 
Si1—O7—Si1B—C38B 45.5 (7) O17—Si2—C85—C86 174.6 (12) 
O7—Si1B—C35B—C38B 63.0 (14) C83—Si2—C85—C86 -63.7 (14) 
C34B—Si1B—C35B—C38B -76.6 (16) C84—Si2—C85—C86 59.3 (16) 
C33B—Si1B—C35B—C38B 174.1 (13) O17—Si2—C85—C87 59.9 (10) 
O7—Si1B—C35B—C37B -176.5 (17) C83—Si2—C85—C87 -178.4 (10) 
C34B—Si1B—C35B—C37B 44 (2) C84—Si2—C85—C87 -55.4 (12) 
C33B—Si1B—C35B—C37B -65 (2) C66—O17—Si2B—C85B -103.4 (13) 
C38B—Si1B—C35B—C37B 120 (2) Si2—O17—Si2B—C85B 4.9 (11) 
O7—Si1B—C35B—C36B -41.6 (16) C66—O17—Si2B—C84B 62.3 (16) 
C34B—Si1B—C35B—C36B 178.8 (14) Si2—O17—Si2B—C84B 170.6 (16) 
C33B—Si1B—C35B—C36B 69.5 (15) C66—O17—Si2B—C83B 168.8 (11) 
C38B—Si1B—C35B—C36B -104.6 (18) Si2—O17—Si2B—C83B -82.9 (10) 
C37B—C35B—C38B—Si1B -133.6 (19) O17—Si2B—C85B—C86B -175 (2) 
C36B—C35B—C38B—Si1B 108.5 (15) C84B—Si2B—C85B—C86B 20 (3) 
O7—Si1B—C38B—C35B -129.6 (12) C83B—Si2B—C85B—C86B -86 (2) 
C34B—Si1B—C38B—C35B 115.3 (14) O17—Si2B—C85B—C88B -38 (2) 
C33B—Si1B—C38B—C35B -8.4 (18) C84B—Si2B—C85B—C88B 156.8 (18) 
C19—O9—C39—C40 -169.5 (8) C83B—Si2B—C85B—C88B 51.5 (18) 
C39B—O9—C39—C40 84 (4) O17—Si2B—C85B—C87B 60.2 (16) 
O9—C39—C40—C41 97.5 (10) C84B—Si2B—C85B—C87B -105.3 (16) 
O9—C39—C40—C45 -85.5 (10) C83B—Si2B—C85B—C87B 149.5 (15) 
C45—C40—C41—C42 0.0 C69—O19—C89—C90 -146 (2) 
C39—C40—C41—C42 177.1 (8) C89B—O19—C89—C90 -25 (4) 
C40—C41—C42—C43 0.0 O19—C89—C90—C91 -100 (2) 
C41—C42—C43—C44 0.0 O19—C89—C90—C95 83 (3) 
C42—C43—C44—C45 0.0 C95—C90—C91—C92 0.0 
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Table 3.11. (Continued)    
C43—C44—C45—C40 0.0 C89—C90—C91—C92 -177.7 (15) 
C41—C40—C45—C44 0.0 C90—C91—C92—C93 0.0 
C39—C40—C45—C44 -177.0 (8) C91—C92—C93—C94 0.0 
C19—O9—C39B—C40B -163 (2) C92—C93—C94—C95 0.0 
C39—O9—C39B—C40B -79 (4) C93—C94—C95—C90 0.0 
O9—C39B—C40B—C41B 42 (4) C91—C90—C95—C94 0.0 
O9—C39B—C40B—C45B -129 (2) C89—C90—C95—C94 177 (2) 
C45B—C40B—C41B—C42B 0.0 C69—O19—C89B—C90B -178.1 (14) 
C39B—C40B—C41B—C42B -170 (3) C89—O19—C89B—C90B 115 (7) 
C40B—C41B—C42B—C43B 0.0 O19—C89B—C90B—C91B -97.3 (14) 
C41B—C42B—C43B—C44B 0.0 O19—C89B—C90B—C95B 85.1 (17) 
C42B—C43B—C44B—C45B 0.0 C95B—C90B—C91B—C92B 0.0 
C43B—C44B—C45B—C40B 0.0 C89B—C90B—C91B—C92B -177.5 (14) 
C41B—C40B—C45B—C44B 0.0 C90B—C91B—C92B—C93B 0.0 
C39B—C40B—C45B—C44B 172 (2) C91B—C92B—C93B—C94B 0.0 
C51—O11—N11—C69 1.7 (10) C92B—C93B—C94B—C95B 0.0 
N11—O11—C51—C68 1.8 (10) C93B—C94B—C95B—C90B 0.0 
N11—O11—C51—C52 175.3 (8) C91B—C90B—C95B—C94B 0.0 
C68—C51—C52—N13 -140.4 (10) C89B—C90B—C95B—C94B 177.8 (12) 
 
Table 3.12. Hydrogen-bond parameters 
D—H···A D—H (Å) H···A (Å) D···A (Å) D—H···A (°) 
O6—H6···O5 0.84 1.78 2.458 (6) 136.3 
O16—H16···O15 0.84 1.96 2.474 (7) 118.9 
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Figure 3.4a 
 
Figure 3.4b 
 
Figure 3.4. Perspective views showing 50% probability displacement (the H atoms that 
rides on C atoms and the disorder parts have been omitted). 
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Figure 3.5. Three-dimensional supramolecular architecture viewed along the a-axis 
direction. 
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Chapter 4 
Progress Toward the Synthesis of 5-Hetero-Tetracyclines 
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Introduction 
Gram-negative bacterial cells are bounded by two permeability barriers: (1) the 
cytoplasmic membrane, which is permeable to uncharged, lipophilic molecules; and (2) 
the outer membrane, which has a different constitution and is significantly less permeable 
to lipophilic molecules.97 Tetracyclines, like most antibacterials, penetrate the outer 
membrane of Gram-negative cells predominantly by passing through aqueous channels 
provided by porin proteins imbedded in the outer membrane. Antibacterial agents with 
activity against Gram-negative bacteria tend to have higher relative polar surface area 
(see Chapter 1 for discussion) and lower mean molecular mass than antibacterials which 
are only active against Gram-positive organisms. These requirements for Gram-negative 
activity are believed to be driven by the properties of porin proteins. 
OmpF is one of the porin proteins found in the outer membrane of Escherichia 
coli. The X-ray crystal structure of OmpF revealed a trimer of identical subunits, each 
consisting of a ȕ-barrel with 16 transmembrane ȕ-strands.98 At its most constricted (at 
about half the height of the barrel) the pore narrows to an ellipse of cross-section 11 x 7 
Å. Pore diameter increases abruptly to 22 x 15 Å beyond the constriction zone (which is 
                                                 
97 Nikaido, H. Microbio. Mol. Biol. Rev. 2003, 67, 593-656. 
98 Cowan, S. W.; Schirmer, T.; Rummel, G.; Steiert, M.; Ghosh, R.; Pauptit, R. A.; Jansonius, J. N.; 
Rosenbusch, J. P. Nature 1992, 358, 727–733. 
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approximately 9 Å long). The constriction region of OmpK36, a porin found in Klebsiella 
pneumoniae, was found to be almost exactly the same size as that of OmpF.99 
In theory, the introduction of new hydrogen bond-forming substituents on the 
tetracycline scaffold could make the displacement of water molecules associated with 
passage through porin channels less disfavored. Any structural decoration would (to 
lesser or greater extents) increase overall size of the molecule in one or more dimensions, 
which in the case of larger groups could disrupt movement of the small molecule through 
the constricted regions of porin proteins. We were led to consider the possibility that we 
could increase the polarity of tetracyclines without increasing size (and thereby 
disrupting movement through porin channels) by incorporating a heteroatom into the 
polyketide-derived carbocyclic scaffold. 
 The incorporation of a heteroatom (oxygen or nitrogen) at position 5 on the 
tetracycline scaffold would add a hydrogen bonding substituent and increase the polar 
surface area of these antibacterial small molecules without significantly increasing 
molecular weight or size. In theory, this could make the displacement of water molecules 
associated with passage through porin channels less disfavored, thus making penetration 
of Gram-negative cells more efficient. For these reasons, we chose to consider the 
preparation of fully synthetic 5-oxo- and 5-aza-tetracyclines. 
                                                 
99 Dutzler, R.; Rummel, G.; Alberti, S.; Hernández-Allés, S.; Phale, P. S.; Rosenbusch, J. P.; Benedi, V. J.; 
Schirmer, T. Structure 1999, 7, 425–434. 
279 
 
 Unlike the ȕ- and Ȗ-substituted AB precursors to fully synthetic 5a- and 5-
substituted tetracyclines described in preceding chapters, it would not be possible to 
prepare “5-hetero” AB precursors directly from the AB enone 10. We instead considered 
synthesizing these modified AB components by adaptation of our third-generation 
synthesis of the AB enone 10.100 The third-generation synthesis comprises a five-step 
synthetic sequence from two starting materials of near equal complexity, as measured by 
the number of steps required to prepare each starting material. Asymmetry is transferred 
from the B-ring precursor 121 to C4 and C4a via a highly diastereoselective Michael–
Claisen cyclization reaction with the sodium enolate of isoxazole precursor 120 (Scheme 
4.1).101 Michael addition proceeds by addition to the sterically more accessible face of 
cyclohexenone 121 (along a pseudoaxial trajectory) and with complete control of relative 
stereochemistry at C4 and C4a. 
 
                                                 
100 Kummer, D. A.; Li, D.; Dion, A.; Myers, A. G. Chem. Sci. 2011, 2, 1710–1718. 
101 Stork reported the first synthesis of isoxazole ester 120 while developing the 5-benzyloxyisoxazole 
function as a protective group for the A ring of tetracyclines, an innovation that was critical to the 
development of the Myers tetracycline platform. For original work, see: (a) Stork, G.; Hagedorn, A. A. J. 
Am. Chem. Soc. 1978, 100, 3609–3611. (b) Stork, G.; LaClair, J. J.; Spargo, P.; Nargund, R. P.; Totah, N. 
J. Am. Chem. Soc. 1996, 118, 5304–5305. For an optimized protocol for the synthesis of isoxazole 120, see: 
Kummer, D. A. (2011) II. A Practical, Convergent Route to the Key Precursor to the Tetracycline 
Antibiotics. Ph.D. Thesis, Harvard University.  
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Scheme 4.1. Diastereoselective Michael–Claisen cyclization of components 120 and 121. 
  
Michael–Claisen cycloadduct 122 was transformed into the AB enone 10 by the 
following sequence (Scheme 4.2): (1) expulsion of cyclopentadiene from 122 by retro-
Diels–Alder fragmentation, (2) C12a-hydroxylation of 123 with 3-(4-nitrophenyl)-2-
(phenylsulfonyl)-oxaziridine (119),102 (3) C4-epimerization upon heating a solution of 
124 in tetrahydrofuran–methanol with sodium dihydrogen phosphate, and (4) protection 
of the C12a-hydroxyl group of 125 as a tert-butyldimethylsilyl ether. The relative 
stereochemical outcome of the A-ring-forming cyclization described above did not match 
the stereochemistry of tetracyclines at C4, but this result proved advantageous as the 
dimethylamino group of intermediate 123 directs the approach of oxaziridine 119 to the 
sterically more accessible lower face, providing hydroxylation product 124 with the 
required stereochemistry at C12a. 
                                                 
102 Vishwakarma, L. C.; Stringer, O. D.; Davis, F. A. Organic Syntheses 1993, Coll. Vol. 8, 546. 
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Scheme 4.2. Synthesis of AB enone 10 from Michael–Claisen cycloadduct 122. 
  
It was well known prior to this work that various conditions could be used to 
effect epimerization at C4 of tetracyclines. Lederle scientists observed in 1955 that 
tetracycline is converted to a mixture of C4 stereoisomers in 1M sodium dihydrogen 
phosphate–methanol (2:1, 25 °C).103 It has also been demonstrated that a mixture of C4 
epimers of sancycline (6-deoxy-6-demethyltetracycline) can be isomerized to provide 
predominantly the natural stereoisomer by treatment with calcium (II) chloride in a 
water-butanol mixture containing ethanolamine (pH 8.5, reflux).104 
 
                                                 
103 (a) Doerschuk, A. P.; Bitler, B. A.; McCormick, J. R. D. J. Am. Chem. Soc. 1955, 77, 4687. (b) 
McCormick, J. R. D.; Fox, S. M.; Smith, L. L.; Bitler, B. A.; Reichenthal, J.; Origoni, V. E.; Muller, W. H.; 
Winterbottom, R.; Doerschuk, A. P. J. Am. Chem. Soc. 1957, 79, 2849. 
104 M. M. Noseworthy. U.S. Patent 3,009,956, November 21, 1961. 
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Retrosynthetic Strategy and Background 
We envisioned preparing 5-hetero-tetracyclines using an iterative Michael–
Claisen strategy, a conceptual approach that had been successful in the third-generation 
synthesis of the AB enone 10. 5-Hetero-tetracyclines could be formed by cyclization 
reactions of D-ring precursors with 5-hetero AB precursors (represented by structure 126, 
where X is oxygen or protected nitrogen; Scheme 4.3). 5-Hetero AB precursors could in 
turn be accessed via A-ring-forming Michael–Claisen cyclizations of isoxazole ester 
anions and heterocyclic B-ring precursors. Dihydro-4-pyranone 127 was selected as a 
potential precursor to the B ring of 5-oxo-tetracyclines. There is literature precedent for a 
diastereoselective conjugate addition reaction of the enantiomer of 127 with a thiol 
nucleophile, with addition occurring from the face opposite the isopropylidene 
substituent.105 An analogous stereochemical outcome in the cyclization we envisioned 
would provide the correct stereochemistry at C4a. Numerous challenges were anticipated 
in transforming the Michael–Claisen product 128 into AB precursor 129, including 
removal of the B-ring isopropylidene substituent, stereoselective C12a-hydroxylation and 
C4-epimerization. Efforts toward the synthesis of 5-oxo AB enone 129 are described 
below. 
                                                 
105 Witczak, Z. J.; Lorchak, D.; Nguyen, N. Carbohydrates Res. 2007, 342, 1929–1933. 
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Scheme 4.3. Retrosynthesis of 5-hetero-tetracyclines: an iterative Michael–Claisen 
cyclization strategy. 
 
 There are a few examples in the literature that provide precedent for the Michael–
Claisen cyclizations proposed in Scheme 4.3 above. Hauser described a regiospecific 
annulation reaction of the sulfone-stabilized phthalide anion derived from 130 with 
benzopyranone 131, affording Michael–Claisen cyclization product 132 in 27% yield (eq 
1, Scheme 4.4).106 Tatsuta reported an efficient coupling reaction involving phthalide 133 
and oxocyclic enone 134 (eq 2); oxidation of the cyclization product afforded quinone 
135 in 64% yield over two steps.107 This is the only example of which we are aware of an 
                                                 
106 Hauser, F. M.; Hewawasam, P.; Baghdanov, V. M. J. Org. Chem. 1988, 53, 223-224. 
107 Tatsuta, K.; Tanaka, Y.; Kojima, M.; Ikegami, H. Chem. Lett. 2002, 14–15. 
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electrophile of this type (dihydro-4-pyranone) undergoing a successful Michael–Claisen 
reaction. There is also some precedent for cyclizations involving Į,ȕ-unsaturated lactone 
Michael acceptors (see eq 3 for an example).108 
 
Scheme 4.4. Literature examples of Michael–Claisen and Michael–Dieckmann reaction 
sequences involving oxocyclic enones: benzopyranone, dihydro-4-pyranone and Į,ȕ-
unsaturated lactone Michael acceptors. 
  
There are two examples in the literature of Michael–Claisen reactions sequences 
of benzylic anions and azacyclic enone electrophiles.109 In both examples the Michael 
                                                 
108 Examples of Michael–Claisen reactions involving Į,ȕ-unsaturated lactones as Michael acceptors: (a) 
Tatsuta, K.; Yamazaki, T.; Mase, T.; Yoshimoto, T. Tetrahedron Lett. 1998, 39, 1771–1772. (b) 
Braukmuller, S.; Brückner, R. Eur. J. Org. Chem. 2006, 2110–2118. 
109 (a) Alvarez, M.; Ajana, W.; Lopez-Calahorra, F.; Joule, J. A. J. Chem. Soc. Perkin Trans. 1 1994, 917-
919. (b) Ajana, W.; Lopez-Calahorra, F.; Joule, J. A.; Alvarez, M. Tetrahedron 1997, 53, 341-356. 
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acceptor is N-methoxycarbamoyl-4-quinolone (137). Reaction of 137 with the dithiane-
stabilized benzylic anion derived from methyl ester 136 afforded Michael–Claisen 
product 138 in 64% yield (eq 1, Scheme 4.5). In addition, quinolone 137 was found to 
undergo a Michael–Claisen reaction with the phthalide anion of pyridine N-oxide 139, 
providing the product 140 following post-cyclization transformations (eq 2). Similar 
cyclization reactions of 4-pyridone and dihydro-4-pyridone electrophiles have not been 
reported as far as we are aware, but these azacyclic enones have been shown to undergo 
conjugate addition reactions with organometallic reagents.110,111 
 
Scheme 4.5. Literature examples of Michael–Claisen cyclizations of benzylic anions and 
N-methoxycarbamoyl-4-quinolone (137). 
 
                                                 
110 Examples of conjugate addition reactions of N-carbamoyl-4-pyridones: Dieter, R. K.; Guo, F. J. Org. 
Chem. 2009, 74, 3843–3848. 
111 Examples of conjugate addition reactions of a dihydro-4-pyridone electrophile: (a) Ye, X. M. et al. 
Bioorg. Med. Chem. Lett. 2010, 20, 2195–2199. (b) Jagt, R. B. C.; de Vries, J. G.; Feringa, B. L.; 
Minnaard, A. J. Org. Lett. 2005, 7, 2433–2435. 
286 
 
Results 
Before targeting 5-hetero AB precursors it was first necessary to investigate the 
feasibility of constructing the C ring of 5-hetero-tetracyclines by Michael–Claisen 
cyclization. The results of model systems are presented in Scheme 4.6 below. Addition of 
N-benzyloxycarbamoyl-dihydro-4-pyridone 141 (1 equiv)112 to a solution of the anion 
formed by LDA deprotonation of D-ring precursor 81 (2 equiv) in the presence of 
TMEDA (4 equiv) at –78 °C, followed by warming of the reaction mixture to –10 °C 
provided the desired Michael–Claisen product 142 in 64% yield after purification by 
flash-column chromatography. As far as we are aware, this is the first example of a 
Michael–Claisen reaction with a dihydro-4-pyridone as the conjugate acceptor. This 
reaction was also successful in the absence of TMEDA, although product 142 was 
formed in slightly lower yield. The analogous cyclization reaction of N-
benzyloxycarbamoyl-quinolone 143 was extremely efficient without TMEDA additive, 
affording Michael–Claisen cycloadduct 144 in 85% yield following purification.113 The 
feasibility our synthetic plan to access 5-hetero-tetracyclines using Michael–Claisen 
                                                 
112 N-Benzyloxycarbamoyl-dihydro-4-pyridone 141 was prepared from 4-piperidone monohydrate 
hydrochloride by treatment with benzyl chloroformate (1 equiv) and sodium hydroxide (2 equiv) followed 
by oxidation of the acylation product, N-benzyloxy-4-piperidone, with o-iodoxybenzoic acid (IBX) in the 
presence of 4-methylmorpholine N-oxide. For oxidation conditions, see: Nicolaou, K. C.; Gray, D. L. F.; 
Montagnon, T.; Harrison, S. T. Angew. Chem. Int. Ed. 2002, 41, 996–1000. 
113 N-Benzyloxycarbamoyl-4-quinolone 143 was prepared from 2’-nitroacetophenone according to 
procedures detailed in the following literature precedents: (a) Tois, J.; Vahermo, M.; Koskinen, A. 
Tetrahedron Lett. 2005, 46, 735–737. (b) Shintani, R.; Yamagami, T.; Kimura, T.; Hayashi, T. Org. Lett. 
2005, 7, 5317–5319. 
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chemistry was further affirmed by a successful cyclization reaction of D-ring precursor 
81 with dihydro-4-pyranone 145,114 providing the desired product 146 in 39% yield. 
 
Scheme 4.6. Michael–Claisen cyclization reactions of D-ring precursor 81 with dihydro-
4-pyridone, 4-quinolone and dihydro-4-pyranone electrophiles. 
 
Once the feasibility of constructing the C ring of 5-hetero-tetracyclines using 
Michael–Claisen cyclizations had been established, synthetic approaches to 5-hetero AB 
precursors could be considered and developed. Heterocyclic enone 127 was identified as 
a possible precursor to the B ring of 5-oxo AB enone 129 (see Scheme 4.3 above). This 
potential B-ring precursor (127) was prepared as a single enantiomer via an efficient 
                                                 
114 For the preparation of dihydro-4-pyranone 145, see: (a) Paquette, L. A.; Oplinger, J. A. Tetrahedron 
1989, 45, 107–124. (b) Smith, A. B.; Fukui, M. J. Am. Chem. Soc. 1987, 109, 1269–1272. 
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three-step sequence adapted from literature precedent (Scheme 4.7). D-(–)-Arabinose 
(147) was converted into the corresponding bis-O-isopropylidene derivative 148 upon 
prolonged stirring with a catalytic quantity of tetrabutylammonium tribromide in dry 
acetone (80% yield, 2 d, 12-g batch).115 Treatment of bis-O-isopropylidene 148 with an 
excess of lithium diisopropylamide afforded allylic alcohol 149 as the product of a 
lithiation–elimination sequence.116 In a significant improvement upon a literature 
procedure, oxidation of allylic alcohol 149 was achieved rapidly and efficiently with 
tetrapropylammonium perruthenate (10 mol %) and N-methylmorpholine N-oxide (NMO, 
1.5 equiv), providing the potential B–ring precursor 127 in 75% yield.117 
 
Scheme 4.7. Synthesis of heterocyclic enone 127, a possible B-ring precursor. 
 
                                                 
115 Khan, A. T.; Khan, M. M.; Adhikary, A. Carbohydrates Res. 2011, 346, 673–677. 
116 Klemer, A.; Jung, G. Chem. Ber. 1981, 114, 1192–1195. 
117 Ley, S. V.; Norman, J.; Griffith, W. P.; Marsden, S. P. Synthesis 1994, 7, 639–666. 
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The next challenge was to construct the A ring of 5-oxo-tetracyclines by a 
Michael–Claisen reaction of B-ring precursor 127 with isoxazole ester anions known 
from prior research to be effective nucleophiles in analogous A-ring-forming 
cyclizations. Attempted cyclization of 127 with the anion derived from methyl ester 
isoxazole 120 was not successful. The major product of this cyclization attempt was 
compound 152 (Scheme 4.8). A possible mechanism for the formation of 152 is 
presented below. This product could be formed by Michael addition of the isoxazole ester 
anion (to form enolate 150) followed by sequential B-ring opening, expulsion of acetone 
(to give alkoxide 151), tautomerization and cyclization to form the B ring. No Michael–
Claisen products were observed in this reaction, indicating that the energy barrier for 
Claisen cyclization is higher than that for B-ring opening of enolate intermediate 150. 
 
Scheme 4.8. Unsuccessful A-ring cyclization attempt with isoxazole methyl ester 120. 
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It was hoped that this problem could be overcome by increasing the 
electrophilicity of the isoxazole ester. Addition of B-ring precursor 127 (1 equiv) to a 
solution of the anion formed by NaHMDS deprotonation of the phenyl ester isoxazole 
153 at –78 °C, followed by warming of the reaction mixture to –15 °C and stirring at this 
temperature for 2 ½ h afforded the Michael–Claisen product 128 in 40% yield as a single 
diastereomer after purification by flash-column chromatography and rp-HPLC (Scheme 
4.9 below). NMR analysis revealed trace amounts of by-products in the crude product 
mixture, but no diastereomers of 128 were isolated following purification. The 
stereochemical outcome of the cyclization is homologous with the outcome of the A-ring-
forming cyclization reaction in the third-generation synthesis of the AB enone 10.100 
 
Scheme 4.9. Synthesis of trimethylsilyl ether 155 via sequential diastereoselective 
reactions: Michael–Claisen coupling of isoxazole phenyl ester 153 and B-ring precursor 
127, followed by C12a-hydroxylation. 
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 With Michael–Claisen product 128 in hand, we next sought to introduce 
hydroxylation at C12a using optimized conditions that were developed for the third-
generation synthesis of the AB enone 10. It was not known whether the isopropylidene 
substituent would block approach of the electrophilic oxidant from the lower face, 
potentially eroding the stereoselectivity observed in the third-generation synthesis. 
Fortuitously, addition of lithium tert-butoxide to a THF solution of 128 and 3-(4-
nitrophenyl)-2-(phenylsulfonyl)-oxaziridine (119)102 at –40 °C followed by warming of 
the reaction mixture to –5 °C afforded the desired C12a-hydroxylated compound 154 as 
the only major product (Scheme 4.9 above). Partial purification of 154 followed by 
protection of the C12a-hydroxyl group as a trimethylsilyl ether by treatment with 1-
(trimethylsilyl)imidazole (5 equiv) at 0 °C afforded compound 155 in 43% yield over two 
steps. The relative stereochemical outcomes of all reactions in this synthetic sequence 
were confirmed by an X-ray crystal structure of C12a-hydroxylation product 154 (Figure 
4.1). 
 
Figure 4.1. X-ray crystal structure of C12a-hydroxylation product 154. 
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 Two significant challenges remained in order to convert trimethylsilyl ether 155 
(or the C12a-hydroxy compound 154) into an AB precursor to 5-oxo-tetracyclines: (1) 
inversion of C4 stereochemistry, and (2) removal of the B-ring “chiral auxiliary” and 
formation of an enone. 
Initial investigations indicate that C4-epimerization may be an intractable 
problem in this system. Heating of a solution of trimethylsilyl ether 155 in aqueous 
sodium dihydrogen phosphate, methanol and tetrahydrofuran at 60 °C quickly led to 
formation of a dark red reaction mixture. Following work-up and purification it was 
found that the starting material had been cleanly converted to a red solid which was 
characterized as diketone 156 (70% yield, Scheme 4.10). Interestingly, graduate 
researcher Fan Liu observed formation of the same decomposition product (156, 92% 
yield) from piperidone 157 (a possible precursor to 5-aza-tetracyclines) under identical 
conditions. 
 
Scheme 4.10. Attempts to achieve C4-epimerization led to decomposition. 
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Attempts to achieve C4-epimerization using both acidic and basic conditions have 
led to the formation of diketone 156. The highly distinctive dark red color of 156 has 
been observed upon formation of even small amounts of this product in various reaction 
mixtures. Treatment of substrates 154 and 155 with bases such as DBU and phosphazene 
P4-t-Bu in various solvents with different reaction temperatures either provided recovered 
starting material or led to decomposition. An attempt to form an extended C1–C4 enolate 
by treatment of a THF solution of 155 with an excess of NaHMDS at –78 °C afforded 
recovered starting material. The characteristic dark red color of diketone 156 was also 
observed upon prolonged exposure of 12a-hydroxylation product 154 to silica gel, and 
upon attempts to purify this compound by reverse-phase HPLC (methanol–water solvent 
system). A possible mechanism for the formation of 156 from various precursors to 5-
hetero AB enones is presented in Scheme 4.11. 
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Scheme 4.11. Possible mechanism for the formation of decomposition product 156. 
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 Despite these failures, we also sought to find conditions for removal of the 
acetonide functionality and formation of a B-ring enone (Scheme 4.12 below). Addition 
of boron trichloride to a solution of acetonide 155 in dichloromethane at –78 °C followed 
by warming to 0 °C provided diol 158 (29%) and enol 159 (32%). Treatment of enol 159 
with trifluoromethanesulfonic anhydride (Tf2O, 1.5 equiv) and 2,6-lutidine afforded 
enone triflate 160 in 56% yield following purification by flash-column chromatography. 
Diol 158 could also be converted to 160 using an excess of Tf2O (2.5 equiv) and 2,6-
lutidine (5 equiv). A dark red color was observed quickly following purification of enone 
triflate 160, and complete decomposition to diketone 156 occurred upon standing 
overnight at 23 °C under an inert atmosphere. An attempt to achieve palladium-catalyzed 
reduction of triflate 160 immediately following purification also led to decomposition. 
 
Scheme 4.12. Synthesis of enone triflate 160. 
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Conclusion 
 The chemical innovations described herein have established the viability of an 
iterative Michael–Claisen strategy for the synthesis of 5-hetero-tetracyclines. The 
substrate scope of the Michael–Claisen cyclization reaction has been expanded to include 
new heterocyclic enone electrophiles such as dihydro-4-pyridones.  
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Experimental Section 
 
Michael–Claisen cyclization product 142. A freshly prepared solution of lithium 
diisopropylamide in tetrahydrofuran (1.0 M, 418 µL, 0.418 mmol, 2.1 equiv) was added 
dropwise via syringe to a solution of phenyl ester 81 (138 mg, 0.398 mmol, 2.0 equiv) 
and TMEDA (120 µL, 0.796 mmol, 4.0 equiv) in tetrahydrofuran (2.5 mL) at –78 °C, 
forming a bright red solution. After stirring at –78 °C for 45 min, a solution of N-
benzyloxycarbamoyl-2,3-dihydro-4-pyridone 141 (46 mg, 0.199 mmol, 1 equiv) in 
tetrahydrofuran (0.5 ml) was added to the reaction solution dropwise via syringe. The 
resulting mixture was stirred at –78 °C for 10 min, then was allowed to warm slowly to –
10 °C over 50 min. Aqueous potassium phosphate buffer solution (pH 7.0, 0.2 M, 25 mL) 
was then added to the reaction solution and the resulting mixture was allowed to warm to 
23 °C. The product mixture was extracted with ethyl acetate (20 mL, then 10 mL). The 
organic extracts were combined and the combined solution was dried over anhydrous 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
product was purified by flash-column chromatography (12% ethyl acetate–hexanes), 
providing Michael–Claisen cyclization product 142 as a pale yellow solid (60 mg, 62%). 
Rf = 0.19 (15% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 15.32 (s, 1H), 
7.38-7.33 (m, 5H), 7.24 (app t, 1H, J = 8.8 Hz), 7.08 (dd, 1H, J = 8.8, 3.9 Hz), 5.20 (AB 
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quartet, 2H), 4.88 (brd, 1H, J = 9.8 Hz), 4.41 (brs, 1H), 3.46 (brd, 1H, J = 13.7 Hz), 3.11 
(app t, 1H, J = 12.7, 11.7 Hz), 2.61 (app t, 2H, J = 14.6, 13.7 Hz), 2.38 (brd, 1H, J = 17.6 
Hz), 1.58 (s, 9H); 13C NMR (125 MHz, CDCl3) į 184.2, 180.8, 157.3 (d, J = 245.3 Hz), 
154.8, 151.5, 146.5 (d, J = 2.7 Hz), 136.1, 128.6, 128.2, 128.1, 127.7 (d, J = 19.2 Hz), 
125.1 (d, J = 3.7 Hz), 123.4 (d, J = 8.2 Hz), 120.4 (d, J = 23.8 Hz), 110.6, 105.9, 84.0, 
67.6, 48.9, 37.4, 31.9, 27.7; FTIR (neat film), 1761 (m), 1701 (m), 1225 (s), 1144 (s), 733 
(s) cm–1; HRMS–ESI (m/z): [M+Na]+ calcd for C26H26FNNaO7, 506.1591; found, 
506.1549. 
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Michael–Claisen cyclization product 144. A freshly prepared solution of lithium 
diisopropylamide in tetrahydrofuran (1.0 M, 421 µL, 0.421 mmol, 2.1 equiv) was added 
dropwise via syringe to a solution of phenyl ester 81 (139 mg, 0.401 mmol, 2.0 equiv) in 
tetrahydrofuran (2.5 mL) at –78 °C, forming a bright red solution. After stirring at –78 °C 
for 35 min, a solution of N-benzyloxycarbamoyl-quinolone 143 (56 mg, 0.201 mmol, 1 
equiv) in tetrahydrofuran (0.5 ml) was added to the reaction solution dropwise via 
syringe. The resulting mixture was stirred at –78 °C for 10 min, then was allowed to 
warm slowly to –10 °C over 75 min. Aqueous potassium phosphate buffer solution (pH 
7.0, 0.2 M, 25 mL) was then added to the reaction solution and the resulting mixture was 
allowed to warm to 23 °C. The product mixture was extracted with ethyl acetate (2 × 30 
mL). The organic extracts were combined and the combined solution was dried over 
anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. The product was purified by flash-column chromatography (8% ethyl 
acetate–hexanes), providing Michael–Claisen cyclization product 144 as an orange-
yellow solid (91 mg, 85%). 
Rf = 0.37 (15% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 14.59 (s, 1H), 7.86 
(d, 1H, J = 7.8 Hz), 7.74 (d, 1H, J = 8.8 Hz), 7.42-7.33 (m, 6H), 7.24 (app t, 1H, J = 8.8, 
7.8 Hz), 7.14 (app t, 1H, J = 8.8, 7.8 Hz), 7.09 (dd, 1H, J = 8.8, 3.9 Hz), 5.51 (dd, 1H, J = 
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12.7, 3.9 Hz), 5.30 (AB quartet, 2H), 3.50 (dd, 1H, J = 14.6, 3.9 Hz), 2.92 (app t, 1H, J = 
14.6, 13.6 Hz), 1.60 (s, 9H); 13C NMR (125 MHz, CDCl3) į 182.8, 166.8, 157.3 (d, J = 
245.3 Hz), 154.4, 151.5, 146.3 (d, J = 2.7 Hz), 138.1, 135.4, 132.8, 128.6, 128.4, 128.2, 
126.6 (d, J = 19.2 Hz), 125.6 (d, J = 3.7 Hz), 124.8, 124.2, 123.8, 123.6 (d, J = 8.2 Hz), 
121.8, 120.7 (d, J = 24.7 Hz), 107.0, 84.1, 68.4, 53.3, 29.6, 27.7; FTIR (neat film), 1759 
(m), 1713 (m), 1285 (s), 1265 (s), 1225 (s), 1140 (s) cm–1; HRMS–ESI (m/z): [M+Na]+ 
calcd for C30H26FNNaO7, 554.1586; found, 554.1571. 
300 
 
 
Michael–Claisen cyclization product 146. A freshly prepared solution of lithium 
diisopropylamide in tetrahydrofuran (1.0 M, 171 µL, 0.171 mmol, 2.1 equiv) was added 
dropwise via syringe to a solution of phenyl ester 81 (56.5 mg, 0.163 mmol, 2.0 equiv) 
and TMEDA (49.2 µL, 0.326 mmol, 4.0 equiv) in tetrahydrofuran (1.25 mL) at –78 °C, 
forming a bright red solution. After stirring at –78 °C for 30 min, a solution of 2,3-
dihydro-4-pyranone 145 (8 mg, 0.082 mmol, 1 equiv) in tetrahydrofuran (0.25 ml) was 
added to the reaction solution dropwise via syringe. The resulting mixture was stirred at –
78 °C for 5 min, then was allowed to warm slowly to –10 °C over 55 min. Aqueous 
potassium phosphate buffer solution (pH 7.0, 0.2 M, 15 mL) was then added to the 
reaction solution and the resulting mixture was allowed to warm to 23 °C. The product 
mixture was extracted with dichloromethane (2 × 15 mL). The organic extracts were 
combined and the combined solution was dried over anhydrous sodium sulfate. The dried 
solution was filtered and the filtrate was concentrated. The product was purified by flash-
column chromatography (9% ethyl acetate–hexanes, grading to 12%), providing 
Michael–Claisen cyclization product 146 as a pale orange-yellow solid (11 mg, 39%). 
Rf = 0.29 (15% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 15.37 (s, 1H), 7.22 
(app t, 1H, J = 8.8, 7.8 Hz), 7.05 (dd, 1H, J = 8.8, 4.9 Hz), 4.56 (dd, 1H, J = 12.7, 4.8 
Hz), 4.21 (dd, 1H, J = 11.7, 7.8 Hz), 3.82 (app td, 1H, J = 11.7, 3.9 Hz), 3.43 (dd, 1H, J = 
15.6, 5.9 Hz), 2.85-2.78 (m, 1H), 2.62 (app t, 1H, J = 14.7, 13.7 Hz), 2.35 (dd, 1H, J = 
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18.6, 3.9 Hz), 1.57 (s, 9H); 13C NMR (125 MHz, CDCl3) į 182.4, 181.3, 157.1 (d, J = 
245.3), 151.5, 146.1 (d, J = 2.7 Hz), 126.4 (d, J = 19.2 Hz), 125.1 (d, J = 3.7 Hz), 123.3 
(d, J = 8.3 Hz), 120.2 (d, J = 23.8 Hz), 108.5, 84.0, 70.5, 63.5, 31.5, 27.9 (d, J = 2.7 Hz), 
27.7; FTIR (neat film), 1759 (m), 1614 (w), 1279 (m), 1225 (s), 1144 (s) cm–1; HRMS–
ESI (m/z): [M+H]+ calcd for C18H19FNaO6, 373.1063; found, 373.1025. 
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Bis-O-isopropylidene 148.118 Tetrabutylammonium tribromide (1.29 g, 2.66 mmol, 0.04 
equiv) was added in one portion to a white suspension of D-(–)-arabinose (147, 10.0 g, 
66.6 mmol, 1 equiv) in dry acetone (250 mL, dried over anhydrous calcium sulfate) at 23 
°C. The resulting mixture was stirred at 23 °C for 2 d, whereupon triethylamine (1.0 mL) 
was added carefully. The yellow product solution was concentrated. The crude product 
was purified by flash-column chromatography (2% acetone–hexanes, grading to 5%), 
affording bis-O-isopropylidene 148 as a white solid (12.3 g, 80%). 1H NMR data for 148 
closely matched that reported in the literature.119 
                                                 
118 This procedure is adapted from that of Khan et al.: Khan, A. T.; Khan, M. M.; Adhikary, A. 
Carbohydrates Res. 2011, 346, 673–677. 
119 Pedatella, S.; Guaragna, A.; D’Alonzo, D.; De Nisco, M.; Palumbo, G. Synthesis 2006, 2, 305–308. 
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Allylic alcohol 149.120 A round-bottomed flask containing a solution of bis-O-
isopropylidene 148 (13.8 g, 59.9 mmol, 1 equiv) in tetrahydrofuran (500 mL) was placed 
in a cooling bath containing an ice–water mixture. A commercial solution of lithium 
diisopropylamide (2.0 M in tetrahydrofuran–heptane–ethylbenzene, 102 mL, 204 mmol, 
3.4 equiv) was added carefully via cannula over 20 min to the cooled starting material 
solution. The resulting mixture was stirred for 30 min, whereupon the cooling bath was 
removed. The reaction mixture was allowed to warm to 23 °C. After stirring at this 
temperature for 6 h, the reaction flask was placed in a cooling water bath and water (400 
mL) was added carefully. The cooling bath was removed and the product mixture was 
poured into a separatory funnel containing chloroform (400 mL). The phases were 
separated and the aqueous phase was further extracted with chloroform (400 mL, then 
200 mL). The organic extracts were combined and the combined solution was dried over 
anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. The product was purified by flash-column chromatography (20% ethyl 
acetate–hexanes, grading to 25%), providing allylic alcohol 149 as a pale yellow solid 
(5.05 g, 49%). 
                                                 
120 This procedure is adapted from that of Klemer et al.: Klemer, A.; Jung, G. Chem. Ber. 1981, 114, 1192–
1195. 
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Rf = 0.22 (30% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 6.34 (d, 1H, J = 
6.3 Hz), 5.44 (d, 1H, J = 2.9 Hz), 4.96-4.93 (m, 1H), 4.20-4.18 (m, 2H), 2.33 (d, 1H, J = 
4.9 Hz), 1.45 (s, 3H), 1.39 (s, 3H); 13C NMR (125 MHz, CDCl3) į 143.2, 111.0, 99.0, 
93.4, 77.9, 60.3, 27.7, 25.8; FTIR (neat film), 3431 (br), 1651 (m), 1227 (s), 1076 (s), 
1022 (s) cm–1. 
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Dihydro-4-pyranone 127. Tetrapropylammonium perruthenate (343 mg, 0.976 mmol, 
0.1 equiv) was added portionwise over 5 min to a cooled mixture (ice–water cooling 
bath) of allylic alcohol 149 (1.68 g, 9.76 mmol, 1 equiv), N-methylmorpholine N-oxide 
(1.72 g, 14.6 mmol, 1.5 equiv) and powdered 4Å molecular sieves in anhydrous 
dichloromethane (25 mL). The cooling bath was removed and the reaction mixture was 
allowed to warm to 23 °C. After stirring at this temperature for 20 min, the reaction 
mixture was filtered through a thick pad of silica gel, washing through with ethyl acetate. 
The filtrate was concentrated. The crude product was purified by flash-column 
chromatography (20% ethyl acetate–hexanes), affording dihydro-4-pyranone 127 as a 
very pale yellow solid (1.25 g, 75%). 
Rf = 0.26 (30% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.25 (d, 1H, J = 
6.0 Hz), 5.88 (d, 1H, J = 3.7 Hz), 5.43 (d, 1H, J = 6.4 Hz), 4.19 (d, 1H, J = 2.7 Hz), 1.52 
(s, 3H), 1.43 (s, 3H); 13C NMR (125 MHz, CDCl3) į 186.3, 160.7, 113.3, 103.8, 101.0, 
76.7, 27.4, 25.7; FTIR (neat film), 1678 (s), 1599 (s), 1223 (s), 1032 (s) cm–1. 
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Methyl ester 152. A 1.0 M solution of sodium bis(trimethylsilyl)amide in 
tetrahydrofuran (197 µL, 0.197 mmol, 2.1 equiv) was added dropwise via syringe to a 
solution of methyl 3-benzyloxy-5-(dimethylaminomethyl)isoxazole-4-carboxylate 120 
(54.6 mg, 0.188 mmol, 2.0 equiv) in tetrahydrofuran (1.5 mL) at –78 °C (dry ice–acetone 
bath). The resulting yellow solution was stirred at this temperature for 5 min, then was 
allowed to warm to –20 °C (dry ice–acetonitrile bath). After stirring at –20 °C for 30 min, 
the reaction flask was placed in a dry ice–acetone bath at –78 °C. After stirring at this 
temperature for a further 5 min, a solution of B-ring precursor 127 (16.0 mg, 0.094 mmol, 
1 equiv) in tetrahydrofuran (0.3 mL) was added slowly to the isoxazole anion solution at 
–78 °C. The reaction mixture was stirred at this temperature for 5 min, then was allowed 
to warm slowly to 23 °C over 70 min. Aqueous potassium phosphate buffer solution (pH 
7.0, 0.2 M, 10 mL) and dichloromethane (10 mL) were added in sequence and the phases 
were separated. The aqueous phase was extracted with dichloromethane (10 mL). The 
organic extracts were combined and the combined solution was dried over anhydrous 
sodium sulfate. The dried solution was filtered and the filtrate was concentrated. The 
product was purified by flash-column chromatography (25% ethyl acetate–hexanes, 
grading to 30%), affording methyl ester 152 as a yellow solid (14.0 mg, 37%). 
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Rf = 0.09 (30% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.49 (d, 2H, J = 
7.8 Hz), 7.42-7.35 (m, 3H), 7.20 (s, 1H), 5.36 (s, 2H), 5.34 (brs, 1H), 4.94-4.89 (m, 1H), 
4.80 (d, 1H, J = 9.8 Hz), 3.86 (s, 3H), 2.98 (dd, 1H, J = 17.6, 3.5 Hz), 2.74 (dd, 1H, J = 
17.6, 14.7 Hz), 2.26 (s, 6H); 13C NMR (125 MHz, CDCl3) į 187.5, 174.2, 168.8, 161.6, 
145.0, 136.7, 135.4, 128.6, 128.4, 127.8, 104.3, 76.8, 72.0, 62.3, 51.9, 42.1, 38.2; FTIR 
(neat film), 1717 (m), 1674 (w), 1634 (w), 1613 (m), 1508 (m), 1173 (s), 1113 (s), 733 
(s) cm–1; HRMS–ESI (m/z): [M+H]+ calcd for C19H23N2O6, 403.1500; found, 403.1524. 
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Michael–Claisen cyclization product 128. A 1.0 M solution of sodium 
bis(trimethylsilyl)amide in tetrahydrofuran (12.1 mL, 12.1 mmol, 2.05 equiv) was added 
dropwise via syringe to a solution of phenyl 3-benzyloxy-5-
(dimethylaminomethyl)isoxazole-4-carboxylate 153 (4.14 g, 11.8 mmol, 2.0 equiv) in 
tetrahydrofuran (100 mL) at –78 °C (dry ice–acetone bath). The resulting brownish 
yellow solution was stirred at this temperature for 5 min, then was allowed to warm to –
30 °C (dry ice–acetonitrile bath). After stirring at –30 °C for 40 min, the reaction flask 
was placed in a dry ice–acetone bath at –78 °C. After stirring at this temperature for a 
further 5 min, a solution of B-ring precursor 127 (1.00 g, 5.88 mmol, 1 equiv) in 
tetrahydrofuran (7.0 mL) was added slowly to the orange isoxazole anion solution at –78 
°C. The reaction mixture was stirred at this temperature for 5 min, then was allowed to 
warm slowly to –15 °C over 80 min. After stirring at –15 °C for a further 2 h, saturated 
aqueous ammonium chloride solution (30 mL) was added. The cooling bath was removed 
and the reaction flask was allowed to warm to 23 °C. Water (150 mL) and ethyl acetate 
(200 mL) were added and the phases were separated. The aqueous phase was extracted 
with ethyl acetate (200 mL). The organic extracts were combined and the combined 
solution was dried over anhydrous sodium sulfate. The dried solution was filtered and the 
filtrate was concentrated. The product was purified first by flash-column chromatography 
(18% acetone–hexanes, grading to 24%), then by preparative HPLC on an Agilent Prep 
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C18 column [10 µm, 250 x 21.2 mm, UV detection at 350 nm, solvent A: water, solvent 
B: methanol, gradient elution with 70–90% B over 50 min, flow rate: 15 mL/min, 5 
batches]. Fractions eluting 14–20 min were collected and concentrated, providing the 
Michael–Claisen cyclization product 128 as a yellow solid (1.00 g, 40%). 
Rf = 0.15 (25% acetone–hexanes); 1H NMR (500 MHz, CDCl3) į 13.62 (s, 1H), 7.49 (d, 
2H, J = 7.8 Hz), 7.40–7.34 (m, 3H), 5.96 (d, 1H, J = 4.9 Hz), 5.37 (s, 2H), 5.10 (d, 1H, J 
= 6.8 Hz), 4.54 (d, 1H, J = 4.9 Hz), 4.22 (d, 1H, J = 7.8 Hz), 2.32 (s, 6H), 1.42 (s, 6H); 
13C NMR (125 MHz, CDCl3) į 182.3, 175.5, 167.3, 167.2, 134.8, 128.6, 128.6, 128.3, 
109.5, 108.9, 106.5, 98.4, 72.6, 68.7, 64.6, 58.1, 42.2, 27.0, 26.8; FTIR (neat film), 2932 
(w), 1699 (s), 1649 (s), 1510 (s), 1250 (s), 1125 (s), 836 (s) cm–1; HRMS–ESI (m/z): 
[M+H]+ calcd for C22H24N2O7, 429.1662; found, 429.1656. 
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Trimethylsilyl ether 155. A commercial solution of lithium tert-butoxide in 
tetrahydrofuran (1.0 M, 305 µL, 0.305 mmol, 0.3 equiv) was added dropwise via syringe 
to a stirred suspension of 3-(4-nitrophenyl)-2-(phenylsulfonyl)-oxaziridine102 (404 mg, 
1.32 mmol, 1.3 equiv) and the Michael–Claisen cyclization product 128 (435 mg, 1.02 
mmol, 1 equiv) in tetrahydrofuran (6.0 mL) at –40 °C. The resulting mixture was allowed 
to warm slowly to –5 °C over 30 min. After stirring at –5 °C for 1 h, saturated aqueous 
sodium bicarbonate solution (40 mL) was added and the product was extracted with ethyl 
acetate (2 x 40 mL). The organic extracts were combined and the combined solution was 
dried over anhydrous sodium sulfate. The dried solution was filtered and the filtrate was 
concentrated. The product was partially purified by flash-column chromatography (30% 
ethyl acetate–hexanes), affording impure tertiary alcohol 154 (mass of impure product = 
395 mg). The impure hydroxylation product 154 was dissolved in dichloromethane (5.0 
mL) and the resulting solution was cooled to 0 °C. 1-(Trimethylsilyl)imidazole (652 µL, 
4.44 mmol, 5.0 equiv) was added dropwise to the cooled solution of hydroxylation 
product 154. After stirring at 0 °C for 1 h, the reaction mixture was diluted with 
dichloromethane (10 mL) and saturated aqueous sodium bicarbonate solution (10 mL) 
was added dropwise over 5 min with an ice–water cooling bath. The resulting mixture 
was allowed to warm to room temperature whereupon dichloromethane (10 mL) and 
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water (10 mL) were added. The phases were separated and the aqueous phase was 
extracted with dichloromethane (20 mL). The organic extracts were combined and the 
combined solution was dried over anhydrous sodium sulfate. The dried solution was 
filtered and the filtrate was concentrated. The crude product was purified by flash-column 
chromatography (12% ethyl acetate–hexanes, grading to 15%), providing trimethylsilyl 
ether 155 as a pale yellow solid (223 mg, 43% over two steps). 
Rf = 0.18 (15% ethyl acetate-hexanes); 1H NMR (500 MHz, CDCl3) į 7.46 (d, 2H, J = 
7.3 Hz), 7.38-7.32 (m, 3H), 5.74 (d, 1H, J = 5.0 Hz), 5.37 (s, 2H), 4.79 (d, 1H, J = 2.7 
Hz), 4.48 (d, 1H, J = 5.5 Hz), 4.45 (d, 1H, J = 3.2 Hz), 2.62 (s, 6H), 1.43 (s, 3H), 1.41 (s, 
3H), 0.08 (s, 9H); 13C NMR (125 MHz, CDCl3) į 200.9, 186.6, 179.4, 168.0, 134.8, 
128.5, 128.5, 128.1, 110.0, 105.1, 99.4, 86.4, 77.4, 76.5, 72.4, 59.2, 43.3, 27.4, 26.9, 1.7; 
FTIR (neat film), 1753 (m), 1703 (m), 1512 (s), 1157 (s), 1072 (s), 849 (s) cm–1; HRMS–
ESI (m/z): [M+H]+ calcd for C25H33N2O8Si, 517.2001; found, 517.2022. 
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X-Ray Crystallography (C12a-hydroxylation product 154):  A crystal mounted on a 
diffractometer was collected data at 180 K.  The intensities of the reflections were 
collected by means of a Bruker APEX II DUO CCD diffractometer (CuKD radiation, 
O=1.54178 Å), and equipped with an Oxford Cryosystems nitrogen flow apparatus.  The 
collection method involved 1.0q scans in Z at 30q, 55q, 80q and 115q in 2T.  Data 
integration down to 0.84 Å resolution was carried out using SAINT V7.46 A with 
reflection spot size optimization.121  Absorption corrections were made with the program 
SADABS.121 The structure was solved by the direct methods procedure and refined by 
least-squares methods again F2 using SHELXS-97 and SHELXL-97.122 Non-hydrogen 
atoms were refined anisotropically, and hydrogen atoms were allowed to ride on the 
respective atoms. Crystal data as well as details of data collection and refinement are 
summarized in Table 4.1, geometric parameters are shown in Table 4.2, and hydrogen-
bond parameters are listed in Table 4.3. The Ortep plots produced with SHELXL-97 
program, and the other drawings were produced with Accelrys DS Visualizer 2.0.123 
 
 
 
 
                                                 
121 Bruker AXS APEX II, Bruker AXS, Madison, Wisconsin, 2009. 
122 G. M. Sheldrick, Acta Cryst. 2008, A64, 112-122. 
123 Accelrys DS Visualizer v2.0.1, Accelrys Software. Inc., 2007. 
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Table 4.1. Experimental details 
 V-PMW-526 
Crystal data 
Chemical formula C22H24N2O8 
Mr 444.43 
Crystal system, space group Monoclinic, P21 
Temperature (K) 100 
a, b, c (Å) 9.5161 (2), 17.6610 (3), 13.0462 (2) 
ȕ (°) 107.255 (1) 
V (Å3) 2093.91 (7) 
Z 4 
Radiation type Cu KĮ 
µ (mm-1) 0.91 
Crystal size (mm) 0.03 × 0.01 × 0.01 
Data collection 
Diffractometer Bruker D8 goniometer with CCD area detector diffractometer 
Absorption correction Multi-scan  
SADABS 
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Table 4.1. (Continued)  
 Tmin, Tmax 0.973, 0.991 
No. of measured, independent 
and observed [I > 2ı(I)] 
reflections 
33387, 6774, 6441   
Rint 0.038 
Refinement 
R[F2 > 2ı(F2)], wR(F2), S 0.028,  0.066,  1.05 
No. of reflections 6774 
No. of parameters 593 
No. of restraints 1 
H-atom treatment H atoms treated by a mixture of independent and constrained refinement 
ǻUmax, ǻUmin (e Å-3) 0.17, -0.15 
Absolute structure Flack H D (1983), Acta Cryst. A39, 876-881 
Flack parameter 0.02 (10) 
 
Computer programs: APEX2 v2009.3.0 (Bruker-AXS, 2009), SAINT 7.46A (Bruker-
AXS, 2009), SHELXS97 (Sheldrick, 2008), SHELXL97 (Sheldrick, 2008), Bruker 
SHELXTL (Sheldrick, 2008). 
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Table 4.2. Geometric parameters (Å, º) 
C1—N1 1.307 (2) C31—N3 1.315 (2) 
C1—O1 1.328 (2) C31—O11 1.328 (2) 
C1—C2 1.429 (3) C31—C32 1.423 (3) 
C2—C11 1.360 (3) C32—C41 1.351 (3) 
C2—C3 1.447 (3) C32—C33 1.460 (2) 
C3—O2 1.217 (2) C33—O12 1.213 (2) 
C3—C4 1.549 (3) C33—C34 1.546 (3) 
C4—O3 1.408 (2) C34—O13 1.407 (2) 
C4—C5 1.521 (2) C34—C35 1.526 (3) 
C4—C9 1.542 (2) C34—C39 1.551 (2) 
C5—O4 1.202 (2) C35—O14 1.205 (2) 
C5—C6 1.527 (3) C35—C36 1.519 (3) 
C6—O5 1.407 (2) C36—O15 1.404 (2) 
C6—C8 1.531 (2) C36—C38 1.523 (2) 
C6—H6 1.0000 C36—H36 1.0000 
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Table 4.2. (Continued)    
C7—O5 1.434 (2) C37—O15 1.442 (2) 
C7—O6 1.446 (2) C37—O16 1.446 (2) 
C7—C20 1.505 (3) C37—C49 1.501 (3) 
C7—C19 1.511 (3) C37—C50 1.514 (3) 
C8—O7 1.394 (2) C38—O17 1.398 (2) 
C8—O6 1.416 (2) C38—O16 1.423 (2) 
C8—H8 1.0000 C38—H38 1.0000 
C9—O7 1.429 (2) C39—O17 1.425 (2) 
C9—C10 1.550 (2) C39—C40 1.549 (2) 
C9—H9 1.0000 C39—H39 1.0000 
C10—N2 1.464 (2) C40—N4 1.472 (2) 
C10—C11 1.501 (3) C40—C41 1.494 (3) 
C10—H10 1.0000 C40—H40 1.0000 
C11—O8 1.330 (2) C41—O18 1.333 (2) 
C12—O1 1.456 (2) C42—O11 1.457 (2) 
C12—C13 1.502 (3) C42—C43 1.501 (3) 
317 
 
Table 4.2. (Continued)    
C12—H12A 0.9900 C42—H42A 0.9900 
C12—H12B 0.9900 C42—H42B 0.9900 
C13—C18 1.380 (3) C43—C44 1.393 (3) 
C13—C14 1.394 (3) C43—C48 1.397 (3) 
C14—C15 1.390 (3) C44—C45 1.390 (3) 
C14—H14 0.9500 C44—H44 0.9500 
C15—C16 1.367 (4) C45—C46 1.375 (3) 
C15—H15 0.9500 C45—H45 0.9500 
C16—C17 1.372 (3) C46—C47 1.389 (3) 
C16—H16 0.9500 C46—H46 0.9500 
C17—C18 1.387 (3) C47—C48 1.382 (3) 
C17—H17 0.9500 C47—H47 0.9500 
C18—H18 0.9500 C48—H48 0.9500 
C19—H19A 0.9800 C49—H49A 0.9800 
C19—H19B 0.9800 C49—H49B 0.9800 
C19—H19C 0.9800 C49—H49C 0.9800 
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Table 4.2. (Continued)    
C20—H20A 0.9800 C50—H50A 0.9800 
C20—H20B 0.9800 C50—H50B 0.9800 
C20—H20C 0.9800 C50—H50C 0.9800 
C21—N2 1.458 (3) C51—N4 1.468 (2) 
C21—H21A 0.9800 C51—H51A 0.9800 
C21—H21B 0.9800 C51—H51B 0.9800 
C21—H21C 0.9800 C51—H51C 0.9800 
C22—N2 1.466 (3) C52—N4 1.476 (3) 
C22—H22A 0.9800 C52—H52A 0.9800 
C22—H22B 0.9800 C52—H52B 0.9800 
C22—H22C 0.9800 C52—H52C 0.9800 
N1—O8 1.448 (2) N3—O18 1.4343 (19) 
O3—H3 0.90 (3) O13—H13 0.87 (3) 
 
N1—C1—O1 125.05 (17) N3—C31—O11 123.85 (16) 
N1—C1—C2 112.66 (17) N3—C31—C32 112.13 (16) 
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Table 4.2. (Continued)    
O1—C1—C2 122.21 (16) O11—C31—C32 123.94 (16) 
C11—C2—C1 103.57 (16) C41—C32—C31 104.02 (15) 
C11—C2—C3 123.97 (18) C41—C32—C33 122.80 (16) 
C1—C2—C3 132.43 (17) C31—C32—C33 133.18 (16) 
O2—C3—C2 125.31 (18) O12—C33—C32 125.09 (17) 
O2—C3—C4 121.30 (17) O12—C33—C34 121.96 (16) 
C2—C3—C4 113.37 (15) C32—C33—C34 112.84 (15) 
O3—C4—C5 112.00 (14) O13—C34—C35 111.76 (14) 
O3—C4—C9 110.37 (14) O13—C34—C33 106.97 (14) 
C5—C4—C9 108.76 (14) C35—C34—C33 108.32 (15) 
O3—C4—C3 107.42 (15) O13—C34—C39 109.47 (14) 
C5—C4—C3 107.85 (15) C35—C34—C39 108.37 (14) 
C9—C4—C3 110.41 (14) C33—C34—C39 111.98 (14) 
O4—C5—C4 121.55 (17) O14—C35—C36 121.70 (17) 
O4—C5—C6 121.48 (16) O14—C35—C34 120.63 (17) 
C4—C5—C6 116.96 (15) C36—C35—C34 117.67 (14) 
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Table 4.2. (Continued)    
O5—C6—C5 112.59 (15) O15—C36—C35 112.00 (14) 
O5—C6—C8 103.25 (14) O15—C36—C38 103.00 (14) 
C5—C6—C8 113.72 (14) C35—C36—C38 112.57 (15) 
O5—C6—H6 109.0 O15—C36—H36 109.7 
C5—C6—H6 109.0 C35—C36—H36 109.7 
C8—C6—H6 109.0 C38—C36—H36 109.7 
O5—C7—O6 105.33 (14) O15—C37—O16 105.64 (13) 
O5—C7—C20 108.47 (16) O15—C37—C49 111.96 (15) 
O6—C7—C20 109.71 (16) O16—C37—C49 108.52 (16) 
O5—C7—C19 111.26 (16) O15—C37—C50 107.28 (16) 
O6—C7—C19 108.58 (16) O16—C37—C50 110.39 (15) 
C20—C7—C19 113.20 (19) C49—C37—C50 112.81 (17) 
O7—C8—O6 111.22 (14) O17—C38—O16 111.08 (14) 
O7—C8—C6 115.42 (15) O17—C38—C36 115.21 (15) 
O6—C8—C6 103.12 (15) O16—C38—C36 102.20 (14) 
O7—C8—H8 108.9 O17—C38—H38 109.4 
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Table 4.2. (Continued)    
O6—C8—H8 108.9 O16—C38—H38 109.4 
C6—C8—H8 108.9 C36—C38—H38 109.4 
O7—C9—C4 107.08 (14) O17—C39—C40 106.40 (13) 
O7—C9—C10 106.36 (14) O17—C39—C34 108.99 (14) 
C4—C9—C10 113.55 (14) C40—C39—C34 113.84 (14) 
O7—C9—H9 109.9 O17—C39—H39 109.2 
C4—C9—H9 109.9 C40—C39—H39 109.2 
C10—C9—H9 109.9 C34—C39—H39 109.2 
N2—C10—C11 113.77 (15) N4—C40—C41 112.22 (14) 
N2—C10—C9 116.78 (15) N4—C40—C39 117.08 (15) 
C11—C10—C9 106.17 (14) C41—C40—C39 107.96 (14) 
N2—C10—H10 106.5 N4—C40—H40 106.3 
C11—C10—H10 106.5 C41—C40—H40 106.3 
C9—C10—H10 106.5 C39—C40—H40 106.3 
O8—C11—C2 110.96 (17) O18—C41—C32 110.79 (16) 
O8—C11—C10 123.03 (16) O18—C41—C40 121.42 (15) 
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Table 4.2. (Continued)    
C2—C11—C10 125.95 (16) C32—C41—C40 127.66 (16) 
O1—C12—C13 108.31 (15) O11—C42—C43 109.34 (14) 
O1—C12—H12A 110.0 O11—C42—H42A 109.8 
C13—C12—H12A 110.0 C43—C42—H42A 109.8 
O1—C12—H12B 110.0 O11—C42—H42B 109.8 
C13—C12—H12B 110.0 C43—C42—H42B 109.8 
H12A—C12—H12B 108.4 H42A—C42—H42B 108.3 
C18—C13—C14 118.0 (2) C44—C43—C48 118.93 (18) 
C18—C13—C12 119.89 (17) C44—C43—C42 122.94 (17) 
C14—C13—C12 122.12 (19) C48—C43—C42 118.09 (16) 
C15—C14—C13 120.4 (2) C45—C44—C43 119.91 (18) 
C15—C14—H14 119.8 C45—C44—H44 120.0 
C13—C14—H14 119.8 C43—C44—H44 120.0 
C16—C15—C14 120.5 (2) C46—C45—C44 120.73 (18) 
C16—C15—H15 119.7 C46—C45—H45 119.6 
C14—C15—H15 119.7 C44—C45—H45 119.6 
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Table 4.2. (Continued)    
C15—C16—C17 119.7 (2) C45—C46—C47 119.86 (19) 
C15—C16—H16 120.2 C45—C46—H46 120.1 
C17—C16—H16 120.2 C47—C46—H46 120.1 
C16—C17—C18 120.1 (2) C48—C47—C46 119.89 (19) 
C16—C17—H17 119.9 C48—C47—H47 120.1 
C18—C17—H17 119.9 C46—C47—H47 120.1 
C13—C18—C17 121.22 (18) C47—C48—C43 120.66 (18) 
C13—C18—H18 119.4 C47—C48—H48 119.7 
C17—C18—H18 119.4 C43—C48—H48 119.7 
C7—C19—H19A 109.5 C37—C49—H49A 109.5 
C7—C19—H19B 109.5 C37—C49—H49B 109.5 
H19A—C19—H19B 109.5 H49A—C49—H49B 109.5 
C7—C19—H19C 109.5 C37—C49—H49C 109.5 
H19A—C19—H19C 109.5 H49A—C49—H49C 109.5 
H19B—C19—H19C 109.5 H49B—C49—H49C 109.5 
C7—C20—H20A 109.5 C37—C50—H50A 109.5 
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Table 4.2. (Continued)    
C7—C20—H20B 109.5 C37—C50—H50B 109.5 
H20A—C20—H20B 109.5 H50A—C50—H50B 109.5 
C7—C20—H20C 109.5 C37—C50—H50C 109.5 
H20A—C20—H20C 109.5 H50A—C50—H50C 109.5 
H20B—C20—H20C 109.5 H50B—C50—H50C 109.5 
N2—C21—H21A 109.5 N4—C51—H51A 109.5 
N2—C21—H21B 109.5 N4—C51—H51B 109.5 
H21A—C21—H21B 109.5 H51A—C51—H51B 109.5 
N2—C21—H21C 109.5 N4—C51—H51C 109.5 
H21A—C21—H21C 109.5 H51A—C51—H51C 109.5 
H21B—C21—H21C 109.5 H51B—C51—H51C 109.5 
N2—C22—H22A 109.5 N4—C52—H52A 109.5 
N2—C22—H22B 109.5 N4—C52—H52B 109.5 
H22A—C22—H22B 109.5 H52A—C52—H52B 109.5 
N2—C22—H22C 109.5 N4—C52—H52C 109.5 
H22A—C22—H22C 109.5 H52A—C52—H52C 109.5 
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Table 4.2. (Continued)    
H22B—C22—H22C 109.5 H52B—C52—H52C 109.5 
C1—N1—O8 104.29 (14) C31—N3—O18 104.38 (13) 
C21—N2—C10 111.45 (15) C51—N4—C40 111.14 (14) 
C21—N2—C22 109.98 (16) C51—N4—C52 110.08 (15) 
C10—N2—C22 117.13 (14) C40—N4—C52 116.75 (14) 
C1—O1—C12 116.77 (15) C31—O11—C42 115.91 (14) 
C4—O3—H3 109.9 (18) C34—O13—H13 106.9 (17) 
C6—O5—C7 108.05 (13) C36—O15—C37 108.05 (13) 
C8—O6—C7 109.74 (13) C38—O16—C37 108.24 (13) 
C8—O7—C9 115.50 (14) C38—O17—C39 115.65 (13) 
C11—O8—N1 108.48 (13) C41—O18—N3 108.61 (13) 
 
N1—C1—C2—C11 2.3 (2) N3—C31—C32—C41 3.0 (2) 
O1—C1—C2—C11 -174.62 (17) O11—C31—C32—C41 -173.92 (16) 
N1—C1—C2—C3 -175.66 (19) N3—C31—C32—C33 -176.46 (18) 
O1—C1—C2—C3 7.5 (3) O11—C31—C32—C33 6.6 (3) 
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Table 4.2. (Continued)    
C11—C2—C3—O2 -168.86 (19) C41—C32—C33—O12 -166.79 (18) 
C1—C2—C3—O2 8.7 (3) C31—C32—C33—O12 12.6 (3) 
C11—C2—C3—C4 12.8 (3) C41—C32—C33—C34 17.0 (2) 
C1—C2—C3—C4 -169.64 (19) C31—C32—C33—C34 -163.66 (18) 
O2—C3—C4—O3 -95.7 (2) O12—C33—C34—O13 -96.5 (2) 
C2—C3—C4—O3 82.68 (18) C32—C33—C34—O13 79.89 (17) 
O2—C3—C4—C5 25.2 (2) O12—C33—C34—C35 24.1 (2) 
C2—C3—C4—C5 -156.42 (15) C32—C33—C34—C35 -159.49 (15) 
O2—C3—C4—C9 143.88 (18) O12—C33—C34—C39 143.59 (17) 
C2—C3—C4—C9 -37.7 (2) C32—C33—C34—C39 -40.0 (2) 
O3—C4—C5—O4 14.3 (2) O13—C34—C35—O14 15.6 (2) 
C9—C4—C5—O4 136.56 (18) C33—C34—C35—O14 -102.0 (2) 
C3—C4—C5—O4 -103.7 (2) C39—C34—C35—O14 136.33 (18) 
O3—C4—C5—C6 -166.24 (15) O13—C34—C35—C36 -164.94 (15) 
C9—C4—C5—C6 -44.0 (2) C33—C34—C35—C36 77.47 (19) 
C3—C4—C5—C6 75.77 (19) C39—C34—C35—C36 -44.2 (2) 
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Table 4.2. (Continued)    
O4—C5—C6—O5 -35.2 (2) O14—C35—C36—O15 -31.4 (2) 
C4—C5—C6—O5 145.32 (15) C34—C35—C36—O15 149.19 (15) 
O4—C5—C6—C8 -152.22 (17) O14—C35—C36—C38 -146.88 (18) 
C4—C5—C6—C8 28.3 (2) C34—C35—C36—C38 33.7 (2) 
O5—C6—C8—O7 -151.86 (15) O15—C36—C38—O17 -156.30 (15) 
C5—C6—C8—O7 -29.5 (2) C35—C36—C38—O17 -35.5 (2) 
O5—C6—C8—O6 -30.37 (17) O15—C36—C38—O16 -35.74 (17) 
C5—C6—C8—O6 91.94 (17) C35—C36—C38—O16 85.08 (17) 
O3—C4—C9—O7 -176.43 (14) O13—C34—C39—O17 178.49 (14) 
C5—C4—C9—O7 60.32 (18) C35—C34—C39—O17 56.37 (18) 
C3—C4—C9—O7 -57.82 (18) C33—C34—C39—O17 -63.05 (18) 
O3—C4—C9—C10 -59.34 (19) O13—C34—C39—C40 -62.92 (19) 
C5—C4—C9—C10 177.42 (15) C35—C34—C39—C40 174.96 (14) 
C3—C4—C9—C10 59.28 (19) C33—C34—C39—C40 55.5 (2) 
O7—C9—C10—N2 -60.33 (19) O17—C39—C40—N4 -50.47 (19) 
C4—C9—C10—N2 -177.85 (15) C34—C39—C40—N4 -170.53 (15) 
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Table 4.2. (Continued)    
O7—C9—C10—C11 67.73 (17) O17—C39—C40—C41 77.28 (17) 
C4—C9—C10—C11 -49.79 (19) C34—C39—C40—C41 -42.77 (19) 
C1—C2—C11—O8 -1.9 (2) C31—C32—C41—O18 -2.6 (2) 
C3—C2—C11—O8 176.28 (17) C33—C32—C41—O18 176.91 (16) 
C1—C2—C11—C10 175.38 (17) C31—C32—C41—C40 173.18 (17) 
C3—C2—C11—C10 -6.5 (3) C33—C32—C41—C40 -7.3 (3) 
N2—C10—C11—O8 -29.2 (2) N4—C40—C41—O18 -34.4 (2) 
C9—C10—C11—O8 -158.99 (16) C39—C40—C41—O18 -164.85 (15) 
N2—C10—C11—C2 153.90 (18) N4—C40—C41—C32 150.24 (17) 
C9—C10—C11—C2 24.1 (2) C39—C40—C41—C32 19.7 (2) 
O1—C12—C13—C18 143.90 (18) O11—C42—C43—C44 -10.8 (2) 
O1—C12—C13—C14 -36.4 (2) O11—C42—C43—C48 171.70 (16) 
C18—C13—C14—C15 1.1 (3) C48—C43—C44—C45 1.0 (3) 
C12—C13—C14—C15 -178.61 (19) C42—C43—C44—C45 -176.51 (18) 
C13—C14—C15—C16 0.0 (3) C43—C44—C45—C46 -0.1 (3) 
C14—C15—C16—C17 -0.6 (3) C44—C45—C46—C47 -0.9 (3) 
329 
 
Table 4.2. (Continued)    
C15—C16—C17—C18 0.1 (3) C45—C46—C47—C48 0.9 (3) 
C14—C13—C18—C17 -1.6 (3) C46—C47—C48—C43 0.0 (3) 
C12—C13—C18—C17 178.11 (19) C44—C43—C48—C47 -0.9 (3) 
C16—C17—C18—C13 1.0 (3) C42—C43—C48—C47 176.68 (18) 
O1—C1—N1—O8 175.07 (17) O11—C31—N3—O18 174.81 (16) 
C2—C1—N1—O8 -1.7 (2) C32—C31—N3—O18 -2.11 (19) 
C11—C10—N2—C21 176.40 (15) C41—C40—N4—C51 -179.95 (15) 
C9—C10—N2—C21 -59.3 (2) C39—C40—N4—C51 -54.3 (2) 
C11—C10—N2—C22 -55.7 (2) C41—C40—N4—C52 -52.6 (2) 
C9—C10—N2—C22 68.5 (2) C39—C40—N4—C52 73.1 (2) 
N1—C1—O1—C12 -4.1 (3) N3—C31—O11—C42 -8.9 (3) 
C2—C1—O1—C12 172.35 (17) C32—C31—O11—C42 167.68 (16) 
C13—C12—O1—C1 -148.03 (16) C43—C42—O11—C31 -144.68 (16) 
C5—C6—O5—C7 -91.18 (16) C35—C36—O15—C37 -90.26 (17) 
C8—C6—O5—C7 31.89 (18) C38—C36—O15—C37 30.95 (18) 
O6—C7—O5—C6 -21.19 (19) O16—C37—O15—C36 -14.48 (18) 
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Table 4.2. (Continued)    
C20—C7—O5—C6 -138.59 (16) C49—C37—O15—C36 103.47 (17) 
C19—C7—O5—C6 96.28 (19) C50—C37—O15—C36 -132.25 (15) 
O7—C8—O6—C7 142.43 (15) O17—C38—O16—C37 150.94 (14) 
C6—C8—O6—C7 18.15 (18) C36—C38—O16—C37 27.55 (17) 
O5—C7—O6—C8 0.52 (19) O15—C37—O16—C38 -9.60 (18) 
C20—C7—O6—C8 117.08 (17) C49—C37—O16—C38 -129.83 (16) 
C19—C7—O6—C8 -118.74 (17) C50—C37—O16—C38 106.06 (18) 
O6—C8—O7—C9 -65.49 (19) O16—C38—O17—C39 -62.13 (19) 
C6—C8—O7—C9 51.5 (2) C36—C38—O17—C39 53.4 (2) 
C4—C9—O7—C8 -67.14 (18) C40—C39—O17—C38 172.73 (14) 
C10—C9—O7—C8 171.14 (14) C34—C39—O17—C38 -64.12 (18) 
C2—C11—O8—N1 0.9 (2) C32—C41—O18—N3 1.48 (19) 
C10—C11—O8—N1 -176.38 (16) C40—C41—O18—N3 -174.63 (15) 
C1—N1—O8—C11 0.48 (19) C31—N3—O18—C41 0.43 (18) 
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Table 4.3. Hydrogen-bond parameters 
D—H···A D—H (Å) H···A (Å) D···A (Å) D—H···A (°) 
O3—H3···N4i 0.90 (3) 2.03 (3) 2.893 (2) 161 (3) 
O13—H13···N2ii 0.87 (3) 2.12 (3) 2.915 (2) 151 (2) 
 
Symmetry code(s):  (i) x+1, y, z; (ii) x-1, y, z-1. 
   
 
Figure 4.1a 
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Figure 4.1b 
Figure 4.1. Perspective views showing 50% probability displacement. 
 
Figure 4.2. Three-dimensional supramolecular architecture viewed along the a-axis 
direction. 
b
c
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